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ABSTRACT 
Activation of the NO-cGMP pathway is associated with myocardial protection 
against ischaemia/reperfusion injury. However, high-cholesterol diets alter 
function of this pathway and these alterations have been implicated in both 
ischaemic/reperfusion injury and the development of ischaemic heart disease. 
Little is known about the effects of supplements such as Red Palm Oil (RPO) 
on the myocardial NO-cGMP-signalling pathway. RPO consists of saturated, 
mono-unsaturated and poly-unsaturated fatty acids and is rich in antioxidants 
such as β-carotene and Vitamin E (tocopherols and tocotrienols). The aims of 
this study were: 1) to determine whether dietary RPO-supplemention protects 
against ischaemia/reperfusion injury in rats fed a standard rat chow (control) 
and cholesterol-enriched diets and 2) if so, to investigate possible mechanisms 
for this protection.  
Male Long-Evans rats were fed a standard rat chow or a standard rat chow 
plus cholesterol and/or RPO-supplementation for 6 weeks. Myocardial 
functional recovery was measured and hearts were freeze-clamped for 
determination of myocardial phospholipid, cAMP/cGMP concentrations, total 
myocardial nitric oxide concentrations, lipid hydroperoxide production and 
superoxide dismutase- and nitric oxide synthase activity in isolated rat hearts 
subjected to 25 minutes of normothermic total global ischaemia. In addition, 
the degree of phosphorylation of extracellular signal-regulated kinase (ERK), 
p38, c-Jun N-terminal protein kinase (JNK) and protein kinase B (PKB/Akt) 
was investigated. Furthermore, the effect of RPO-supplementation on 
caspase-3 activation and poly (ADP-ribose) polymerase (PARP)-cleavage in 
hearts subjected to ischaemia and reperfusion was also investigated. 
 XXII
Our data show that dietary RPO-supplementation protects the hearts of rats on 
a standard rat chow (control) and hypercholesterolaemic diet against 
ischaemia/reperfusion injury as reflected by improved aortic output recovery. 
Increased intracellular cardiomyocyte NO concentrations as observed in 
control hearts supplemented with RPO after 120 minutes hypoxia may 
contribute to the elevated cGMP concentration and may confer some of the 
cardioprotection to the ischaemic/reperfused heart. Although improved 
functional recovery with RPO-supplementation of a high-cholesterol diet was 
also associated with an increase in intracellular cardiomyocyte NO production 
after hypoxia compared to the non-hypoxic conditions, it could not be linked to 
increased NO-cGMP signalling. These data are in agreement with other 
studies, which showed that high-cholesterol diet impairs NO-cGMP signalling 
and confirms our hypothesis that elevated cGMP concentrations may not be 
the only mechanism of protection. We have also shown that RPO-
supplementation caused increased phosphorylation of p38 and PKB, reduced 
phosphorylation of JNK and attenuation of PARP cleavage, which may 
contribute to the protection of the cell against apoptosis.  
 
Based on our results we propose that the myocardial protection offered by 
RPO-supplementation of rats on a normal and hypercholesterolaemic diet may 
be associated with either its antioxidant characteristics and/or changes in the 
fatty acid composition of the myocardium during ischaemia/reperfusion. 
Furthermore, we demonstrated for the first time that RPO-supplementation 
protects the isolated perfused working rat heart during reperfusion from 
ischaemia/reperfusion-induced injury through a MAPK-dependent pathway. 
 XXIII
 
UITTREKSEL 
Aktivering van die NO-cGMP sein transduksie pad word geassosieer met 
miokardiale beskerming teen isgemie/herperfusie skade. Hoë cholesterol diëte 
verander egter die funksie van die pad en hierdie veranderings speel ‘n rol in 
beide isgemie/herperfusie besering en die ontwikkeling van isgemiese 
hartsiekte.  
Daar is egter min inligting beskikbaar oor die uitwerking van aanvullings soos 
rooi palm olie (RPO) op die miokardiale NO-cGMP sein transduksie pad. RPO 
bevat versadigde, mono-onversadigde en poli-onversadigde vetsure en is ryk 
aan anti-oksidante nl. β-karotene en vitamien E (tokoferole en tokotriënole). 
Die doelwitte van hierdie studie was: 1) om vas te stel of ‘n RPO-aanvulling 
beskerming bied teen isgemie/herperfusie besering in rotte wat gevoed is met 
‘n standaard rotmengsel (kontrole) en cholesterol-verrykte dieet en 2) indien 
wel, om moontlike meganismes van beskerming te ondersoek.  
 
Long-Evans manlike rotte is vir 6 weke gevoer met ‘n standaard rotmengsel of 
‘n standaard rotmengsel plus cholesterol en/of RPO-aanvulling. Miokardiale 
funksionele herstel is gemeet en harte is gevriesklamp vir die bepaling van 
miokardiale fosfolipied, cAMP/cGMP, totale stikstofoksied, lipied 
hidroperoksied, superoksied dismutase en stikstofoksied sintase in 
geïsoleerde rotharte wat vir 25 minute onderwerp was aan normotermiese 
totale globale isgemie. Hiermee saam is die graad van fosforilering van 
ekstrasellulêre sein gereguleerde kinase (ERK), p38 mitogeen-geaktiveerde 
proteïen kinase (p38 MAPK), c-Jun-N-terminale proteïenkinase (JNK) en 
 XXIV
proteïen kinase B (PKB/Akt) ondersoek, asook kaspase-3 aktivering en poli 
(ADP-ribose) polimerase (PARP) kliewing in harte blootgestel aan isgemie en 
herperfusie.  
 
Ons resultate toon dat RPO-aanvulling van rotte op ‘n normale en 
hipercholesterolemiese dieet die hart beskerm soos getoon deur verbeterde 
herstel van aortiese uitset. Verhoogde intrasellulêre miokardiale NO vlakke in 
kontrole harte met ‘n RPO-aanvulling wat blootgestel was aan 120 minute 
hipoksie, mag bygedra het tot die verhoogde cGMP vlakke en beskerming van 
die hart tydens isgemie en herperfusie. Alhoewel verbeterde funksionele 
herstel met RPO-aanvulling van ‘n hoë cholesterol dieet ook geassosieer is 
met ‘n toename in intrasellulêre miokardiale NO produksie ná hipoksiese 
toestande, kon dit nie verbind word met verhoogde aktivering van die NO-
cGMP sein transduksie pad nie. Hierdie resultate stem ooreen met ander 
studies wat aangetoon het dat hoë-cholesterol diëte die NO-cGMP seinpad 
onderdruk. Hierdie bevinding bevestig ons hipotese dat verhoogde cGMP 
vlakke moontlik nie die enigste beskermingsmeganisme is nie. Ons resultate 
het ook gewys dat RPO-aanvulling fosforilering van p38 en PKB/Akt verhoog, 
fosforilering van JNK verminder en PARP kliewing onderdruk. Dit dui op 
beskerming van die sel teen apoptose.  
 
Ons resultate dui aan dat die miokardiale beskerming wat RPO-dieet 
aanvulling bied moontlik geassosieer kan word met sy anti-oksidant eienskap 
en/of veranderinge in die vetsuur samestelling van die miokardium tydens 
isgemie/herperfusie. Ons het ook vir die eerste keer bewys dat RPO-aanvulling 
 XXV
die geïsoleerde geperfuseerde werkende rothart gedurende herperfusie 
beskerm teen isgemie/herperfusie besering deur die aktivering en/of 
deaktivering van die MAPK afhanklike pad.  
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CHAPTER 1 
 
INTRODUCTION 
 
 
Palm oil and its liquid fraction, palm olein, are consumed worldwide as cooking 
oils and as constituents of margarines. These oils are also incorporated into fat 
blends used in the manufacturing of a variety of food products and in home 
food preparation. It plays a meaningful role in meeting energy needs and 
contributes to essential fatty acid (C18:2n-6) needs in many regions of the 
world (reviewed by Cottrell, 1991). Refined red palm oil (RPO) used in this 
study consists of 51% saturated fatty acids (SFAs), 38% monounsaturated 
fatty acids (MUFAs), 11% polyunsaturated fatty acids (PUFAs) and contains no 
less than 500 parts per million (ppm) carotenoids, 60% as β-carotene and 25% 
as α-carotene. The vitamin E content is about 500 ppm of which 70% is 
tocotrienols and 30% tocopherols (Nagendran et al., 2000; Sundram et al., 
2003).  
 
Most previous studies with palm oil in humans and animals have focused on 
lipoproteins and cardiovascular disease where clinical trials have evaluated the 
effect of palm oil on blood lipids and lipoproteins. These studies suggest that 
palm oil does not raise serum total cholesterol (TC) or LDL cholesterol levels to 
the extent expected when a moderate-fat, moderate-cholesterol diet is 
consumed. This can possibly be ascribed to the fatty acid composition of palm 
oil (Chandrasekharan, 1999; Theriault et al., 1999; Kritchevsky, 2000; 
Sundram and Basiron). However, when hypercholesterolaemic subjects and 
high fat liquid formula diets were used, palm oil-supplementation appeared to 
raise TC and LDL cholesterol (Sundram and Basiron).  
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The use of RPO per se in previous studies has been limited and more 
literature refers to the use of fractionated tocotrienol in studies that 
predominantly focus on lipid metabolism, atherosclerosis and cancer. We 
therefore used dietary RPO that contained both fatty acids and antioxidants 
while we investigated the cellular mechanisms that may be involved in the 
cardioprotection against ischaemia/reperfusion injury.  
 
To our knowledge Serbinova and co-workers (1992) were the first to 
demonstrate that a palm oil vitamin E mixture containing both α-tocopherol and 
α-tocotrienol improved reperfusion functional recovery in a Langendorff-
perfused rat heart. This protection was due to the ability of both α-tocopherols 
and α-tocotrienols to scavenge free radicals during reperfusion, but the 
researchers argued that α-tocotrienols might have been the more potent free 
radical scavenger of the two.  
 
The composition of RPO allows for this protection to be offered by either the 
fatty acid constituents or the anti-oxidative carotenoids, tocopherols and 
tocotrienols or both. Since the antioxidant content of RPO is very high, it may 
well be argued that protection may also be offered via the NO-cGMP pathway, 
but the possible role of the fatty acids also needs consideration and 
clarification. It has been shown that longer chain n-3 fatty acids offer protection 
against ischaemia/reperfusion injury through MAPK-, PKB/Akt- and caspase 
dependant pathways (Engelbrecht et al., submitted).  
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To our knowledge the cardioprotection offered by RPO and the role of NO-
cGMP signalling has not been investigated under normal and/or conditions 
such as ischaemia or reperfusion. Recent studies suggested that the MAPK, 
PKB/Akt and signal transduction caspases might also be involved in the 
regulation of apoptosis in response to myocardial ischaemia/reperfusion. 
Therefore, we used the ischaemic/reperfused working rat heart model to 
elucidate whether the function and activity of these pathways (NO-cGMP, 
MAPK, PKB/Akt and caspases) are altered and contribute to the red palm oil-
induced protection against ischaemia/reperfusion injury.  
 
Nitric Oxide (NO) is, by virtue of its vasodilator, antioxidant, anti-platelet and 
anti-neutrophil actions, an essential molecule for normal heart function 
(reviewed by Ferdinandy and Schultz, 2003). It has been shown to be 
cardioprotective in the ischaemic heart (reviewed by Bolli, 2001). However, NO 
is detrimental when it is combined with superoxide (O2-) to form peroxynitrite 
(ONOO-), which rapidly decomposes to highly reactive oxidant species, leading 
to tissue injury (reviewed by Ferdinandy and Schultz, 2003). There is a critical 
balance between cellular concentrations of NO, O2- and superoxide dismutase 
(SOD) which physiologically favour NO production, but in pathological 
conditions such as ischaemia and reperfusion injury, result in ONOO- formation 
(reviewed by Ferdinandy and Schultz, 2003). A role for reactive oxygen 
species, including the superoxide radical (O2-), hydrogen peroxide (H2O2) and 
hydroxyl radical (.OH) have long been implicated in the pathogenesis of 
ischaemia/reperfusion injury. These oxygen free radicals can react with nucleic 
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acids, proteins and lipids, resulting in damage to the cell membrane or 
intracellular organelles (Gilham et al., 1997). 
 
Myocardial NO formation is increased during ischaemia and reperfusion, 
offering protection against ischaemia/reperfusion injury (Williams et al., 1995; 
Araki et al., 2000; Bolli, 2001).  Protective effects of NO are mediated through 
the production of cGMP. NO is known to increase myocardial cGMP, and it has 
been suggested that the protective effect of NO is related to a mechanism 
secondary to the stimulation of guanylyl cyclase within the vascular wall or in 
ventricular myocytes (Beresewics et al., 1995; Maulik et al., 1995; Depré et al., 
1996). NO donors given during ischaemia possibly protect the myocardium by 
increasing tissue cGMP and decreasing cytosolic Ca2+ overload (Du Toit et al., 
2001). These investigators found that nitric oxide donor treatment reduces 
ischaemia/reperfusion injury by increasing cGMP concentrations and 
suggested that the cAMP-to-cGMP ratio might play an important role in NO 
induced cardioprotection. Maulik and co-workers (1995) showed that NO plays 
a significant role in transmembrane signalling in the ischaemic myocardium. 
This group suggested that NO signalling is switched off due to inactivation of 
NO by reactive oxygen species and was the first to suggest that reactive 
oxygen species may alter NO-cGMP signalling.  
 
Increases in cAMP concentrations associated with ischaemia would increase 
Ca2+ concentrations and exacerbate ischaemic/reperfusion injury (Du Toit et 
al., 2001). In this regard it is possible that cGMP may attenuate this type of 
injury by inhibiting the cAMP induced increase in the slow inward calcium 
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current, thus leading to a decrease in cytosolic calcium levels (Summi and 
Sperelakis, 1995). Therefore, cGMP appears to be an endogenous intracellular 
cardioprotectant (Pabla et al., 1995). 
 
Cardiac stress adaptation is possibly jeopardized in hyperlipidaemia due to 
altered NO-cGMP pathway function in vascular and myocardial tissue. 
Szilvassy and co-workers (2001) found that a cholesterol-enriched diet 
decreased both vascular NO and cGMP concentrations and increased aortic 
O2- production. Several other studies have also shown that a high cholesterol 
diet impairs NO-cGMP signalling in both endothelium and non-endothelial cells 
with a significant decrease in cardiac NO-concentrations (Deliconstantinos et 
al., 1995; Ferdinandy et al., 1997; Scekeres et al., 1997). Giricz and co-
workers (2003) found an increase in O2- production with decreased cardiac 
NO-concentrations in cholesterol-fed rats. However, nitric oxide synthase 
(NOS) activity was unchanged. These data suggest that NO synthesis was not 
impaired, but that increased O2- production was responsible for the decreased 
NO-concentrations in the hyperlipidaemic myocardium. Furthermore, 
hyperlipidaemia stimulates ONOO- generation in the heart, which leads to 
myocardial dysfunction (Onody et al., 2003). Newaz and co-workers (2003) 
showed an antioxidant protection by γ-tocotrienols in hypertensive rats when 
compared with normotensive control animals. These authors suggested that 
improved NOS activity in blood vessels and increased NO availability were 
mediated through the antioxidant properties of γ-tocotrienol where it effectively 
scavenges the free radicals. Venditti and co-workers (1999) also reported that 
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vitamin E treatment offers protection against ischaemia/reperfusion-induced 
oxidative stress, but the precise mechanism of action is unclear.  
 
Diniz and co-workers (2004) showed that changes in dietary fatty acid 
composition affect cardiac oxidative stress. These authors showed that, 
despite their beneficial effects on serum lipid concentrations, diets rich in 
polyunsaturated fatty acids (PUFAs) are deleterious to the heart by increasing 
cardiac susceptibility to lipid peroxidation. PUFA-fed rats also showed 
diminished SOD activities as compared to saturated fatty acid (SFA)-fed rats in 
this particular study. Although many animal feeding studies have shown that 
fish oil diets rich in n-3 PUFAs prevent ischaemia-induced cardiac arrhythmias 
(Nair et al., 1997; Kang and Leaf 2000; Jump, 2002), only a few reports have 
been published on the protective effects of RPO-supplementation against 
ischaemia/reperfusion injury (Abeywardena et al., 1991; Charnock et al., 1991; 
Abeywardena and Charnock, 1995).  
 
We speculate that compositional changes in myocardial phospholipid fatty 
acids during ischaemia may be involved in the regulation of several signal 
transduction pathways in the heart in direct response to ischaemia/reperfusion-
induced injury. One of the best-characterized signal transduction pathways in 
the heart is the family of mitogen-activated protein kinases (MAPKs). The 
MAPKs are a family of serine-threonine kinases that are activated in response 
to a variety of extracellular stimuli (Robinson and Cobb, 1997; Ip and Davis, 
1998). Three major MAPKs, including extracellular signal-regulated protein 
kinase (ERK), p38, and c-Jun N-terminal protein kinase (JNK) have been 
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implicated in the response to ischaemia and reperfusion in the heart 
(Bogoyevitch et al., 1996; Knight and Buxton, 1996). All three MAPKs have 
been shown to play pivotal roles in transmission of signals from cell surface 
receptors to the nucleus and are involved in cell growth, differentiation and 
apoptosis (Mansour et al., 1994; Leppa et al., 1998; Nemoto et al., 1998). 
Another potential target of RPO might be the serine/threonine kinase PKB/Akt. 
PKB/Akt contains a pleckstrin homology (PH) domain that is part of a slightly 
larger portion in the NH2 terminus, called the Akt homology domain. The 
phosphoinositide 3-kinase (PI3-K) product phosphatidylinositiol-3,4-
bisphosphate bind in vitro directly to the PH domain and increases enzyme 
activity (Downward, 1998). PKB/Akt has been shown to be activated by factors 
that stimulate PI3-K including thrombin, platelet-derived growth factor, and 
insulin (Downward, 1998). There is also increasing evidence that the PKB/Akt 
pathway participates in ischaemia/reperfusion-induced injury (Brar et al., 2002; 
Andreucci et al., 2003).  
 
In order to assess the mechanisms of protection, the isolated perfused rat 
heart model was used to determine whether dietary RPO-supplementation was 
associated with changes in the regulation of the MAPKs and PKB/Akt in 
ischaemia/reperfusion. To our knowledge no previous studies have 
investigated the effect of dietary RPO-supplementation on these signalling 
pathways during and after ischaemia. 
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1.1 Aims of the study 
 
The aims of this study were: 
1) to determine whether dietary RPO-supplementation protects against 
ischaemia/reperfusion injury in the isolated perfused rat heart from animals 
on a standard rat chow diet  
2) to determine whether dietary RPO-supplementation offers the same 
protection when cholesterol is added to the diet  
3) to elucidate the mechanisms of protection which include the NO-cGMP 
signalling pathway, myocardial total phospholipid fatty acid compositional 
changes during ischaemia and MAPK, PKB/Akt and caspase activities. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Dietary fats and oils in health 
A balanced diet, including oils and fats that supply energy and essential fatty 
acids is needed for good health. The World Health Organization (WHO) 
recommends that humans consume about 20-25 kg oils and fats per capita per 
year (Ong and Goh, 2002). 
 
There are many sources of oils and fats, but soybean, palm oil, sunflower seed 
oil and rape seed oil constitute 60-70% of the world’s production (Ong and 
Goh, 2002). Fats and oils are classified as saturated, monounsaturated and 
polyunsaturated depending on which fatty acids are dominant. The fatty acid 
compositions of the most important oils and fats are summarized in Table 2.1. 
 
Plant oils, like coconut oil and palm oil, can be considered highly structured, 
usually having the sn-2 positional fatty acids unsaturated and the 1,3-fatty 
acids saturated on the triacylglycerol molecule. The belief that palm oil should 
be classified nutritionally with saturated fats is therefore debatable. 
Furthermore, research has also confirmed that palm oil is a non-genetically 
modified, cholesterol-free, trans-free oil that contains phytonutrients such as α-
carotene, β-carotene, vitamin E tocopherols and tocotrienols, lycopene and 
other carotenoids (Goh et al., 1985; Sundram et al., 2003). These findings 
merit a re-evaluation of the nutritional properties of palm oil and palm olein 
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particularly since it has become one of the most important edible oils for 
human consumption worldwide. 
  
Table 2.1 Saturated, monounsaturated and polyunsaturated fatty acids in 
palm products, other oils and fats 
 
Oil SFA MUFA PUFA P/S 
ratio 
U/S 
ratio 
P2/S2 
ratio 
U2/S2 
ratio 
Rape seed 
Canola 
Sunflower 
Olive 
Corn 
Soybean 
Groundnut 
Cotton seed 
Lard 
Palm olein 
Palm oil 
Red palm oil 
Cocoa butter 
Butter 
Hydrogenated 
soybean a 
Palm kernel 
Coconut 
5,0 
7,0 
11,7 
13,0 
13,3 
16,0 
20,0 
27,7 
43,0 
46,8 
49,5 
50.8 
60,0 
63,4 
64,0+ 
trans 
84,0 
92,2 
71,0 
61,0 
18,0 
79,1 
28,4 
23,5 
38,7 
19,8 
47,0 
41,5 
40,3 
38.3 
36,5 
32,5 
 
26,0 
14,0 
6,2 
24,0 
32,0 
68,6 
7,9 
58,3 
60,5 
41,3 
52,5 
10,0 
12,0 
9,6 
10.9 
3,4 
4,5 
 
4,0 
2,0 
1,6 
4,8 
4,67 
5,9 
0,6 
4,4 
3,8 
2,1 
1,9 
0,2 
0,3 
0,2 
0.2 
0,2 
0,1 
 
0,1 
0,02 
0,02 
 
19,0 
13,3 
7,4 
6,7 
6,5 
5,3 
4,0 
2,6 
1,3 
1,1 
1,0 
1.0 
0,7 
0,6 
 
0,5 
0,2 
0,1 
95,0 
155,0 
- 
10,6 
28,0 
64,0 
14,8 
6,32 
0,04 
6,9 
1,7 
- 
2,3 
0,03 
 
- 
- 
0,02 
166,0 
330,0 
- 
73,0 
39,0 
85,0 
38,0 
8,8 
0,2 
22,0 
6,7 
- 
24,0 
0,2 
 
- 
- 
0,05 
 
P/S and U/S: polyunsaturated/saturated and monounsaturated+ polyunsaturated/ 
saturated fatty acid ratios, respectively. P2, S2, U2: polyunsaturated, saturated and total 
unsaturated fatty acids, respectively, at position sn-2 of the triacylglycerol molecule.  
a Typical sample, saturated 22%, trans fatty acids 42%.  
(reproduced from Ong and Goh, 2002) 
 
2.2 Fatty acids 
2.2.1 Saturated-, monounsaturated- and polyunsaturated fatty acids in 
cardiovascular health 
 
Lipids are important dietary constituents and serve in the body as an efficient 
source of energy when stored in adipose tissue. They are also required by the 
body for cell structure and membrane function and as a source of precursors 
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for eicosanoid synthesis. Lipid components like cholesterol and phospholipids 
regulate membrane-associated functions such as activities of membrane 
bound enzymes, receptors and ion channels (Clandinin et al., 1991).  
 
Lipids are composed of fatty acids of different chain lengths and degrees of 
saturation. The differences in chain length and degrees of saturation are 
known to influence cardiovascular health (Nair et al., 1997). Fatty acids are 
classified into three types, namely saturated fatty acids (SFAs), 
monounsaturated fatty acids (MUFAs) and polyunsaturated fatty acids 
(PUFAs). The three major fatty acid families found in mammalian tissue are the 
n-9 series, the n-6 series and the n-3 series. Figure 2.1 shows the biosynthesis 
pathway of long chain PUFAs in animals (Pereira et al., 2003).  
 
The main PUFA in the Western diet is linoleic acid, found mostly in vegetable 
oils such as safflower seed oil, sunflower seed oil, cotton seed oil, corn oil and 
soybean oil (Nair et al., 1997). The common SFAs in our diet are myristic-, 
palmitic- and stearic acids derived largely from animal fats, dairy products and 
manufactured foods. Saturated fatty acids such as palmitic acid (C16:0), can 
be synthesised from carbohydrates present in the diet (Nair et al., 1997). 
Palmitic acid can then be elongated to stearic acid (C18:0). The MUFA content 
of our diet is accounted for by oleic acid (C18:1), the predominant component 
of canola oil, olive oil and sunola oil (Nair et al., 1997).  
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Figure 2.1 Biosynthesis pathway of long-chain PUFAs in animals. The common 
pathway for synthesis of n-6 and n-3 long chain fatty acids is shown in bold 
arrows and retroconversion is shown in dashed, gray arrows (reproduced from 
Pereira et al., 2003)  
 
The Western diet generally includes at least 30-40% of its energy as fat, 
resulting in a 40% energy intake from lipid sources having SFAs and PUFAs 
(Schrauwen and Westerterp, 2000). Current recommendations are to increase 
dietary vegetable oils to increase the ratio of PUFAs to SFAs, lower serum 
cholesterol and indirectly prevent atherosclerosis (Heyden, 1994). However, 
one could ask whether the increase in PUFA consumption, despite the 
decrease in serum cholesterol, is really good for health. Fats high in PUFAs 
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are more susceptible to oxidation than SFAs. Therefore, PUFAs in the 
absence of adequate antioxidants increase oxidative stress in the heart and 
contribute to cardiac dysfunction and myocardial damage by increasing cardiac 
susceptibilty to lipid peroxidation. (Mehta et al., 1994; Esposito et al., 1999; 
Hart et al., 1999; Droge, 2002; Faine et al., 2002; Novelli et al., 2002; Diniz et 
al., 2004).  
 
Little is known about the metabolic effects of dietary fatty acids on markers 
used to evaluate oxidative stress in the heart. However, Diniz and co-workers 
(2004) showed that rats on a high SFA diet had lower myocardial 
hydroperoxide concentrations than did PUFA-supplemented animals. This 
demonstrates the importance of the PUFA:SFA ratio on lipid peroxidation. The 
readiness with which fatty acids peroxidize is proportional to the number of 
double bonds, and a positive correlation between the amount of PUFA in the 
diet and the rate of microsomal lipid peroxidation has been demonstrated in 
rats (Mehta et al., 1994). The oxidative stability of the cardiac cells is 
determined by the balance between factors such as PUFAs, which change the 
PUFA:SFA ratio in the membrane and enhance the sensitivity to lipid 
peroxidation and the levels of antioxidants (Diniz et al., 2004). These 
observations support the concept that the sensitivity of cardiac tissue to 
oxidative stress may depend on dietary factors. 
 
There are many nutritional qualities and benefits of the dietary use of palm oil. 
Palm oil, like other vegetable oils, is cholesterol free. Having a moderate level 
of saturation, it does not require hydrogenation for use as a fat component in 
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foods and, as such, does not contain trans fatty acids (Cottrell, 1991). It is rich 
in natural antioxidants, which makes it a safe, stable and versatile oil with 
many positive health and nutritional attributes (Nagendran et al., 2000). 
 
2.2.2 Essential fatty acids 
Essential fatty acids (EFAs) are defined as those fatty acids which cannot be 
biosynthesised or are synthesised in inadequate amounts by animals and 
humans that require these nutrients for various physiological processes such 
as growth and maintenance of health (Horrobin, 1990).  
 
Linoleic acid (C18:2n-6; LA) and α-linolenic acid (C18:3n-3; ALA), the parents 
of the n-6 and n-3 family of fatty acids, respectively, are essential fatty acids 
that cannot be synthesised in the body and have to be supplied by diet (Figure 
2.2; Nair et al., 1997). Linoleic acid is found mostly in vegetable oils such as 
safflower seed oil, sunflower seed oil, cotton seed oil, corn oil and soybean oil. 
Other long chain PUFAs, like arachidonic acid (C20:4n-6; AA), are synthesised 
in human tissue via desaturation and chain elongation from LA which is by far 
the dominant precursor fatty acid for eicosanoid formation provided by the 
Western diet. Significant amounts of α-linolenic acid are found in green 
vegetables and in vegetable oils like linseed oil, canola seed oil and soybean 
oil. Eicosapentaenoic acid (C20:5n-3; EPA) and docosahexaenoic acid 
(C22:6n-3; DHA) are synthesised via a series of alternating desaturation and 
chain elongation steps from ALA and are also found in high concentrations in 
fish oils. LA and ALA compete for desaturation and chain elongation, therefore 
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a proper balance is essential to optimize AA and DHA in membranes (Nair et 
al., 1997).  
 
 
2.2.3 Physiological role of essential fatty acids  
Although many animal feeding studies have shown that fish oil diets rich in n-3 
PUFAs prevent ischaemia-induced cardiac arrhythmias (Nair et al., 1997; Kang 
and Leaf, 2000; Jump, 2002), only a few reports have been published on the 
protective effects of palm oil-supplementation against ischaemia/reperfusion 
injury (Abeywardena et al., 1991, Charnock et al., 1991; Abeywardena and 
Charnock, 1995). Several mechanisms for protection by fish oil diets have 
been proposed. However, all the mechanisms suggested appear to be 
interrelated and it is not known whether their effects are independent or are 
compounded and also in what sequence they take place (Nair et al., 1997).  
 
The polyunsaturated fatty acids, arachidonic acid (C20:4n-6; AA) and 
eicosapentaenoic acid (C20:5n-3; EPA) are metabolised through 
cyclooxygenase and lipoxygenase pathways to form eicosanoids, including 
prostaglandins (PGs), thromboxanes (TXs), prostacyclins (PGIs) and 
leukotrienes (LTs) (Figure 2.2). 
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Figure 2.2 Biosynthesis of eicosanoids from dietary fatty acids. 
LT=leukotrienes; PG=prostaglandins; TX=thromboxane (reproduced from Nair 
et al., 1997) 
 
Eicosanoids are known to have a variety of cardiovascular effects: 1) all 
prostaglandins derived from AA are arrhythmogenic, of which PGF2 is the most 
potent, 2) PGE1 from Dihomo-γ-linolenic acid (C20:3n-6; DGLA) appears to 
have concentration-dependent effects with low concentrations being 
antiarrhythmic and high concentrations arrhythmogenic, 3) the precursor fatty 
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acids (free n-6 series AA and EPA n-3 series) are able to prevent eicosanoid-
induced arrhythmias, 4) the eicosanoids derived from EPA are generally less 
arrhythmogenic, 5) lipoxygenase metabolites of both AA and EPA are neither 
arrhythmogenic nor antiarrhythmic (Li et al., 1997; Yunyuan et al., 1997). The 
role of AA in arrhythmias is of particular interest. Most investigations on the link 
between fish oils and cardiovascular disease have demonstrated competition 
between AA and EPA to become substrates in the production of eicosanoids. 
When fish oils are included in the diet, the n-3 PUFAs (EPA and DHA) 
compete with AA in several ways: 1) they inhibit delta 6 (Δ6) activity to 
decrease AA biosynthesis (Garg et al., 1988), 2) they compete with AA for the 
sn-2 position in triacylglycerols and membrane phospholipids and thereby 
reduce plasma and cellular levels of AA (Siess et al., 1988), 3) EPA competes 
with AA as the substrate for the cyclooxygenase enzyme thus inhibiting the 
production of thromboxane A2 (TXA2) by platelets (Fischer and Weber, 1984).  
 
Research has shown that dietary supplementation of different edible oils may 
influence cardiovascular function due to compositional changes in the PUFAs 
of the myocardial membrane phospholipids after ischaemia and reperfusion 
(Abeywardena et al., 1991; Abeywardena and Charnock, 1995). The presence 
of fish oil in the diet results in increased incorporation of n-3 PUFAs (EPA and 
DHA), mainly at the expense of n-6 unsaturated arachidonic acid. The 
significant increase in DHA associated with fish oil supplementation is likely to 
be due not only to a direct incorporation of DHA from the diet, but also to an 
increased elongation and further desaturation of EPA (Abeywardena and 
Charnock, 1995). Both fish oil- and RPO-supplementation caused a significant 
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inhibition of myocardial thromboxane A2 production. Abeywardena and co-
workers (1991) speculated that n-3 PUFAs (EPA and DHA) might act as 
specific inhibitors of thromboxane synthases, whereas the effect of RPO is 
unlikely to be mediated via fatty acids. Charnock and co-workers (1991) 
investigated the effect of long-term feeding with various dietary fats and oils on 
cardiac arrhythmias in an animal model. These authors showed that dietary 
supplementation with saturated animal fat (SF) increased the susceptibility to 
develop cardiac arrhythmias under ischaemic stress whereas the 
polyunsaturated fatty acids of sunflower seed oil (SSO) reduced this 
susceptibility. RPO-supplementation produced results that lay between those 
for the SF and SSO groups. Furthermore, the number of animals displaying 
severe ventricular fibrillation was reduced after RPO-supplementation when 
compared with SF feeding (Charnock et al., 1991). From the limited data 
available, it is unclear whether these results are related to the ratio of 
polyunsaturated to saturated fatty acids of the diets, or to the fatty acid 
composition of the myocardial membranes. These effects may even been 
mediated by differential actions of the dietary fats on myocardial eicosanoid 
production. In addition, it has been suggested by Gapor and co-workers (1989) 
that palm oil antioxidants in a palm oil/fish oil-supplementation may also prove 
to be useful for protection of the less stable polyunsaturated fatty acids in fish 
oils.  
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2.3 Cholesterol-enriched diets 
2.3.1 Introduction to cholesterol-enriched diets 
A high-cholesterol diet is regarded as an important factor in the development of 
cardiovascular disease, since it leads to development of hyperlipidaemia, 
atherosclerosis and ischaemic heart disease (Puskas et al., 2004).  
 
2.3.2 Mechanisms of myocardial effects of hyperlipidaemia 
The exact biochemical mechanisms of the direct effects of high-cholesterol diet 
hyperlipidaemia on the myocardium are still a question of debate. However, 
the following mechanisms have been shown to play a role in the cardiac 
effects of hyperlipidaemia: 1) inhibition of the mevalonate pathway (Ferdinandy 
et al., 1998), 2) decrease in NO bioavailability and cGMP metabolism 
(Ferdinandy et al., 1997; Szekeres et al., 1997), 3) increase in free radical and 
peroxynitrite production (Onody et al., 2003), 4) inhibition of heat shock 
response (Csont et al., 2002), 5) expression of oxidized low-density lipoprotein 
receptors which induced apoptosis (Chen et al., 2002). Recent studies 
identified gene activity changes in atherosclerotic plaques in human and 
animal blood vessels and rat hearts (Puskas et al., 2004). 
 
2.4 Palm oil 
2.4.1 Introduction to palm oil 
Crude palm oil is produced from the fruit of the Elaeis guineensis tree 
(Nagendran et al., 2000; Sundram et al., 2003) and has a long history of food 
use dating back over 5 000 years. Palm oil is one of the 16 edible oils 
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possessing an FAO/WHO Food standard under the Codex Alimentarius 
Commission Programme, which comprises 122 member countries (Codex 
Alimentarius, 1983). Palm oil is a traditional food source native to West Africa. 
From its origin in Africa, oil palm has crossed the oceans of the world to 
become an important plantation crop in countries like Malaysia. Here it 
emerged as the most prolific oil bearing crop in the world. A single tree has an 
economic lifespan of 20-30 years and annually bears 10-12 fruit bunches, each 
weighing between 20-30 kg.  
 
2.4.2 Composition of palm oil 
Crude palm oil consists of glycerides and small quantities of non-glyceride 
components including free fatty acids, trace metals, moisture and impurities, 
and minor components. The minor components in crude palm oil are 
carotenoids, tocopherols, tocotrienols, sterols, phospholipids, squalene and 
hydrocarbons (Goh et al., 1985, Sundram et al., 2003). Of these the 
carotenoids, tocopherols and tocotrienols are the most important minor 
components and together they contribute to the stability and nutritional 
properties of palm oil (Ooi et al., 1996). A novel process involving pre-
treatment of crude palm oil, followed by deacidification and deodorization using 
molecular distillation, can be used to produce a carotene-rich refined edible 
palm oil. The product is a refined red palm oil that meets standard refined 
edible oil specifications and retains up to 80% of the carotene and vitamin E 
originally present in the crude palm oil. The oil contains no less than 500 ppm 
carotene, 90% of which is present as α- and β-carotene. The vitamin E content 
is about 500 ppm of which 70% is in the form of tocotrienols (mainly as α-, β- 
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and γ tocotrienols). Other important minor components present in this oil are 
ubiquinones and phytosterols (Nagendran et al., 2000; Sundram et al., 2003). 
 
2.4.3 Modulation of lipids and lipoproteins by dietary palm oil-
supplementation 
 
Since a high blood cholesterol level is a risk factor for cardiovascular disease, 
numerous studies have investigated the effects of dietary lipids on cholesterol 
levels. Research has shown that most unsaturated fatty acids have a 
cholesterol-lowering effect, whereas saturated fatty acids increase serum 
cholesterol (Diniz et al., 2004).  
 
Several clinical trials evaluated the effect of palm oil on blood lipids and 
lipoproteins and showed that palm oil does not raise serum total cholesterol 
(TC) or LDL cholesterol concentrations to the extent expected based on its 
fatty acid composition (Chandrasekharan, 1999; Theriault et al., 1999; 
Kritchevsky et al., 2000; Sundram and Basiron). These studies suggest that 
the cholesterolaemic effects of palm oil depend on several factors including 
fatty acid composition (Table 2.2). The saturated fatty acids of palm oil consist 
of palmitic acid (44%) and stearic acid (5%), and the unsaturated fatty acids 
are oleic acid (39%) and linoleic acid (10%) (Ong and Goh, 2002). 
 
Many studies have confirmed the nutritional value of palm oil as a result of the 
high monounsaturation at the crucial sn-2 position of the oil’s triacylglycerols, 
making this oil as healthy as olive oil. The monounsaturated and 
polyunsaturated fatty acids constitute 87% of the total fatty acids at the sn-2 
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position (Ong and Goh, 2002). Comparison of palm oil with a variety of 
monounsaturated edible oils including rape seed, canola and olive oils has 
shown that serum cholesterol and LDL-cholesterol are not elevated by palm oil 
(Sundram and Basiron). Furthermore, substitution of palmitic acid from palm oil 
for the lauric acid and myristic acid combination of palm kernel oil and coconut 
oil leads to a decrease in serum cholesterol and LDL-cholesterol (Ong and 
Goh, 2002).  
 
Research has shown that the contribution of dietary fats to blood lipids and 
cholesterol modulation is a sequence of the digestion, absorption and 
metabolism of the fats. Lipolytic hydrolysis of palm oil’s glyceride containing 
predominantly oleic acid at the sn-2 position and palmitic and stearic acids at 
the sn-1 and sn-3 positions allow for the ready absorption of the sn-2 
monoglycerols, while the saturated free fatty acids remain poorly absorbed. 
Therefore, dietary palm oil in balanced diets (when a moderate-fat, moderate-
cholesterol diet is consumed) generally reduces blood cholesterol and 
triacylglycerol, while raising the HDL-cholesterol (Ong and Goh, 2002).  
 
Apart from these fatty acids (Table 2.2), there is evidence that the tocotrienols 
in palm oil products may have a hypocholesterolaemic effect. This is mediated 
by the ability of the tocotrienols to suppress 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase, a rate-limiting enzyme in cholesterol 
biosynthesis (Khor et al., 1995; Theriault et al., 1999; Sundram and Basiron) 
(Figure 2.3).  
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Table 2.2 Fatty acid composition of palm oil and its effects on blood cholesterol  
Fatty acid Composition (%) Effects on blood cholesterol 
 
Lauric acid 12:0 
Myristic acid 14:0 
Palmitic acid 16:0 
Stearic acid 18:0 
Oleic acid 18:1 
Linoleic acid 18:2 
Others 16:1;18:3 
Total in palm oil 
 
 
0,2 
1,1 
44,3 
4,6 
39,0 
10,5 
0,3 
100,0 
 
Negative or neutral 
Negative 
Neutral or slightly negative 
Neutral 
Positive 
Positive 
Positive 
Positive 
Palm oil and palm olein contain insignificant amounts of cholesterol-elevating saturated 
fatty acids (12:0 and 14:0); negative means cholesterol-raising; positive means no effect 
or decreasing cholesterol (reproduced from Ong and Goh, 2002) 
 
 
2.4.4 Epidemiological studies: lipids 
After almost 50 years of little concern about the increased consumption of 
hydrogenated fats at the expense of saturated fatty acids, Mensink and Katen 
(1990) showed that trans fatty acids increased serum total and LDL-cholesterol 
and decreased the beneficial HDL-cholesterol. Research confirmed these 
results which have since been seen as the standard of comparison that leads 
to the conclusion that trans fatty acids increased the risk for cardiovascular 
disease similarly to saturated fatty acids (Wood et al., 1993; Sundram et al., 
1997). The Harvard research group led by Willet and co-workers (1999) 
spearheaded studies elucidating the effects of trans fatty acids using 
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epidemiological data from the Nurses Health Study consisting of 85 095 
women.  
 
Acetyl CoA 
 
 
 
β -Hydroxy-β -methylglutaryl-CoA (HMG-CoA) 
      
 
   HMG-CoA Reductase 
(HMG-CoA) 
 
Mevalonate 
 
 
 
Farnesyl    Farnesol 
 
 
 
Squalene 
 
        Tocotrienol 
 
 
 
Cholesterol  
 
Figure 2.3 Mechanism of the cholesterol suppressive action of tocotrienol. 
Tocotrienols prenylated side-chain is thought to induce prenyl pyrophosphate 
pyrophosphatase that catalyzes the dephosphorylation of farnesyl with a 
concomitant increase in cellular farnesol. Farnesol, in turn, downregulates HMG 
CoA reductase activity by a post-transcriptional process involving protein 
degradation. This action is different from that of cholesterol, which exerts a 
feedback transcriptional effect on HMG-CoA reductase activity (reproduced 
from Theriault et al., 1999). 
 
 
They examined the association between trans fatty acids and incidence of non-
fatal myocardial infarction or death from coronary heart disease in these 
women who were followed for eight years. A positive and significant 
association between trans fatty acids and Coronary Heart Disease (CHD) was 
apparent. A follow-up study in 239 patients (Ascherio et al., 1994) also showed 
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 25
a positive association between trans fatty acids (in margarine) and myocardial 
infarction. Trans fatty acid intake was associated with increased serum total 
and LDL-cholesterol and negatively related to HDL-cholesterol in men suffering 
a myocardial infarction.  
 
The relative risk for Cardiovascular Disease (CVD) was increased by 27% as a 
result of trans fatty acid consumption. These studies clearly established an 
association between trans fatty acid consumption and increased incidence and 
death from CVD and it was estimated that almost 80 000 deaths in the United 
States alone are associated with continued consumption of foods rich in trans 
fatty acids.  
 
2.4.5 Cardiovascular protection offered by palm oil components 
2.4.5.1 Carotenoids  
A comparison between Carotino palm oil and other vegetable oils (Table 2.3) 
shows that palm oil is the only one that is naturally rich in carotenoids. It is 15 
times richer in carotenes than carrots and contains 50 times more carotenes 
than tomatoes (Kamen, 2000).  
Table 2.3 Comparison between Carotino palm oil and other vegetable oils 
 Carotino 
Premium 
(Palm oil) 
Carotino 
classic 
(Palm oil) 
Sunflower 
seed oil 
Safflower 
seed oil  
Corn oil Olive 
oil 
Vitamin E 
mg/kg 
80  50  39 17,4  20,7 7,6 
Carotene 
mg/kg 
50  12,5 0 0 0 0  
(reproduced from Kamen, 2000) 
 
Carotenoids are a group of red, orange and yellow pigments found in plant 
foods, particularly fruit and vegetables. β-Carotene is an effective antioxidant 
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as it is one of the most powerful singlet oxygen quenchers. It can dissipate the 
energy of singlet oxygen, thus preventing this active molecule from generating 
free radicals (Bagchi and Puri, 1998).  
 
2.4.5.2 Vitamin E (tocopherols and tocotrienols) 
Vitamin E is the collective name for eight compounds, namely four tocopherols 
and four tocotrienols (Bagchi and Puri, 1998). The biological activity of vitamin 
E has generally been associated with its well-defined antioxidant property, 
especially against lipid peroxidation in biological membranes (Theriault et al., 
1999). Vitamin E is highly lipophilic and is believed to be the major lipid-soluble 
chain-breaking antioxidant found in blood plasma and protects polyunsaturated 
fatty acids in cell membranes from peroxidation (Bagchi and Puri, 1998). 
Within biological membranes, vitamin E is believed to intercalate with 
phospholipids and provide protection to PUFAs. Oxidation of PUFAs leads to 
disturbances in membrane structure and function and is damaging to cell 
structure. Vitamin E is highly efficient at preventing the auto-oxidation of lipids 
and it appears as if this is its primary function in biological tissue (Burton and 
Ingold, 1981). It is a singlet oxygen quencher and neutralises these highly 
reactive and unstable molecules (Kamal-Eldin and Appelqvist, 1996). α-
Tocopherol is considered to be the most active form of vitamin E. However, 
research has suggested tocotrienol to be a better antioxidant (Serbinova et al., 
1991; Suzuki et al., 1993). 
 
More recently, alternative non-antioxidant functions of vitamin E have been 
proposed and in particular that of a “gene regulator”. Effects of vitamin E have 
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been observed at the level of mRNA or protein and could be consequent to 
regulation of gene transcription, mRNA stability, protein translation, protein 
stability and post-translational events (Ricciarelli et al., 2001; Assi et al., 2002).  
Moreover, tocotrienol has been shown to possess novel hypocholesterolaemic 
effects together with an ability to reduce the atherogenic apolipoprotein B and 
lipoprotein(a) serum concentrations (Hood, 1995). In addition, tocotrienol has 
been suggested to have an anti-thrombotic and anti-tumour effect indicating 
that tocotrienol may serve as an effective agent in the prevention and/or 
treatment of cardiovascular disease and cancer (Guthrie et al., 1995; Qureshi 
et al., 1997).  
 
Vitamin E is known to afford protection against ischaemia and reperfusion 
injury (Bagchi and Puri, 1998). Epidemiological evidence strongly associates 
high vitamin E intake with reduced risk of coronary heart disease. Stephens 
and co-workers (1996) showed that vitamin E treatment significantly reduced 
the risk of cardiovascular deaths as well as non-fatal myocardial infarctions.  
 
While all vegetable oils have tocopherols, palm oil has also tocotrienols in 
abundance. In fact, among vegetables, palm oil is the only rich source of 
tocotrienols (Kamen, 2000). In rat ischaemia/reperfusion studies, α-tocotrienol 
protected more efficiently against oxidative stress than α-tocopherol as shown 
by improved reperfusion function recovery in a Langendorff perfused rat heart 
(Serbinova et al., 1992). This higher antioxidant activity of the tocotrienols has 
been attributed to a number of mechanisms including efficient interaction with 
free radical species, higher recycling efficiency of the chromanoxyl radical and 
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uniform distribution of tocotrienols in membrane bilayers (Serbinova et al., 
1991; Theriault et al., 1999).  
 
Yoshida and co-workers (2003) carried out a comparative study on the action 
of tocopherols and tocotrienols as antioxidants and found that: 1) the 
tocopherols and tocotrienols exerted the same effects on free radical 
scavenging and lipid-peroxidation in solution and liposomal membranes, 2) 
tocopherols increased the rigidity of liposomal membranes more significantly 
than tocotrienols, 3) tocopherols and tocotrienols showed similar mobilities 
within the liposomal membranes, but tocotrienols were more readily transferred 
between the membranes and incorporated into the membranes than 
tocopherols. These findings are in agreement with data reported previously by 
Sen and co-workers (2000) that tocotrienols were more readily incorporated 
into cultured cells than tocopherols. Therefore, tocotrienols appear to be more 
effective antioxidants than tocopherols due to higher uptake.  
 
Although both tocopherols and tocotrienols are natural antioxidants, the 
apparent ‘antioxidant activities’ of tocopherols and tocotrienols may vary 
depending on the experimental conditions applied. The inconsistent results 
reported previously for the antioxidant activities of tocopherols and tocotrienols 
may be ascribed partly to the different experimental conditions and evaluation 
methods used (Yoshida et al., 2003). 
 
Toxicological and pharmacological studies in rats found that palm tocotrienols 
are safe without adverse side effects when consumed at doses as high as  
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2500 mg per kg body weight. The recommended human dosage is 50-100 mg 
per 60 kg body weight (Oo et al., 1992). 
 
2.4.5.3 Ubiquinones 
Crude palm oil contains small quantities of ubiquinones of which coenzyme Q10 
(CoQ10) is the most common. Although it is present at a relatively low 
concentration in crude palm oil, CoQ10 has been reported to boost the immune 
system, relieve angina and afford protection against heart disease and 
reduction of high blood pressure (Nagendran et al., 2000). 
 
CoQ10 plays a major role in the mitochondrial electron-transport system and as 
an antioxidant protects the ischaemic/reperfused myocardium in rats (Hano et 
al., 1994). Yokoyama and co-workers (1996) proposed that CoQ10 is a free 
radical scavenger and preserves coronary vessel mechanical function 
following ischaemia/reperfusion injury via a direct antioxidant mechanism.  
 
2.4.6 Palm oil protection against breast cancer 
Components of palm oil such as coenzyme Q10, tocotrienols and vitamin E 
succinate have possible protective effects against breast cancer (Guthrie et al., 
1995). 
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2.4.6.1 Coenzyme Q10 (CoQ10) protection 
Since the 1960’s studies have shown that cancer patients often have 
decreased blood levels of CoQ10 due to increased consumption of this 
coenzyme by oxygen free radical scavenging. In particular, breast cancer 
patients who underwent radical mastectomy were found to have significantly 
decreased tumour concentrations of CoQ10 compared to levels in normal 
surrounding tissues. Therefore, CoQ10 may have a protective effect on breast 
tissue (Portakal et al., 2000). 
 
CoQ10 has also demonstrated promise in treating breast cancer. In a clinical 
study 32 patients were treated with CoQ10 (90 mg) in addition to other 
antioxidants and fatty acids (Lockwood et al., 1994). Six of these patients 
showed partial tumour regression. In one of these cases the dose of CoQ10 
was increased to 390 mg and within one month the tumour was no longer 
palpable. Within two months the mammography confirmed the absence of 
tumour. In another case, a patient took 300 mg of CoQ10 for residual tumour 
tissue (post non-radical surgery) and within three months there was non-
residual tumour tissue. This overt complete regression of breast tumours in 
these two cases, coupled with further reports of disappearance of breast 
cancer metastases (liver and elsewhere) in several other cases (Lockwood et 
al., 1995), demonstrates the potential of CoQ10 therapy in breast cancer.  
 
Furthermore, there are promising results for the use of CoQ10 in protecting 
against heart damage related to chemotherapy. Animal studies found that 
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CoQ10 could reduce the adverse cardiac effects of these chemotherapy drugs 
(Folkers, 1996).  
 
2.4.6.2 Tocotrienol protection 
Tocotrienols elicit powerful anticancer properties and studies have confirmed 
tocotrienol activity to be much stronger than that of tocopherols (Schwenke et 
al., 2002). Tocotrienols possess the ability to stimulate the selective killing of 
cancer cells through programmed cell death (apoptosis) and to reduce cancer 
cell proliferation while leaving normal cells unaffected (Kline et al., 2001).  
 
2.4.6.3 Vitamin E succinate protection 
Vitamin E succinate, a derivative of fat-soluble vitamin E, has been shown to 
inhibit tumour cell growth in vitro and in vivo (Cameron et al., 2003). Since 
vitamin E is considered the main chain breaking lipophilic antioxidant in serum 
and tissue, its role as a potential chemopreventative agent and its use in the 
adjuvant treatment of aggressive human breast cancer appears reasonable.  
 
2.4.7 Effects of palm oil-supplementation on NO-cGMP signalling 
Nitric Oxide (NO) is an important regulator of both cardiac and vascular 
function and tissue reperfusion (reviewed by Ferdinandy and Schultz, 2003). 
Little is known about the effects and possible protective mechanisms of palm 
oil-supplementation against myocardial ischaemia/reperfusion injury, 
particularly pertaining to N0-cGMP signalling. 
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2.5 Role of nitric oxide in myocardial ischaemia and reperfusion 
2.5.1 Introduction to nitric oxide cardiovascular protection 
Ischaemic heart disease, which is characterized by insufficient blood supply to 
regions of the myocardium, develops as a consequence of many pathological 
conditions including hypertension, atherosclerosis, hyperlipidaemia and 
diabetes. The development of cardioprotective agents which improve 
myocardial function, decrease the incidence of arrthythmias, lessen the 
necrotic tissue mass and delay the onset of necrosis during 
ischaemia/reperfusion, is of great clinical importance (reviewed by Ferdinandy 
and Schultz, 2003).  
 
Over the past decade many studies have focused on the role of NO in 
myocardial ischaemia. The overwhelming majority of the studies published, 
support a cytoprotective role for NO (either endogenous or exogenous) in 
myocardial ischaemia/reperfusion injury, both in vitro and in vivo (reviewed by 
Bolli, 2001).  
 
Sources of basal NO production by Ca2+-dependent NO synthases (NOS) 
include coronary endothelium, endocardial endothelium, cardiac nerves and 
cardiomyocytes of the normal heart (Curtis and Pabla, 1997). NO serves a 
number of important physiological roles in the regulation of cardiac function 
including coronary vasodilation, inhibiting platelet and neutrophil actions, 
antioxidant effects, modulation of cardiac contractile function and inhibition of 
cardiac contractile energy consumption (Hare and Comerford, 1995; Xie and 
Wolin, 1996).  
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NO offers cardioprotection against ischaemia/reperfusion injury (Maulik et al., 
1995; Williams et al., 1995; Araki et al., 2000; Bolli, 2001). Several 
mechanisms of cardioprotection include stimulation of soluble guanylate 
cyclase and thus bringing about reduction of Ca2+, partly through activation of 
cGMP-dependent protein kinase and termination of chain propagating lipid 
radical reactions caused by oxidative stress (Rubbo et al., 1994).  
 
However, NO is detrimental when it is combined with superoxide (O2-) to form 
peroxynitrite (ONOO-), which rapidly decomposes to highly reactive oxidant 
species leading to tissue injury (Figure 2.4). There is a critical balance between 
cellular concentrations of NO, O2- and superoxide dismutase (SOD) which 
physiologically favours NO production, but in pathological conditions such as 
ischaemia and reperfusion, results in ONOO- formation (reviewed by 
Ferdinandy and Schultz, 2003). Illarion and co-workers (2002) reviewed the 
role of reactive oxygen species, focusing mainly on superoxide radicals (O2-), 
hydrogen peroxide (H2O2) and hydroxyl radical (.OH), which have long been 
implicated in the pathogenesis of ischaemia/reperfusion injury. These oxygen 
free radicals can react with nucleic acids, proteins and lipids, resulting in 
damage to the cell membrane or intracellular organelles. Vitamin E acts as a 
free radical scavenger that can react with oxygen, superoxide anion radicals 
and hydroxyl radicals (Wall, 2000; Abuda et al., 2004) (Figure 2.4). 
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Figure 2.4 Cellular mechanisms of nitric oxide (NO), superoxide (O2-), and 
peroxynitrite (ONOO-) actions. 
 
 
2.5.2 Mechanisms of cardiovascular protective effect of nitric oxide 
The precise mechanism(s) whereby NO protects the myocardium against 
ischaemia/reperfusion injury remains unclear. Some of the many hypotheses 
that have been put forward will be discussed.  
 
2.5.2.1 NO-cGMP signalling 
NO and/or its second messenger, cGMP, have been shown to exert a number 
of actions that are expected to be beneficial during myocardial ischaemia 
including inhibition of Ca2+ influx into myocytes, antagonism of the effects of β-
adrenergic stimulation, decreasing myocardial contractility and opening of 
sarcolemmal KATP channels. The reduced Ca2+ current may alleviate the Ca2+ 
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overload associated with acute myocardial ischaemia - one of the major 
mechanisms of ischaemic injury (reviewed by Bolli, 2001). 
 
NO is known to increase myocardial cGMP and it can be speculated that the 
protective effect of NO is related to a mechanism secondary to the stimulation 
of guanylyl cyclase within the vascular wall or in ventricular myocytes 
(Beresewics et al., 1995; Maulik et al., 1995; Depré et al., 1996) (Figure 2.4). 
NO donors administered during ischaemia possibly protect the myocardium by 
increasing tissue cGMP and decreasing cytosolic Ca2+ overload (Du Toit et al., 
2001). Du Toit and co-workers (2001) found that nitric oxide donor treatment 
reduces ischaemia/reperfusion injury by increasing cGMP concentrations and 
suggested that the cAMP-to-cGMP ratio might play an important role in 
cardioprotection. Maulik and co-workers (1995) showed that NO plays a 
significant role in transmembrane signalling in the ischaemic myocardium. This 
group suggested that NO signalling is switched off due to inactivation of NO by 
reactive oxygen species and was the first to suggest that reactive oxygen 
species may alter NO-cGMP signalling.  
 
Increases in cAMP concentrations associated with ischaemia would increase 
Ca2+ concentrations and exacerbate ischaemic/reperfusion injury (Du Toit et 
al., 2001). In this regard it is possible that cGMP may attenuate this type of 
injury by inhibiting the cAMP induced increase in slow inward calcium current, 
thus leading to a decrease in cytosolic calcium levels (Sumii and Sperelakis, 
1995). Therefore, cGMP appears to be an endogenous intracellular 
cardioprotectant (Pabla et al., 1995; Pabla and Curtis, 1995). 
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2.5.2.2 Cholesterol-enriched diet and NO-cGMP signalling  
It is well known that high cholesterol concentrations influence the NO-cGMP 
signalling pathway. Therefore, cardiac stress adaptation is possibly 
jeopardized in hyperlipidaemia due to altered NO-cGMP pathway function in 
vascular and myocardial tissue. Szilvassy and co-workers (2001) found that a 
cholesterol-enriched diet decreased both vascular NO and cGMP 
concentrations and increased aortic O2- and ONOO- production. Several other 
studies have also shown that a high-cholesterol diet impairs NO-cGMP 
signalling in both endothelium (Deliconstantinos et al., 1995) and non-
endothelial cells with a significant decrease in cardiac NO concentrations 
(Ferdinandy et al., 1997; Szekeres et al., 1997). Giricz and co-workers (2003) 
found that although cardiac NO-concentration in cholesterol-fed rats was 
decreased, nitric oxide synthase (NOS) activity was unchanged which may 
suggest that NO synthesis was not impaired. The mechanism leading to 
decreased cardiac NO level in hyperlipidaemia remains unknown. However, it 
is well known that hyperlipidaemia leads to increased production of reactive 
oxygen species (ROS) in the vasculature (Kojda and Harrison, 1999). For 
example, hyperlipidaemia stimulates ONOO- generation in the heart, which 
leads to myocardial dysfunction (Onody et al., 2003). It could be speculated 
that increased O2- production (Giricz and co-workers, 2003) is responsible for 
the decreased NO concentrations in the hyperlipidaemic myocardium since 
NADPH oxidase activity due to hyperlipidaemia is a major source of increased 
O2- production (Warnholtz et al., 1999).  
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Natural antioxidants can act as scavengers of damaging oxygen free radicals 
(Cotrell, 1991; Chandrasekharan, 1999; Theriault et al., 1999; Kritchevsky, 
2000; Wall, 2000). Vitamin E acts as a free radical scavenger that can react 
with oxygen, superoxide anion radicals and hydroxyl radicals (Wall, 2000; 
Abuda et al., 2004). Due to its lipid solubility, it is predominantly a chain 
breaking antioxidant within the lipoprotein (Wall, 2000; Abuda et al., 2004). 
Chow and co-workers (2002) reported that dietary vitamin E is capable of 
reducing the production and/or availibilty of not only O2-, but also NO and 
ONOO-. By reducing available O2- and NO, vitamin E may alleviate nitric 
toxicity via reduced formation of reactive ONOO-. However, it is not clear if the 
action of vitamin E to reduce the generation of O2- and other ROS species is 
independent of its antioxidant function (Chow and Hong, 2002). Newaz and co-
workers (2003) showed an antioxidant protection by γ-tocotrienols in 
hypertensive rats when compared with control animals. These authors 
suggested that improved NOS activity in blood vessels and increased NO 
availability were mediated through the antioxidant properties of γ-tocotrienol 
where it effectively scavenges the free radicals. Venditti and co-workers (1999) 
also reported that vitamin E treatment offers protection against 
ischaemia/reperfusion-induced oxidative stress. However, the precise 
mechanism of action is unknown. 
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2.5.2.3 Antioxidant properties of nitric oxide 
By virtue of its antioxidant properties, NO offers protection specifically through 
its ability to attenuate the deleterious free radical actions of O2- and to 
terminate ONOO- mediated lipid radical chain propagation (Rubbo et al., 1994). 
 
2.5.2.4 Nitric oxide and production of cytoprotective prostanoids 
A previously unrecognized mechanism by which NO protects the ischaemic 
myocardium has recently emerged, namely, stimulation of cyclooxygenase-2 
(COX-2) activity with consequent production of cytoprotective prostanoids such 
as prostaglandin (PGE2 and PGI2) (Shinmuri et al., 2000).  
 
2.5.2.5 Therapeutical potential of nitric oxide 
Research has shown that NO plays a fundamental biological role in protecting 
the heart against ischaemia/reperfusion injury. The recognition that production 
of NO represents nature’s own protective mechanism against ischaemia offers 
fertile practical implications. Many opportunities loom on the horizon for 
enhancing NO availability in a manner that would be therapeutically desirable 
(Bolli, 2001). 
 
2.6 Mitogen-activated protein kinases (MAPKs) 
2.6.1 Apoptosis  
Programmed cell death (apoptosis) is essential to many biological processes in 
multicellular organisms including embryonic development, immune responses, 
tissue homeostasis and normal cell turnover (reviewed by Lin, 2003). 
 39
Research has shown that both necrosis and apoptosis play a significant role in 
myocardial ischaemia/reperfusion injury (Kajstura et al., 1996). Stress 
conditions such as ischaemia (especially when followed by reperfusion) and 
oxygen free radicals can elicit cardiomyocyte apoptosis, as has been 
demonstrated in both cell cultures and isolated perfusion (reviewed by 
Feuerstein and Young, 1999).  
 
2.6.2 Signalling pathways and apoptosis 
Regulatory mechanisms controlling proliferation, differentiation or apoptosis of 
cells involve intracellular protein kinases that can transduce signals detected 
on the cell’s surface into changes in gene expression. There is growing 
evidence that multiple mitogen-activated protein (MAP) kinases and protein 
kinase B (PKB/Akt) are activated during ischaemia and/or reperfusion and may 
contribute to the structural and functional changes after myocardial 
ischaemia/reperfusion injury (Abe et al., 2000). However, reports on their 
precise roles are still conflicting (reviewed by Steenbergen, 2002). 
Three major MAP kinase cascades that have been extensively studied in the 
heart include extracellular signal regulated kinases (ERKs), c-Jun N-terminal 
kinases (JNK 1 and JNK 2), and p38 kinases, of which the p38α and p38β 
isoforms are found to play a role in myocardial tissue (Takeishi et al., 1999). 
MAP kinases are proline-directed serine/threonine kinases that are activated in 
response to a wide variety of stimuli including growth factors, G-protein 
coupled receptors and environmental stresses (Robinson and Cobb, 1997; 
Sugden and Clerk, 1998). The MAP kinases themselves require dual 
phosphorylation on a Threonine-X-Tyrosine (Thr-X-Tyr) motif to become active 
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and each of these enzymes is a target for discrete but closely related 
phosphorylation cascades in which the sequential activation of three kinases 
constitutes a common signalling mode (Gartner et al., 1992; Fanger et al., 
1997; Siow et al., 1997). 
 
2.6.3 Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) 
modulate mitogen-activated protein kinases (MAPK) activity 
Mirnikjoo and co-workers (2001) reported that n-3 fatty acids modulate 
activation of extracellular signalling pathways by inhibiting the in vitro activities 
of cAMP-dependent protein kinase, protein kinase C (PKC), Ca2+/calmodulin 
dependent protein kinase 2 and the mitogen activated protein kinases 
(MAPKs). These authors showed that DHA and EPA act as broad-spectrum 
kinase inhibitors, blocking not only the activity of PKC but also the activity of 
MAPK. These results were confirmed by Denys and co-workers (2002) who 
showed that EPA and DHA regulate human T-cell function by modulating 
MAPK enzyme activity. Other studies have shown that EPA also inhibits 
hypoxia-reoxygenation-induced injury by attenuating upregulation of MMP-1, 
thereby reducing phosphorylation of p38 (Cheng et al., 2003).  
 
2.6.4 The major multiple mitogen-activated protein kinase (MAPK) and 
PKB/Akt signalling pathways 
2.6.4.1 p38 MAPK 
At least 6 isoforms of the p38 MAPK group have been cloned, purified and 
characterized, namely p38 α1/α2 (Han et al., 1994; Lee et al., 1994), p38 
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β1/β2 (Jiang et al., 1996), p38 γ (Li et al., 1996; Mertens et al., 1996) and p38δ 
(Jiang et al., 1997; Wang et al., 1997)  
 
Ultraviolet light, mechanical stress, hyper-osmotic shock, 
hypoxia/reoxygenation, reactive oxygen species, pro-inflammatory cytokines 
such as interleukin-1 and tumour necrosis factor alpha (TNF-α), and to a lesser 
extent growth factors (Sugden and Clerk, 1998; Bogoyevitch, 2000), are some 
of the extracellular stresses that activate p38 MAPK during ischaemia and 
remain active during reperfusion (Pombo et al., 1994; Bogoyevitch et al., 1996; 
Kyriakis and Avruch, 1996). Activation of p38 has been implicated in 
transcription, protein synthesis, cell surface receptor expression and 
cytoskeleton integrity, ultimately affecting cell survival or leading to apoptosis 
and may even mediate cardiac hypertrophy (Obata et al., 2000). Huot and co-
workers (1997) reported that the p38 MAPK pathway may participate in several 
oxyradical-activated functions of the endothelium that are associated with 
reorganization of the microfilament network. 
 
There is considerable controversy regarding the role of p38 in ischaemic injury 
and in preconditioning. Research has shown both protective and detrimental 
effects for p38 activation in ischaemia/reperfusion injury, where the p38α 
isoform may be pro-apoptotic and the p38β isoform may be anti-apoptotic 
(reviewed by Steenbergen, 2002).  
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2.6.4.1.1 Inhibition of p38 MAPK 
A strong correlation between p38 activation and induction of apoptosis has 
been reported in cardiac myocytes exposed to ischaemia/reperfusion 
(Bogoyevitch et al., 1996). Research has shown that inhibition of p38 MAPK 
activity during extended periods of ischaemia is cardioprotective (Mackay and 
Mochly-Rosen, 1999; Barancik et al., 2000; Saurin et al., 2000). In a cultured 
neonatal rat cardiac myocyte model, inhibition of p38 MAPK protects against 
ischaemic injury as evidenced by a reduction in LDH release (Mackay and 
Mochly-Rosen, 1999; Saurin et al., 2000). Barancik and co-workers (2000) 
reported that the SB203580 inhibitor of p38 protected pig myocardium against 
ischaemic injury, suggesting that p38 activation may accelerate ischaemic cell 
death. Several studies indicated that p38 MAPK activation also plays a critical 
role in promoting myocardial apoptosis (Ma et al., 1999; Mackay and Mochly-
Rosen, 1999; Yue et al., 2000). Ma and co-workers (1999) showed that p38 
MAPK activity increased during ischaemia in isolated perfused rabbit heart, but 
administration of SB203580 before ischaemia and during reperfusion 
completely inhibited p38 MAPK activation, suggesting that inhibiting p38 was 
cardioprotective. Yue and co-workers (2000) also showed that SB203580 
improved cardiac contractile function and offered cardioprotection in isolated 
ischaemic rat hearts by inhibiting p38 MAPK.  
These studies show a correlation between inhibition of p38 MAPK activity and 
cardioprotection against ischaemia/reperfusion injury in myocytes as well as in 
isolated hearts. 
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2.6.4.1.2 Activation of p38 MAPK  
On the other hand, research has also shown a protective role for p38 MAPK 
activation in the heart. Weinbrenner and co-workers (1997) demonstrated that 
tyrosine 182 phosphorylation of p38 MAPK was increased during a sustained 
period of ischaemia in preconditioned hearts compared to non-preconditioned 
hearts, which correlates with protection of preconditioning in the rabbit heart. 
Communal and co-workers (2000) reported that increased p38 MAPK activity 
together with decreased JNK1/2 activity, protects adult rat ventricular myocytes 
against beta-adrenergic receptor-stimulated apoptosis. Nakano and co-
workers (2000) associated the protective effect of ischaemic preconditioning 
with the activation of MAPKAPK2 (a substrate of p38 MAPK) in the isolated 
rabbit heart. Zechner and co-workers (1998) reported myocardial protection 
from apoptosis with overexpression of MAPK kinase 6 (MKK6), an upstream 
activator of p38 MAPK. It appears that a distinct isoform of p38 MAPK, p38β, 
participates in mediating cell survival (Wang et al., 1998). Therefore, 
differential activation of p38 MAPK isoforms may exert opposing effects, where 
p38α is implicated in cell death while p38β may mediate myocardial survival. 
Although differential activation of p38 isoforms was observed in a study of 
simulated ischaemic injury in cultured neonatal cardiomyocytes (Saurin et al., 
2000), more research is needed on the effects of p38 isoforms in the intact 
adult myocardium. Differences in experimental protocol could also have 
contributed to these conflicting results of p38 isoforms. 
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2.6.4.2 c-Jun N-terminal kinases (JNK) 
Although JNK phosphorylation appears to be pro-apoptotic in many cell types, 
their exact role in regulating cell death is unclear (Obata et al., 2000; Park et 
al., 2000). Wang and co-workers (1998) reported that activation of JNK by 
transfection of cultured rat neonatal cardiomyocytes with mitogen activated 
protein kinase (MKK7) induced hypertrophy rather than apoptosis, and co-
activation of both JNK and p38 led to apoptosis.  
 
The activation of JNK MAPKs has now been observed in a variety of cell types 
of the cardiovascular system. JNKs are important for cytokine biosynthesis and 
are involved in cell transformation and stress responses (Kyriakis and Avruch, 
1996; Dong et al., 1998; Kuan et al., 1999). In almost all instances, the same 
stimuli that activate p38 also activate the JNKs (Kyriakis and Avruch, 1996). 
One exception is myocardial ischaemia/reperfusion where p38 is activated 
during ischaemia, and JNK during reperfusion (Pombo et al., 1994; 
Bogoyevitch et al., 1996; Kyriakis and Avruch, 1996). Furthermore, it has been  
reported by Laderoute and Webster (1997) that antioxidants inhibit the 
activation of JNKs in cultured myocytes subjected to hypoxia/reoxygenation.  
 
2.6.4.2.1 The role of c-Jun N-terminal kinases (JNK) in apoptosis 
Reoxygenation and reperfusion are known to activate JNK in the heart 
(Bogoyevitch et al., 1996; Laderoute and Webster, 1997; Yue et al., 1998; 
Davis, 2000), which is then translocated to the nucleus during ischaemia 
where it is phosphorylated during the reperfusion period (Pombo et al., 1994; 
Yue et al., 1998). Aoki and workers (2002) reported that the JNK pathway is a 
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direct activator of mitochondrial death machinery without other cellular 
components and provides a molecular linkage from oxidative stress to the 
mitochondrial apoptosis machinery. Lin (2003) proposed that JNK might be a 
modulator rather than an intrinsic component of the apoptotic machinery. Thus, 
JNK facilitates but does not induce apoptosis. These authors hypothesized that 
activated JNK inactivates supressors of the apoptotic machinery. According to 
their model, JNK activation contributes to apoptosis only if the apoptotic 
process has already been activated.  
 
In conclusion, both JNK and p38 are activated by ischaemia/reperfusion in the 
intact heart, but neither has been shown definitely to be pro- or anti-apoptotic.  
 
2.6.4.3 Extracellular signal-regulated kinases (ERK) 
Extracellular signal-regulated kinase-1 (ERK 1) and ERK 2, also known as p44 
and p42 MAPKs, represent the prototypical MAPKs in mammalial cells. A wide 
variety of growth-promoting or hypertrophic agents activate these kinases in 
cardiac myocytes, fibroblasts, smooth muscle cells and endothelial cells 
(Bogoyevitch, 2000). Recently it has been shown that ERK activation also 
takes place in response to mitochondria-derived superoxide production 
secondary to the mitochondrial KATP opening (Samavati et al., 2002). 
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2.6.4.3.1 The role of extracellular signal-regulated kinases (ERK) in 
apoptosis 
The ERK pathway is important for survival of cells by protecting them from 
programmed cell death caused by stress-induced activation of JNK and p38 
(Yue et al., 2000).  
Research has shown that inhibition of ERK enhances ischaemia/reperfusion-
induced apoptosis and that sustained activation of this kinase during simulated 
ischaemia mediates adaptive cytoprotection in cultured neonatal 
cardiomyocytes (Punn et al., 2000; Yue et al., 2000). Omura and co-workers 
(1999) reported that both p42/44-MAPK and JNK were activated in the isolated 
Langendorff perfused rat heart exposed to global ischaemia/reperfusion, 
whereas in another experimental model of ischaemia/reperfusion in the intact 
heart, ERK1/2 activation was shown to attenuate the extent of apoptosis 
subsequent to reperfusion injury (Yue et al., 2000).  
 
Although research has shown that stress or agonist induced ERK1/2 activation 
is associated with protection of cardiac myocytes from apoptosis, little is known 
as how ERK signalling results in cellular protection. Cyclooxygenase-2 (COX-
2) has been identified as a possible downstream mediator of protection in 
association with ERK 1/2 signalling in cardiomyocytes (Adderley et al., 1999).  
 
2.6.4.4 Protein kinase B (PKB/Akt) pathway 
The serine/threonine protein kinase, protein kinase B or AKT (PKB/Akt), has 
emerged as a crucial regulator of cellular processes including apoptosis, 
proliferation and differentiation. PKB/Akt is activated downstream of PI-3-
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kinase by the phosphoinisitide-dependent protein kinases (PDK) PDK-1 and 
PDK-2 (Anderson et al., 1998). PKB/Akt in turn phosphorylates a number of 
downstream targets relevant to cell survival function, including the pro-
apoptotic Bcl-2 family member BAD (Del Peso et al., 1997). Phosphorylation of 
BAD on Ser136 by PKB/Akt inhibits its pro-apoptotic function, thus promoting 
cell survival (Datta et al., 1997). 
 
PKB/Akt has been suggested to be involved in cell survival pathways. Fujio 
and co-workers (2000) showed that PKB/Akt promotes survival of 
cardiomyocytes in vitro and protects against ischaemia/reperfusion injury in the 
mouse heart. Dominant negative alleles of PKB/Akt reduce ability of growth 
factors and other stimuli to maintain cell survival whereas over-expression of 
wild type or activated PKB/Akt can rescue cells from apoptosis induced by 
various stress signals (Kauffmann-Zeh et al., 1997; Kennedy et al., 1997). The 
mechanisms involved in cell survival have only recently begun to emerge. One 
way in which PKB/Akt may promote cell survival, is through direct 
phosphorylation of transcription factors that control the expression of pro- and 
anti-apoptotic genes.  
 
2.6.5 Caspases 
Activation of caspases is associated with apoptotic cell death. Caspases have 
been grouped into an upstream (caspases -1,-2,-4,-5,-8,-9,-10) and a 
downstream (caspases -3,-6,-7) subgroup (Nicholson and Thornberry, 1997). 
All caspases are composed of a prodomain and an enzymatic region. 
Upstream caspases are characterized by long prodomains that appear to 
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contain essential regulatory proteins. However, downstream caspases 
sensitive to DEVD (aspartate-glutamine-valine-aspartate) oligopeptides 
(caspase-3 and caspase-7) normally lead to the lethal proteolytic breakdown of 
cellular target proteins. For activation, the caspase proform has to be cleaved 
into a large subunit and a small subunit within the enzymatic domain that finally 
reassociates to form a complex comprising of two small and two large 
subunits. Substrates for caspases comprise many different proteins including 
nuclear proteins, proteins involved in signal transduction, and cytoskeletal 
targets (Cardone, 1997; Kothakota et al., 1997). Most of these protein 
substrates appear to be cleaved by caspase -3 and -7. Although many of the 
target proteins defined to date have a nuclear localization, apoptotic cell death 
does not depend on the presence of a cell nucleus, as the characteristic 
cytoplasmic features of apoptosis can be observed in anucleate cytoplasts 
(Jacobson et al., 1994).  
 
2.6.5.1 Mechanisms of caspase activation 
Recent data suggest that activation of caspases may take place either within 
death receptor complexes of the cytoplasmic membrane or by a 
mitochondrion-dependent mechanism within the cytosol (Zou et al., 1997).  
 
2.6.5.2 Poly-(ADP-ribose) polymerase (PARP) 
A variety of stimuli induce apoptosis associated with cleavage of PARP by 
caspases (Kaufmann, 1989; Kaufmann et al., 1993). Cleavage and inactivation 
of PARP prevents energy depletion and induction of necrosis. However, acute 
and massive DNA damage induces hyper-activation of PARP leading to 
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necrosis. Therefore, PARP cleavage has a function in the prevention of 
necrotic cell death that would otherwise lead to pathological inflammatory 
responses (Earnshaw, 1995).  
 
Reperfusion injury is associated with caspase-3 activation, which results in 
cleavage of PARP to its proteolysed products (Engelbrecht et al., 2004).  
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CHAPTER 3 
MATERIALS AND METHODS 
3.1 Animal Care 
All animals received humane care in accordance with the Principle of 
Laboratory Animal Care of the National Society of Medical Research and the 
Guide for the Care and use of Laboratory Animals of the National Academy of 
Sciences. (National Institutes of Health Publications no. 80-23, revised 1978). 
 
3.2 Experimental Model 1 
3.2.1 Experimental groups 
 
Male Long-Evans rats were divided into two groups: a control group receiving 
standard rat chow and an experimental group receiving standard rat chow plus 
7g RPO/kg diet for 6 weeks. The rat chow was supplied by Atlas Animal 
Foods, Cape Town, South Africa and regularly analyzed to monitor possible 
variations between batches. Red palm oil used for experimental work was 
supplied by the Malaysian Palm Oil Board. The approximate energy and 
macronutrient content of the two diets are indicated in Table 3.1.  
The rats consumed an average of 25g food/day standard rat chow, containing 
0.625g fat, which provides 8,7% of the energy intake. Protein intake was 4.5g 
(28% of energy intake). In the experimental group, 0.175g RPO baking fat was 
supplemented every morning, for 6 weeks, before they received their daily 
allowance of rat chow. Thus, there was a 21% increase in fat intake in the 
RPO-supplemented experimental group.  
The red palm oil used in this study provided 70,0 μg carotenoids and 87,5 μg 
vitamin E (tocotrienols and tocopherols) additional to any other antioxidants 
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present in the standard rat chow diet (antioxidant nutrient status of standard rat 
chow diet not provided by suppliers due to confidentiality) (Nagadran et al., 
2000).  
 
Table 3.1 Approximate energy and macronutrient content of rat diets 
Nutrient  Standard rat chow diet 
(control) * 
Standard rat chow diet 
supplemented with red 
palm oil **  
Energy (kJ) 272,5 277,6 
Total non-structural 
carbohydrates (g) 
8,375 8,375 
Total protein (g) 4,5 4,5 
Total fat (g) 0,625 0,758 
Total SFA (g) 0,139 0,206 
Total MUFA (g) 0,168 0,219 
Total PUFA (g) 0,297 0,312 
Total n-6 PUFA (g) 0,247 0,248 
Total n-3 PUFA (g) 0,049 0,061 
 
* 25g of standard rat chow per day  
** 25g of standard rat chow plus 0,175g red palm oil per day 
SFA (g) = saturated fatty acids 
MUFA (g) = monounsaturated fatty acids  
PUFA (g) = polyunsaturated fatty acids  
 
3.2.2 Working heart perfusion  
At the end of the feeding programme, rats weighing 300-400g were 
anaesthetized with diethyl ether and intravenously injected with 400 units of 
heparin, before the hearts were rapidly excised and placed in ice-cold Krebs-
Henseleit buffer. Hearts were transferred to the standard working heart 
perfusion apparatus where they were perfused with a Krebs-Henseleit buffer 
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equilibrated with 95% O2 and 5% CO2 at 37 °C (118,5 mM NaCI; 4,75 mM KCI; 
1,2 mM MgCI 6 H2O; 1,36 mM CaCI2;; 25,0 mM NaHCO3; 1,2 mM KH2PO4;; 
11,0 mM glucose) at a perfusion pressure of 100 cm H2O.  
 
The aorta was cannulated and retrograde perfusion with Krebs-Henseleit 
buffer was initiated. During this initial perfusion in the Langendorff mode, 
excess tissue was removed from the heart and the opening to the left atrium 
was cannulated. 
 
Following a 5-minute stabilisation period in the Langendorff mode, hearts were 
switched to the working mode (Figure 3.1). The temperature of both the 
perfusate and the air surrounding the heart was thermostatically controlled and 
checked at regular intervals to ensure that the temperature was maintained at 
37 °C irrespective of coronary flow. A cannula, connected to a pressure 
transducer, was inserted through the apex of the heart into the left ventricle. 
Left ventricular systolic and diastolic pressure, coronary flow (CF), heart rate 
(HR) and aortic output (AO) were measured at 25 minutes into perfusion. 
Hearts were then subjected to 25 minutes of global ischaemia. At the end of 
ischaemia, hearts were reperfused in the Langendorff mode for 10 minutes. In 
order to reduce the incidence of reperfusion arrhythmias, 2% lignocaine 
solution was used for the initial 3 minutes of reperfusion of all hearts. This was 
followed by a 15-minute working heart perfusion period during which cardiac 
function was measured. To assess fatty acid composition and NO-cGMP 
pathway activity, hearts were freeze-clamped with Wollenberger clamps pre-
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cooled in liquid nitrogen, and freeze-dried to analyse for tissue cyclic 
nucleotide concentrations. 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
# Weight of rats increased from birth (approximately 5g) to150g following a 7-week SRC 
diet. 
SRC =Standard rat chow  AO =Aortic output 
TC =Total cholesterol   CF =Coronary flow 
TAG =Triacylglycerol   HR =Heart rate 
HDL-C =High density lipoprotein-  cAMP = cyclic adenosine monophosphate 
              cholesterol   cGMP = cyclic guanosine monophosphate 
RPO=Red palm oil    LVDevP =Left ventricular developed pressure 
             TPL FAs = Percentage fatty acid composition  
of the total phospholipid fraction 
 
Figure 3.1 Study design for Experimental Model 1  
 
 
3.2.3 Parameters measured and calculations used 
 
3.2.3.1 Left ventricular developed pressure (LVDevP) (mmHg) 
Left ventricular systolic-(LVSP) and diastolic (LVDP) pressure were monitored 
at 5-minute intervals during a 25-minute stabilization period and again during 
reperfusion after 25 minutes of global sustained ischaemia (n=10 per group per 
time point). LVDevP (the difference between systolic and diastolic pressure) 
SRC SRC+RPO 
SRC 
6 weeks diet Perfusion No flow ischaemia
Reperfusion 
0    25      50       75 (minutes) 
* *
  25         75 LVDevP AO HR CF 
n=10 per group per time point 
TC   
TAG 
HDL-C  $ 
 
  25 35    50   60  cAMP and cGMP 
n=5 per group per time point 
  25     60  TPL FAs 
n=10 per group per time point 
5-150g # 
7 weeks 
Time Points 
 $ n=10 per group per time point 
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was used to measure mechanical function of the heart. It was calculated by 
comparing the LVDevP before and after ischaemia. 
 
3.2.3.2 Aortic output recovery (AO)(%) 
In order to compare the functional recovery of the hearts in the different 
groups, the heart rate (beats/min), coronary flow (ml/min) and aortic flow 
(ml/min) were measured by collecting 1-minute samples of the respective 
effluent (n=10 per group per time point). Aortic output (AO) recovery was 
calculated by dividing the AO after ischaemia by AO before ischaemia and 
expressing these values as a percentage recovery (see Figure 3.1 for time 
points used). 
 
3.2.3.3 Biochemical analyses 
The cAMP and cGMP concentrations were determined at regular intervals (see 
Figure 3.1) using radioimmunoassay kits obtained from Amersham Corp. 
(Amersham, UK). 
 
3.2.3.3.1 cGMP assay 
The assay is based on the competition between unlabelled cGMP and a fixed 
quantity of 125 I-labeled cGMP for a limited number of binding sites on a cGMP-  
specific antibody. Measurement of the radioactivity in the pellet enables the 
amount of labelled cGMP in the bound fraction to be calculated. The 
concentration of unlabelled cGMP in the sample is then determined by 
interpolation from a standard curve. 
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For cGMP assays freeze-clamped hearts (n=5 per group per time point, see 
Figure 3.1) were freeze-dried and 20-25 mg of dry tissue was extracted in 5% 
trichloroacetic acid. The extracted sample was ether-washed 3 times during 5-
minute wash cycles. These samples were diluted 1:10 (V/V) with assay buffer 
and acetylated for the 125 I-labeled cGMP assay. The IC50 for the cCMP assay 
was 25 pmol/tube (Du Toit et al., 1999).  
 
3.2.3.3.2 cAMP assay 
The assay is based on the competition between unlabelled cAMP and a fixed 
quantity of the tritium labelled compound for binding to a protein which has a 
high specificity and affinity for cAMP. The amount of labelled protein-cAMP 
complex formed is inversely related to the amount of unlabelled cAMP present 
in the assay sample. Measurement of the protein-bound radioactivity enables 
the amount of unlabelled cAMP in the sample to be calculated. Separation of 
the protein bound cAMP from the unbound nucleotide is achieved by 
adsorption of the free nucleotide on to coated charcoal, followed by 
centrifugation. An aliquot of the supernatant is then removed for liquid 
scintillation counting. The concentration of unlabelled cAMP in the sample is 
then determined from a linear standard curve.  
 
For the cAMP assays, 20-25 mg freeze-dried tissue was extracted with 
perchloric acid, neutralized and assayed (n=5 per group per time point, see 
Figure 3.1). The IC50 for this assay was 1,92 mmol/tube (Du Toit et al., 1999).  
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3.2.3.4 Heart muscle total phospholipid fatty acid composition (%)  
Hearts isolated from rats fed standard rat chow or standard rat chow and 7g 
RPO per kg food for 6 weeks were perfused, freeze clamped and freeze-dried. 
The freeze-dried tissue was used to determine myocardial total phospholipid 
fatty acid composition (n=10 per group per time point). Tissue samples were 
extracted with chloroform: methanol (2:1; v/v) according to a modified method 
of Folch and co-workers (1957). Neutral lipids were separated from total 
phospholipids by thin-layer chromatography and the total phospholipid fraction 
analysed for fatty acid composition by gas chromatography. A fatty acid 
mixture was prepared from individual fatty acids (Sigma. St. Louis, MO, USA) 
and used as a standard. (Smuts et al., 1992; Van Jaarsveld et al., 2000).  
 
3.2.3.5 Serum lipids 
Rats were weighed weekly during the RPO-supplementation period and blood 
was collected from the tail vein before and after the 6-week period for both the 
standard rat chow (control) and the RPO-supplemented groups (n=10 per 
group per time point). The blood was centrifuged for 10 minutes at 3 000x g to 
obtain serum and analysed for serum lipid profiles i.e. total cholesterol (TC), 
high-density lipoprotein (HDL)-cholesterol and triacylglycerol. The serum lipid 
profile was determined using a Beckman Synchron Cx 9-instrument and 
Beckman Synchron Cx reagents (Beckman Coulter) employing enzymatic and 
colorimetric methods. 
 
3.2.3.6 Statistical methods 
 
Values are presented as mean ± SEM. Some values are presented as 
percentage change from the baseline values. To calculate the percentage 
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change, the values were devided by baseline values and multiplied by 100. To 
adjust the X-axis to zero, 100 were subtracted from the values obtained. For 
paired comparisons the Student’s t test was used. P<0,05 was considered 
statistically significant. 
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3.3 Experimental Model 2  
3.3.1 Experimental groups 
Seven-week old Long-Evans rats were randomly allocated to 4 groups 
according to the dietary supplementation they received.  
Group 1: Standard rat chow.  
Group 2: Standard rat chow plus RPO (7 g RPO per kg diet).  
Group 3: Standard rat chow, containing 2% cholesterol. 
Group 4: Standard rat chow containing 2% cholesterol plus RPO (7 g RPO per 
kg diet).  
The rats were fed a standard rat chow diet or 2% cholesterol-enriched diet 
(based on previous studies by Giricz et al., 2003) for 6 weeks. Rats of the 
control group consumed an average of 25g food/day standard rat chow, 
containing 0.625g fat, which provides 8,7% of the energy intake. Protein intake 
was 4,5g (28% of energy intake). In two additional groups RPO-baking fat (7g 
RPO per kg diet) was supplemented every morning for 6 weeks to cholesterol-
enriched and standard rat chow diet, respectively, before they received their 
daily allowance of rat chow. Thus, there was a 21% increase in fat intake in the 
RPO-supplemented experimental groups. The red palm oil used in this study 
provided 70,0 μg carotenoids and 87,5 μg vitamin E (tocotrienols and 
tocopherols) additional to that present in the standard rat chow diet 
(antioxidant nutrient status of standard rat chow diet not provided by supplier 
due to confidentiality) (Nagadran et al., 2000).  
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3.3.2 Working heart perfusion and study design 
The same protocol and study design (Figure 3.1 p.53) were used as discussed 
in Experimental Model 1 (see working heart perfusion 3.2.2 p.51). 
 
3.3.3 Parameters measured and calculations used 
 
The same measurements and calculations were used as discussed under 
paragraph 3.2.3 p.53 in Experimental Model 1. In addition, rate pressure 
product recovery was calculated for this study.  
 
3.3.3.1 Rate pressure product recovery (RPP)(%) 
Left ventricular developed pressure (LVDevP) was used to assess mechanical 
function of the heart (n=10 per group per time point). LVDevP recovery (%) = 
LVDevP 25 minutes into reperfusion (post-ischaemic)/ LVDevP 25 minutes into 
perfusion (pre-ischaemic) x 100. 
Functional recovery was expressed as the percentage rate pressure product 
(RPP) recovery using the following formulae: 
RPP =Heart Rate (HR) X LVDevP 
% RPP recovery =(RPP reperfusion/RPP pre-ischaemic) x 100  
 
3.3.3.2 Statistical Methods 
 
Statistical methods were discussed in 3.2.3.6 p.56 (Experimental Model 1). 
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3.4 Experimental Model 3 
 
3.4.1 Experimental groups 
Four groups with the same dietary regimens as described in 3.3.1 p.58 
(Experimental Model 2) were used. Male Wistar rats were used as 
experimental animals. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
# Weight of rats increased from birth (approximately 5g) to150g following a 7-week SRC 
diet. 
NO= Nitric oxide   HR= Heart rate 
NOS= Nitric oxide synthase  CF= Coronary flow 
SOD= Superoxide dismutase  AO= Aortic output 
LPO= Lipid hydroperoxide  LVDevP=Left ventricular developed pressure 
SRC= Standard rat chow  cGMP= cyclic guanosine monophosphate 
Chol= Cholesterol 
RPO=Red palm oil 
 
Figure 3.2 Study design for Experimental Model 3 
 
3.4.2 Working heart perfusion 
The protocol followed has been discussed in detail in 3.2.2 p.51 (Experimental 
Model 1). However, for assessment of myocardial nitric oxide concentrations, 
nitric oxide synthase- and superoxide dismutase activities and lipid 
hydroperoxide production, hearts were freeze-clamped with Wollenberger 
clamps pre-cooled in liquid nitrogen at the following times: at the end of the 
SRC 
6 weeks diet 
Perfusion No flow Ischaemia 
Reperfusion 
  0              25                50               75 (minutes) 
   25       75 HR, CF, AO, LVDevP  
n=7 per group per time point 
 
   25 35      50      60  cGMP  
n=5 per group per time point  
   25 35    60  NO NOS SOD LPO
n=5 per group per time point 
SRC+ Chol
SRC+ Chol +RPO 
SRC + RPO
SRC 
 5-150g# 
7 week 
Time Points 
 61
pre-ischaemic working heart perfusion, after 10 minutes ischaemia and 10 
minutes into reperfusion. Samples were stored at -80 °C for biochemical 
analyses (Figure 3.2 p.60).  
 
3.4.3 Parameters measured and calculations used 
 
3.4.3.1 Cardiac functional parameters and aortic output recovery (AO)(%) 
Measurement of cardiac functional parameters and calculation of aortic output 
recovery have been discussed in section 3.2.3 p.53 under Materials and 
Methods in Chapter 3 (Experimental Model 1). 
 
3.4.3.2 Measurement of cGMP  
Determination of cGMP concentrations has been discussed in 3.2.3.3 p.54 
(Experimental Model 1). 
 
3.4.3.3 Measurement of cardiac nitric oxide concentrations  
 
Approximately 200 mg of cardiac tissue was homogenized in 0,5 ml PBS (pH 
7,4) and centrifuged at 10 000 x g for 20 minutes. The supernatant was ultra-
filtered using a 30 kDa molecular weight cut-off filter (Millipore) and 40 µl of the 
filtrate was assayed. 
 
Myocardial NO concentrations were determined using a Nitrate/Nitrite kit 
(Cayman Chemicals, Cayman Islands) which provides an accurate and 
convenient method for measurement of total nitrate/nitrite concentration in a 
simple two-step process. The first step is the conversion of nitrate to nitrite 
utilizing nitrate reductase. The second step is the addition of the Griess 
Reagents, which convert nitrite into a deep purple azo compound. Photometric 
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measurement of the absorbance due to this chromophore accurately 
determines nitrite concentration.  
 
For direct measurement of intracellular NO, cardiomyocytes from RPO-
supplemented and control hearts were isolated by collagenase perfusion, 
followed by incubation in a Krebs-Henseleit buffer containing 2% bovine serum 
albumin in the presence of 10 μM diaminofluorescein-2/diacetate (DAF-2/ DA) 
(-0,5 x 106 cells/ml). Following incubation and washing, intracellular 
fluorescence of DAF-triazol (DAF-2T, oxidized from DAF-DAF-2/DA) was 
analyzed by flow cytometry (Strijdom et al., 2004).  
 
3.4.3.4 Measurement of cardiac nitric oxide synthase activity  
Approximately 100 mg of cardiac tissue was homogenized in 0,5 ml 
homogenization buffer (1:10 dilution of stock solution, supplied by Cayman 
Chemicals) and centrifuged at 10 000 x g for 15 minutes at 4 °C. For the 
assay, 250 µl of supernatant was used. 
Total NOS activity was measured using a NOS assay-kit which is based on the 
biochemical conversion of L-arginine to L-citrulline by NOS (Cayman 
Chemicals, Cayman Islands). This reaction, which represents a novel 
enzymatic process, involves a 5-electron oxidation of guanidino nitrogen of L-
arginine to NO, together with the stoichiometric production of L-citrulline. 
Advantages of this NOS kit include the use of radioactive substrate [14C] 
arginine that enables sensitivity in the picomole range, as well as the specificity 
of the assay for the NOS pathway due to the direct enzymatic conversion of 
arginine to citrulline in eukaryotic cells. The NOS activity is quantified by 
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counting the radioactivity in the eluate (i.e. the flowthrough after reaction 
samples were added to spin cups and centrifuged for 30 seconds) after 
performing the assay. 
  
3.4.3.5 Measurement of cardiac superoxide dismutase activity 
Approximately 200 mg of cardiac tissue was homogenized in 1,0 ml ice-cold 
HEPES buffer and centrifuged at 1 500 x g for 5 minutes at 4 °C. For the 
assay, 10 µl of the supernatant was used. 
Total activity of SOD was measured using a SOD kit (Cayman Chemicals, 
Cayman Islands) that utilizes a tetrazolium salt for detection of superoxide 
radicals generated by xanthine oxidase and hypoxanthase. One unit of SOD is 
defined as the amount of enzyme required to exhibit 50% dismutation of the 
superoxide radical. The SOD assay measures all three types of SOD.  
 
3.4.3.6 Measurement of cardiac lipid hydroperoxide production 
Approximately 200 mg of cardiac tissue was homogenized in 0,5 ml HPLC-
grade water. An equal volume of Extract R saturated methanol (Cayman 
Chemicals, Cayman Islands) was added and mixed thoroughly by vortexing. 
Cold chloroform (1,0 ml) was then added, mixed thoroughly and centrifuged at 
1,500 x g for 5 minutes at 0 °C. The bottom chloroform layer was collected and 
500 µl of this extract was used for the assay. 
 
Lipid hydroperoxide (LPO) production in cardiac muscle was assessed using a 
LPO assay kit (Cayman Chemicals, Cayman Islands) which measures the 
hydroperoxides directly utilizing the redox reaction with ferrous ions. 
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Hydroperoxides are highly unstable and react readily with ferrous ions to 
produce ferric ions. The resulting ferric ions are detected using thiocyanate ion 
as the chromagen.  
 
3.4.3.7 Statistical Methods 
 
Statistical methods were discussed in 3.2.3.6 p.56 (Experimental Model 1). 
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3.5 Experimental Model 4 
 
3.5.1 Experimental groups 
Two groups with the same dietary regimens as described in 3.2.1 p.50 were 
used. Experimental design is given in Figure 3.3. Male Wistar rats were used 
as experimental animals.  
 
3.5.2 Working heart perfusion 
Protocol followed has been discussed in detail in 3.2.2 p.51 (Experimental 
Model 1). To assess the activity of myocardial MAPKs, hearts were freeze-
clamped with Wollenberger clamps pre-cooled in liquid nitrogen at the end of 
the pre-ischaemic working heart perfusion after 10 minutes ischaemia and 10 
minutes into reperfusion and samples were stored at -80 °C (Figure 3.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
# Weight of rats increased from birth (approximately 5g) to150g following a 7-week SRC 
diet. 
SRC= Standard rat chow 
RPO= Red palm oil 
AO= Aortic output 
MAPKs= Mitogen-activated protein kinases 
 
Figure 3.3 Study design for Experimental Model 4 
 
SRC SRC+RPO 
SRC 
6 weeks diet 
Perfusion No flow 
Ischaemia
Reperfusion 
   0       25         50                      75 (minutes) 
     25            75  AO  
n=7 per group per time point 
     25    35   60  MAPKs 
n=4 for 4 independent experiments 
5-150g # 
7 weeks 
Time Points 
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3.5.3 Parameters measured and calculations used 
 
3.5.3.1 Aortic output recovery (AO)(%) 
Measurement of AO has been discussed in 3.2.3.2 p.54.  
 
3.5.3.2 Western blot analysis 
Cardiac MAPKs and PKB/Akt, as well as caspase-3 and poly (ADP-ribose) 
polymerase (PARP) protein, were extracted with a lysis buffer containing: Tris, 
20 mM; p-nitrophenylphosphate, 20 mM; EGTA, 1mM; sodium fluoride (NaF), 
50 mM; sodium orthovanadate, 0.1 mM; phenylmethyl sulphonyl fluoride 
(PMSF), 1 mM; dithiothreitol (DTT), 1 mM; aprotinin, 10 µg/ml; leupeptin, 10 
µg/ml. Mitogen-activated protein kinase phosphatase-1 (MKP-1) protein was 
extracted with a lysis buffer containing: Hepes, 50 mM; EDTA, 10 mM; EGTA, 
10 mM; PMSF, 1 mM; Aprotinin, 1µg/ml; Leupeptin, 1µg/ml;  Triton, 0,5%. The 
tissue lysates were diluted in Laemmli sample buffer and boiled for 5 minutes 
after the lysate protein content was determined using the Bradford technique 
(Bradford, 1976). For MAPKs and PKB/Akt 10µg protein, and 50µg protein for 
caspase-3 and PARP, were separated by 10% PAGE-SDS-gel 
electrophoresis. The separated proteins were transferred to a PVDF 
membrane (ImmobilonTM P, Millipore). These membranes were routinely 
stained with Ponceau Red for visualization of proteins. Non-specific binding 
sites on the membranes were blocked with 5% fat-free milk in Tris-buffered 
saline, 0.1% Tween 20 (TBST) and then incubated with the primary antibodies 
that recognize phosphospecific ERK p42/p44 (Thr202/Tyr204), p38-MAPK 
(Thr180/Tyr182), JNK p54/p46 (Thr183/Tyr185), PKB (Ser473and Thr308), caspase-3 
(fragment pAb) and PARP (fragment pAb). Membranes were subsequently 
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washed with large volumes of TBST 5 x 5-minutes and the immobilized 
antibody conjugated with a diluted horseradish peroxidase-labelled secondary 
antibody (Amersham Life Sciences). After thorough washing with TBST, 
membranes were covered with ECLTM detection reagents and quickly exposed 
to an autoradiography film (Hyperfilm ECL, RPN 2103) to detect light emission 
through a non-radioactive method (ECLTM Western blotting). Films were 
densitometrically analysed (UN-SCAN-IT, Silkscience) and phosphorylated 
protein values were corrected for minor differences in protein loading, if 
required. Experiments were performed (data not shown) to ensure that all 
signals were within the linear range of detection on the autoradiographs under 
our assay and gel loading conditions. 
 
Antibodies were purchased from Cell Signalling Technology and all other 
chemicals were obtained from Sigma (St Louis, MO). 
 
3.5.3.3 Statistical methods 
 
Data are presented as mean ± SEM. Statistical significance was determined in 
multiple comparisons among independent groups of data in which ANOVA and 
the Bonferroni’s post-hoc test indicated the presence of significant differences. 
A P-value < 0.05 was considered statistically significant. 
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CHAPTER 4 
 
 
 
 
 
 
 
 
Dietary red palm oil supplementation protects against the consequences 
of global ischaemia in the isolated perfused rat heart. 
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4.1 Abstract 
Introduction: Activation of the NO-cGMP pathway is associated with 
myocardial protection against ischaemia. During ischaemia the function of this 
pathway is disturbed. Little is known about the effects of supplements such as 
red palm oil (RPO) on the myocardial NO-cGMP-signalling pathway. RPO 
consists of saturated (SFAs), monounsaturated (MUFAs) and polyunsaturated 
(PUFAs) fatty acids and is rich in natural β-carotene and Vitamin E 
(tocopherols and tocotrienols). Aims: To determine whether dietary RPO-
supplemention protects against the consequences of ischaemia/reperfusion 
and to identify a possible mechanism for this protection. Methods: Long-Evans 
rats were fed a standard rat chow (control) diet or standard rat chow diet plus 
7g RPO per kg diet for 6 weeks. Hearts were excised and mounted on a 
working heart perfusion apparatus. Cardiac function was measured before and 
after hearts were subjected to 25 minutes of global ischaemia. Left ventricular 
systolic (LVSP) and diastolic pressure (LVDP), coronary flow (CF), heart rate 
(HR) and aortic output (AO) were measured. To assess NO-cGMP pathway 
activity, hearts subjected to the same conditions, were freeze-clamped and 
analysed for tissue cAMP and cGMP concentrations using a RIA method. 
Furthermore, composition of myocardial total phospholipid fatty acids was 
analysed by gas chromatography and blood samples were collected for serum 
lipid determinations. Results: The percentage aortic output recovery of hearts 
of the group supplemented with RPO was 72,9 ± 3,5% versus 55,4 ± 2,5% for 
controls (P<0,05). Ten minutes into ischaemia the cGMP concentrations of the 
RPO-supplementation group were significantly higher than the control group 
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(26,5 ± 2,8 pmol/g versus 10,1 ± 1,8 pmol/g). Myocardial total phospholipid 
PUFA content in the group supplemented with RPO increased from 54,5 ± 
1,1% before ischaemia to 59,0 ± 0,3% after ischaemia (P<0,05). Conclusions: 
Our results demonstrate that dietary RPO-supplementation protected hearts 
against ischaemia/reperfusion injury. These findings suggest that dietary RPO 
protect via the NO-cGMP pathway and/or changes in phospholipid PUFA 
composition during ischaemia/reperfusion.  
 
4.2 Introduction 
Palm oil and its liquid fraction, palm olein, are consumed worldwide as cooking 
oils and as constituents of margarines. These oils are also incorporated into fat 
blends used in the manufacturing of a variety of food products and in home 
food preparation. It plays a useful role in meeting energy needs and 
contributing to essential fatty acid (C18: 2n-6) needs in many regions of the 
world (Cottrell, 1991). Red palm oil (RPO) used in this study, contains a 
mixture of SFAs (51%), MUFAs (38%) and PUFAs (11%) (Nagendran et al., 
2000). Several clinical trails have evaluated palm oil’s effects on blood lipids 
and lipoproteins. These studies suggest that palm oil and palm olein diets do 
not raise serum total cholesterol (TC) and LDL cholesterol concentrations to 
the extent expected from their fatty acid composition when a moderate-fat, 
moderate-cholesterol diet is consumed (Therialt et al., 1999; Kritchevsky, 
2000; Sundram and Basiron).  
 
Although many animal feeding studies have shown that fish oil diets rich in n-3 
PUFAs prevent ischaemia-induced cardiac arrhythmias (Nair et al., 1997; Kang 
 71
and Leaf, 2000; Jump, 2002), only a few reports have been published on the 
protective effects of RPO-supplementation against ischaemia/reperfusion 
injury (Abeywardena et al., 1991; Charnock et al., 1991; Abeywardena and 
Charnock, 1995).  
 
Palm oil and palm oil products are also natural occurring sources of the 
antioxidant vitamin E constituents tocopherols and tocotrienols. These natural 
antioxidants act as scavengers of damaging oxygen free radicals. Two studies 
published in the New England Journal of Medicine show that both men and 
women who supplement their diet with at least 100 IU of vitamin E (67μg 
natural α-tocopherol) per day for at least two years have a 37-41% drop in the 
risk of heart disease (Rimm et al., 1993; Stampfer et al., 1993). Vitamin E is 
believed to be the major lipid-peroxidation chain-breaking antioxidant found in 
blood plasma and membranes. The insight into the mechanism of heart injury 
has suggested that administration of antioxidants may lessen oxidative 
damage of the heart. It has been shown that a palm oil vitamin E mixture 
containing both α-tocopherol and α-tocotrienol, was more efficient in the 
protection of the isolated Langendorff heart against ischaemia/reperfusion 
injury than tocopherol alone as measured by its mechanical recovery 
(Serbinova et al., 1992). Palm oil vitamin E completely suppressed LDH 
enzyme leakage from ischaemic hearts, prevented the decrease in ATP and 
creatine phosphate levels, and inhibited the formation of endogenous lipid 
peroxidation products (Serbinova et al., 1992). 
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Nitric Oxide (NO) is an important regulator of both cardiac and vascular 
function and tissue reperfusion (reviewed by Ferdinandy and Schultz, 2003). 
Myocardial NO formation is increased during ischaemia and reperfusion, 
offering protection against ischaemia/reperfusion injury (Maulik et al., 1995; 
Williams et al., 1995; Araka et al., 2000). However, when NO plummets during 
reperfusion, due to rapid quenching by superoxide, the vascular protective 
regulatory properties become dysfunctional. This may lead to exacerbation of 
tissue injury. Reactive oxygen species such as the superoxide radical (O2-), 
hydrogen peroxide (H2O2) and hydroxyl radical (.OH) have long been 
implicated in the pathogenesis of ischaemia/reperfusion injury. These radicals 
are predominant both during ischaemia and at the time of reperfusion, and can 
react with nucleic acids, proteins and lipids, resulting in damage to the cell 
membrane or intracellular organelles (Gilham et al., 1997). Peroxynitrite 
(ONOO-) is generated by a diffusion-limited reaction between O2- and NO 
(Rubbo et al., 1994; Naseem et al., 1995; Ferdinandy and Schultz, 2003). 
 
Protective effects of NO are mediated through the production of cGMP. NO 
donors given during ischaemia possibly protect the myocardium by increasing 
tissue cGMP and decreasing cytosolic Ca2+ overload. Increases in cAMP 
concentrations associated with ischaemia would increase Ca2+ concentrations 
and exacerbate ischaemic and reperfusion injury (Du Toit et al., 2001). In this 
regard it is possible that cGMP may attenuate this type of injury by inhibiting 
the cAMP induced slow inward calcium current, thus leading to a decrease in 
cytosolic calcium concentrations (Sumii and Sperelakis, 1995). 
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Because little is known about the protective effect of RPO and the mechanisms 
involved, our aim was to determine whether dietary RPO-supplementation 
protects against the consequences of ischaemia and reperfusion. 
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4.3 Materials and methods 
4.3.1 Experimental Model  
 
Long-Evans rats were fed a standard rat chow (control) diet or standard rat 
chow diet plus 7g RPO per kg diet for 6 weeks. The working heart perfusion 
method used in this experimental model is described in Chapter 3 under 
Materials and Methods (Experimental Model 1 p.50) and the protocol that was 
followed is summarized in Figure 3.1 p 53. 
 
4.3.2 Measurement of cardiac function 
 
Left ventricular systolic (LVSP) and diastolic pressure (LVDP), coronary flow 
(CF), heart rate (HR) and aortic output (AO) were measured as described in 
Chapter 3 under Materials and Methods (Experimental Model 1 p.50).  
 
4.3.3 Biochemical analyses 
The cAMP and cGMP concentrations were determined using 
radioimmunoassay kits obtained from Amersham Corp. (Amersham, UK). The 
principle and methods were discussed in Chapter 3 under Materials and 
Methods (Experimental Model 1 p.50). 
 
4.3.4 Heart muscle total phospholipid fatty acid composition (%)  
Composition of myocardial total phospholipid fatty acids was analysed by gas 
chromatography as described in Chapter 3 under Materials and Methods 
(Experimental Model 1 p.50). 
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4.3.5 Serum lipids 
The serum lipid profile was determined using a Beckman Synchron Cx 9-
instrument and Beckman Synchron Cx reagents (Beckman Coulter) as 
described in Chapter 3 under Materials and Methods (Experimental Model 1 
p.50). 
 
4.3.6 Statistical methods 
Statistical methods used were discussed in Chapter 3 under Materials and 
Methods (Experimental Model 1 p.50). 
 
4.4 Results 
4.4.1 Left ventricular developed pressure (LVDevP) 
The pre-ischaemic LVDevP of hearts of RPO-supplemented and control 
groups were similar (Figure 4.1). After 25 minutes of global ischaemia and 25 
minutes of reperfusion, the percentage LVDevP recovery of hearts from the 
RPO-supplemented group was 89,0 ± 8,1% as compared to the 81,0 ± 6,0 % 
LVDevP recovery of hearts obtained from rats fed the standard rat chow 
(control) diet (n=10 per group per time point). 
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Figure 4.1 The effect of RPO-supplementation on left ventricular developed
pressure during pre-ischaemic perfusion and reperfusion (n=10 per group per
time point) (mean ± SEM)
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4.4.2 Aortic output recovery (%) 
After 25 minutes of global ischaemia and 25 minutes of reperfusion, 
percentage aortic output (AO) recovery of hearts from the RPO-supplemented 
group was 72,9 ± 3,4% versus 55,4 ± 2,5% for the control group (P<0,05) 
(Figure 4.2) (n=10 per group per time point). 
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Figure 4.2 % Aortic output recovery of hearts in the RPO-supplemented group 
versus hearts of the control group (n=10 per group per time point) (*P<0.05) 
(mean ± SEM) 
 
4.4.3 Effects of RPO-supplementation on ischaemic cAMP and cGMP 
concentrations 
Myocardial cAMP concentrations were not affected by RPO-supplementation 
(n=5 per group per time point) (Figure 4.3). 
The cGMP concentrations at 10 minutes into ischaemia were 26,5 ± 2,8 pmol/g 
in hearts of the RPO-supplemented group, compared to 10,1 ± 1,8 pmol/g in 
hearts of the control group (P<0,05) (n=5 per group per time point) (Figure 
4.4). 
 
 
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
100
15 m in 20 m in 25 m in
Tim e  d u r in g  r e p e r fu s io n
A
or
tic
 O
ut
pu
t R
ec
ov
er
y%
Contro l
RP O
*
 78
Figure 4.3 Myocardial cAMP concentrations for hearts of rats on RPO-
supplemented diet versus hearts of control diet (n=5 per group per time point) 
(mean ± SEM) 
 
Figure 4.4 Myocardial cGMP concentrations for hearts of rats on RPO-
supplemented diet versus hearts of control diet (n=5 per group per time 
point)(*P<0,05) (mean ± SEM) 
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4.4.4 Serum lipids 
Weight increase of rats remained stable between the control group and RPO-
supplemented group after the 6-week supplementation period. 
  
All values in Figures 4.5 represent the percentage change in serum total 
cholesterol-, high density lipoprotein cholesterol and triacylglycerol 
concentrations between the baseline value and the value of the corresponding 
experimental group after the 6-week supplementation period (n=10 per group).  
  
Although there were baseline differences between the control and RPO-
supplemented groups (1,2 ± 0,04 mmol/l versus 1,4 ± 0,04 mmol/l, P<0,05), 
the % change in serum total cholesterol showed no difference between the two 
experimental groups after the 6-week diet period (n=10 per group). 
 
HDL-cholesterol followed a similar trend with baseline differences between 
control and RPO-supplemented groups (1,0 ± 0,03 mmol/l versus 1,2 ± 0,05 
mmol/l, P<0,05), but the % change in HDL-cholesterol showed no difference 
between the two groups after the 6-week diet period (n=10 per group) (Figure 
4.5).  
 
Serum concentrations of triacylglycerol were significantly increased in the 
RPO-supplemented group after 6 weeks on the diet (before: 0,6 ± 0,1 mmol/l 
versus after: 0,9 ± 0,1 mmol/l, P<0,05) (n=10 per group) (Figure 4.5). However, 
percentage change in serum triacylglycerol between  the control- and RPO- 
supplemented groups showed no difference. 
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Figure 4.5 % Change in serum lipid concentration in control and RPO 
supplemented groups after 6 weeks (n=10 per group) (mean ± SEM) 
 
TC = Total cholesterol  
TAG = Triacylglycerol 
HDL-C = High density lipoprotein-cholesterol 
 
4.4.5 Heart muscle total phospholipid fatty acid composition (%)  
Myocardial total phospholipid fatty acid composition is presented in Figure 4.6. 
Our results show that hearts of the group supplemented with RPO caused a 
significant increase in pre-ischaemic (baseline) myocardial total SFA 
composition (38,0 ± 1,0%) versus control hearts (34,4 ± 0,4%) (P<0,05). No 
significant changes occurred in MUFA, PUFA, total n-6 and total n-3 
composition between groups. 
During the perfusion protocol, the event of ischaemia altered fatty acid 
composition. The myocardial total SFA composition decreased significantly 
from 38,0 ± 1,0% before ischaemia to 33,6 ± 0,2% after ischaemia (P<0,05) in 
the hearts of the group supplemented with RPO.  
Concurrently, myocardial total phospholipid PUFA composition in hearts of the 
group supplemented with RPO increased from 54,5 ± 1,1% before ischaemia 
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to 59,0± 0,3% after ischaemia (P<0,05), with no changes in myocardial total 
phospholipid MUFA composition. 
 
 
 
Figure 4.6 Heart muscle total phospholipid fatty acids 20 minutes in perfusion 
and 10 minutes in reperfusion respectively, for RPO supplemented group 
versus control group (n=10 per group) (*P<0,05 for the group before and after 
ischaemia) (#P<0,05 for RPO supplemented group versus the corresponding 
control group) (mean ± SEM) 
 
 
SFA= Total saturated fatty acids 
MUFA= Total monounsaturated fatty acids 
PUFA= Total polyunsaturated fatty acids  
Tn-6= Total n-6 polyunsaturated fatty acids 
Tn-3= Total n-3 polyunsaturated fatty acids 
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4.5 Discussion 
Our results demonstrate that RPO-supplementation offered protection against 
ischaemia/reperfusion injury in the isolated perfused working heart as reflected 
by improved aortic output recovery. These data support the findings of 
Serbinova and co-workers (1992) who showed that palm oil vitamin E was 
more effective in the protection against ischaemia/reperfusion injury in the 
isolated Langendorff perfused heart than tocopherol alone. 
  
Based on our results we propose that the protective effect of RPO may be 
associated with either its antioxidant characteristics and/or changes in the 
myocardial total phospholipid fatty acid composition during 
ischaemia/reperfusion. Abeywardena and co-workers (1991) also argued that 
RPO protection lies in an alliance of fatty acids and endogenous antioxidants 
during ischaemia/reperfusion.  
 
Dietary RPO-supplementation for 6 weeks caused significant changes in heart 
muscle total phospholipid fatty acid composition. The decrease in total 
phospholipid SFA composition of the heart muscle was accompanied by an 
increase in the total phospholipid PUFA composition, which could be 
associated with improved reperfusion aortic output recovery. Normally, linoleic 
acid (LA) undergoes a series of elongations and desaturations to yield 
arachidonic acid (AA). To our knowledge no data exist on the effect of 
ischaemia on elongase and desaturase activity. Many studies have focused on 
the effect of FA on arrhythmias. Contradictory results exist on the effect of AA 
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on the development of arrhythmias. Li and co-workers (1997) found that free 
AA is able to prevent arrhythmias, but the major cyclooxygenase metabolites 
(PGD2, PGE2, PGF2 and TXA2) derived from AA are arrhythmogenic. However, 
prostacyclins (PGI2), also synthesized from AA, are anti-thrombotic agents that 
act as a vasodilator in blood vessels and have an antiarrhythmogenic effect. 
No clear relationship exists between the availability of AA in myocardial 
phospholipids and eicosanoid profile. Abeywardena and co-workers (1991) 
showed that a chemically refined palm oil-supplementation for 12 months had 
no effect on prostacyclin production from AA in rat myocardial tissue. 
Concurrently, thromboxane A2 production was inhibited. Another palm oil 
supplement (with a near-identical fatty acid profile) in the same study showed 
no thromboxane A2 inhibition. This argues that thromboxane A2 production is 
unlikely to be mediated via fatty acids. In another study (Abeywardena et al., 
1995) myocardial prostacyclin production was increased after ischaemia with 
refined, bleached and deodorized palm oil (RBD-PO)-supplementation for 9 
months. However, these authors argue that this increase in prostacyclin 
production may not be mediated by fatty acids alone but that endogenous 
antioxidants may also play a role.  
 
The increase in PUFAs during ischaemia/reperfusion in the current study, 
suggests that PUFAs may be involved in the protection against ischaemia/ 
reperfusion injury. The mechanism of phospholipid fatty acid protection 
remains elusive and needs further investigation.  
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Generally, the mechanism of eicosanoid action is to bind to membrane 
receptors, leading to generation of second messengers such as cAMP and 
Ca2+ (Charnock et al., 1991; Mohan et al., 1995; Li et al., 1997). As myocardial 
cAMP concentrations were not significantly affected throughout the protocol in 
the hearts of the group supplemented with RPO, prevention of fatal cardiac 
arrhythmias may depend on the net effect of these metabolites, which is 
determined by the status of AA metabolism and the contents of n-6 and other 
fatty acids (Abeywardena et al., 1991; Charnock et al., 1991; Mohan et al., 
1995; Li et al., 1997).  
 
Interaction between cardiac endothelium-derived prostaglandins and NO 
determines myocardial performance (Mohan et al., 1995). Our results suggest 
that the NO-cGMP pathway is involved in the protective effect of RPO. The 
elevated cGMP concentrations early in ischaemia may suggest that RPO-
supplementation protected the isolated rat heart against ischaemia/reperfusion 
injury via the NO-cGMP pathway. NO is known to increase myocardial cGMP 
and it can be speculated that the protective effect of NO is related to a 
mechanism secondary to the stimulation of guanylyl cyclase within the 
vascular wall or in ventricular myocytes (Beresewics et al., 1995). Besides its 
effects on myocardial contractility, the NO-cGMP pathway stimulation during 
ischaemia may protect the heart against ischaemia/reperfusion-induced 
calcium overload. In this regard it is possible that cGMP may attenuate this 
type of injury by inhibiting the cAMP-induced slow inward calcium current, thus 
leading to a decrease in cytosolic calcium levels (Du Toit et al., 2001). Another 
protective pathway might include the NO-cGMP dependent pathway in which 
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the sarcolemmal- K ATP channels are opened and the cystolic calcium 
concentrations are lowered (Du Toit et al., 2001). Therefore, cGMP appears to 
be an endogenous intracellular cardioprotectant (Pabla et al., 1995). 
 
Studies have shown that reactive oxygen species (ROS) can oxidize lipids and 
proteins and contribute to myocardial injury (reviewed by Illarion et al., 2002). 
Peroxynitrite (ONOO-) is generated by a diffusion-limited reaction between O2- 
and NO (Naseen et al., 1995; Ferdinandy et al., 2003). Palm oil and palm oil 
products are naturally occurring sources of the antioxidant vitamin E 
constituents tocopherol and tocotrienols, which act as scavengers of these 
damaging oxygen free radicals which may lessen oxidative damage to the 
heart (Serbinova et al., 1991). This may suggest that NO, synthesized from L-
arginine by NO-synthase (NOS), results in enhanced synthesis of cGMP. NO 
synthase activity in the heart is rapidly stimulated by ischaemia and this 
stimulation is maintained during the whole ischaemic episode (Moncado and 
Higgs, 1993; Depré et al., 1996). Our data show that RPO-supplementation 
increases cGMP concentrations that may confer some of the cardioprotection 
to the ischaemic and reperfused rat heart.  
 
Although there were baseline differences between the control and RPO-
supplemented groups, the serum total cholesterol concentration was not 
effected by the 6-week diet. These data are in agreement with other studies 
which showed that not all saturated dietary fats raise serum total cholesterol 
concentration (Theriault et al., 1999; Kritchevsky, 2000; Sundram and 
Basiron). Serum triacylglycerols concentrations were increased in both groups 
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after the 6-week period with a significant difference within the RPO-
supplemented group. The baseline difference in serum total cholesterol 
between the control and RPO-supplemented groups cannot be explained and 
requires further investigation, since rats were randomly allocated to groups. 
 
Currently little documented data exist on the effects of dietary RPO-
supplementation and post ischaemic recovery linked to the NO-cGMP 
pathway, heart muscle total phospholipid fatty acid composition and 
antioxidant status. The findings of this study create opportunities for further 
investigations to elucidate mechanisms involved in cardiac protection.  
 
4.6 Conclusion 
Dietary RPO-supplementation protects against the consequences of global 
ischaemia in the isolated perfused rat heart from animals on a standard rat 
chow (control) diet. The mechanism of protection may involve the NO-cGMP 
pathway and/or myocardial phospholipid fatty acid compositional changes 
during ischaemia/reperfusion.  
 
Little knowledge exists on the protective effects of RPO-supplementation 
against ischaemia/reperfusion injury, especially when supplemented with a 
high-cholesterol diet. It was therefore our next aim to investigate whether RPO-
supplementation offers the same protection against ischaemia/reperfusion 
injury when supplemented with a high-cholesterol diet, which simulates an 
unhealthy dietary intake.  
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CHAPTER 5 
 
 
 
 
 
 
 
 
Dietary red palm oil improves reperfusion cardiac function in the isolated 
perfused rat heart of animals fed a high-cholesterol diet. 
 
 
 
 
 
 
Prostaglandins, Leukotrienes and Essential Fatty Acids (published 2005)  
     
 
  
 
 
 
 
 88
5.1 Abstract 
Introduction: It has been shown that dietary red palm oil (RPO)- 
supplementation of rats on a standard rat chow (SRC) diet improved 
reperfusion function. However, no exact cellular protective mechanisms have 
been established. Aims: The aims of this study were to determine whether 
dietary RPO-supplementation offers the same protection when cholesterol was 
added to the diet and if so, to determine a possible cellular mechanism and a 
role for fatty acids. Methods: Rats were fed a standard rat chow, standard rat 
chow plus cholesterol and/or RPO-supplementation for 6 weeks. Functional 
recovery, myocardial total phospholipid fatty acid composition and 
cAMP/cGMP concentrations were determined in isolated rat hearts subjected 
to 25 minutes of normothermic total global ischaemia. Results: Dietary RPO in 
the presence of cholesterol improved aortic output recovery (63,2 ± 3,1%) 
versus cholesterol only (36,5 ± 6,2%, P<0,05). The improved functional 
recovery of hearts from rats supplemented with RPO versus control group was 
preceded by an elevation in the cGMP concentrations early in ischaemia (RPO 
132,9 ± 36,3% versus control 42,7 ± 24,4%, P<0,05). Concurrently, cAMP 
concentrations decreased (RPO: -8,3 ± 6,9% versus control: 19,9 ± 7,7%, 
P<0,05). Conclusions: Our data suggest that dietary RPO-supplementation 
improved reperfusion aortic output through mechanisms that may include 
activation of the NO-cGMP and inhibition of the cAMP pathway.  
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5.2 Introduction 
Red palm oil consists of 51% saturated fatty acids (SFAs), 38% 
monounsaturated fatty acids (MUFAs), 11% polyunsaturated fatty acids 
(PUFAs) and a spectrum of antioxidants with carotenoids, tocopherols and 
tocotrienols as the major constituents (Nagendran et al., 2000). It has been 
shown by Serbinova and co-workers (1992) that a palm oil vitamin E mixture 
containing both α-tocopherol and α-tocotrienol, improved reperfusion functional 
recovery in a Langendorff perfused rat heart. They argued that the protection 
was induced by the ability of both α-tocopherols and α-tocotrienols to 
scavenge free radicals during reperfusion, but that α-tocotrienols offered more 
efficient protection. Apart from this finding little knowledge exist on the exact 
mechanism of dietary RPO-induced cardioprotection against 
ischaemia/reperfusion injury. The composition of RPO allows for protection to 
be offered by either the fatty acid constituents or the anti-oxidative carotenoids, 
tocopherols and tocotrienols (Abeywardena et al., 1991; Charnock et al., 1991; 
Cottrell, 1991; Abeywardena and Charnock, 1995; Chandrasekharan, 1999; 
Theriault et al., 1999) or both. A possible mechanism that has not been 
investigated may include the myocardial NO-cGMP pathway.  
 
Reactive oxygen species, including superoxide radical (O2-), hydrogen 
peroxide (H2O2) and hydroxyl radical (.OH), have long been implicated in the 
pathogenesis of ischaemia/reperfusion injury. These radicals are generated 
both during ischaemia and at the time of reperfusion and can react with nucleic 
acids, proteins and lipids, resulting in damage to the cell membrane or 
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intracellular organelles (Gilham et al., 1997). Peroxynitrite (ONOO-) is 
generated by a diffusion-limited reaction between O2- and nitric oxide (NO) 
(Rubbo et al., 1994; Naseen et al., 1995; Ferdinandy et al., 1999; Ferdinandy 
and Schultz, 2003).  
 
NO is an important regulator of both cardiac and vascular function and tissue 
reperfusion (reviewed by Ferdinandy and Schultz, 2003). Myocardial NO 
formation is increased during ischaemia and reperfusion, offering protection 
against ischaemia/reperfusion injury (Williams et al., 1995; Araki et al., 2000; 
Bolli, 2001). Protective effects of NO are mediated through the production of 
cGMP. NO is known to increase myocardial cGMP, and it can be speculated 
that the protective effect of NO is related to a mechanism secondary to the 
stimulation of guanylyl cyclase within the vascular wall, or in ventricular 
myocytes (Maulik et al., 1995; Beresewics et al., 1995; Depré et al., 1997). NO 
donors given during ischaemia possibly protect the myocardium by increasing 
tissue cGMP and decreasing cytosolic Ca2+ overload. Increases in cAMP 
concentrations associated with ischaemia would increase Ca2+ concentrations 
and exacerbate ischaemia/reperfusion injury (Du Toit et al., 2001). In this 
regard it is possible that cGMP may attenuate this type of injury by inhibiting 
the cAMP-induced increase in slow inward calcium current, thus leading to a 
decrease in cytosolic calcium concentrations (Sumii and Sperelakis, 1995). 
Therefore, cGMP appears to be an endogenous intracellular cardioprotectant 
(Pabla and Curtis, 1995; Pabla et al., 1995). 
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Cardiac stress adaptation is possibly compromised in hyperlipidaemia due to 
altered NO-cGMP pathway function. Research showed that high-cholesterol 
diets impair NO-cGMP signalling in both endothelium and non-endothelial cells 
with a significant decrease in cardiac NO concentration. Giricz and co-workers 
(2003) found an increase in O2- production in cholesterol-fed rats, which may 
explain the decreased cardiac NO-concentration in hyperlipidaemia.  
 
Despite the SFA content of RPO, several clinical trials have evaluated the 
effect of RPO on blood lipids and lipoproteins. These studies suggest that RPO 
in a moderate fat, moderate cholesterol diet, despite its high content of SFA, 
does not raise serum total cholesterol (TC) or LDL cholesterol concentrations 
(Chandrasekharan, 1999; Theriault et al., 1999; Kritchevsky, 2000; Sundram 
and Basiron). However, when hypercholesterolaemic subjects and high fat 
liquid formula diets were used, RPO-supplementation appeared to raise TC 
and LDL cholesterol (Sundram and Basiron). Little knowledge exists on the 
protective effects of RPO-supplementation against ischaemia/reperfusion 
injury, especially with a high-cholesterol diet (Esterhuyse et al., 2003). 
 
Serbinova and co-workers (1992) focused on the functional effects of palm oil 
vitamin E in the Langendorff perfused rat heart subjected to global ischaemia, 
while the current study investigated a possible role for the cellular signalling 
pathways. We therefore designed a study to investigate the effect of RPO on 
ischaemia/reperfusion injury in the working rat heart model. We also added 
cholesterol to the diet to simulate an unhealthy dietary-cholesterol intake.  
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Our main aims were to determine whether: 1) dietary RPO-supplementation of 
rats on a hypercholesterolaemic diet protected against ischaemia/reperfusion 
injury, 2) the NO-cGMP pathway can be considered as a possible mechanism 
of protection and 3) changes in the composition of myocardial total 
phospholipid fatty acids during ischaemia contributed to this protection. 
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5.3 Materials and Methods 
5.3.1 Experimental Model  
Wistar rats were fed a standard rat chow (SRC), or a SRC plus cholesterol 
diet. In two additional groups, these diets were supplemented with RPO for 6 
weeks. The working heart perfusion method used in this Experimental Model is 
described in Chapter 3 under Materials and Methods (Experimental Model 2 
p.58) and the protocol that was followed is summarized in Figure 3.1 p.53. 
 
5.3.2 Measurement of cardiac function 
 
Left ventricular systolic-(LVSP) and diastolic pressure (LVDP), coronary flow 
(CF), heart rate (HR) and aortic output (AO) were measured as described in 
Chapter 3 under Materials and Methods (Experimental Model 1 p.50). 
Functional recovery was expressed as the percentage rate pressure product 
(RPP) recovery as described in Chapter 3 under Materials and Methods 
(Experimental Model 2 p.58).  
 
5.3.3 Biochemical analyses 
The cAMP and cGMP concentrations were determined using 
radioimmunoassay kits obtained from Amersham Corp. (Amersham, UK). The 
principle and methods were discussed in Chapter 3 under Materials and 
Methods (Experimental Model 1 p.50). 
 
5.3.4 Heart muscle total phospholipid fatty acid composition (%)  
Freeze-dried myocardial tissue from all the groups was used to determine total 
phospholipid fatty acid composition by gas chromatography as described in 
Chapter 3 under Materials and Methods (Experimental Model 1 p.50). 
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5.3.5 Serum lipids 
Blood was collected from the tail vein of the rats on the SRC diet and groups 
supplemented with cholesterol and RPO before and after the 6-week 
supplementation period (n=10 per group). The serum lipid profile was 
determined using a Beckman Synchron Cx 9-instrument and Beckman 
Synchron Cx reagents (Beckman Coulter) as described in Chapter 3 under 
Materials and Methods (Experimental Model 1 p.50).  
 
5.3.6 Statistical methods 
Statistical methods used were described in Chapter 3 under Materials and 
Methods (Experimental Model 1 p.50). 
 
5.4 Results 
5.4.1 % Rate pressure product recovery 
Rate pressure product (RPP) recovery was increased in the RPO-
supplemented group when compared with the control group (89,4 ± 4,7% 
versus 75,0 ± 4,7%, P<0,05) 25 minutes into reperfusion (n=5 per group) 
(Figure 5.1). RPO also improved RPP recovery in the presence of cholesterol 
(cholesterol/RPO: 99,9 ± 4,0% versus cholesterol only: 72,1 ± 2,7%, P<0,05). 
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Figure 5.1 % Rate pressure product recovery in the 4 experimental groups 25 
minutes into reperfusion (n=5 per group) (*P<0,05 for the RPO-supplemented 
group versus the control group) (#P<0,05 for the cholesterol/RPO-supplemented 
group versus the cholesterol group) (mean ± SEM) 
 
5.4.2 Aortic output recovery (%) 
Results are presented in Figure 5.2. The percentage aortic output recovery of 
hearts from RPO-supplemented rats was significantly higher than the 
percentage aortic output recovery in the control hearts, indicating that RPO 
offered protection against ischaemia/reperfusion injury (72,9 ± 3,4% versus 
55,4± 2,5%, P<0,05). Cholesterol-supplementation caused a poor aortic output 
recovery when compared with the control group (35,5 ± 6,2% versus 55,4± 
2,5% P<0,05, respectively). However, when RPO was added to the cholesterol 
diet, the percentage aortic output recovery in the cholesterol/RPO-
supplemented group was significantly increased when compared with the 
cholesterol group (cholesterol/RPO: 63,2 ± 3,1% versus cholesterol: 35,5 ± 
6,2%, P<0,05).  
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Figure 5.2 % Aortic output recovery in the 4 experimental groups 25 minutes 
into reperfusion (n=5 per group) (*P<0,05 for the cholesterol- and RPO-
supplemented groups versus the control group) (#P<0,05 for the 
cholesterol/RPO-supplemented group versus the cholesterol group) (mean ± 
SEM) 
 
5.4.3 Effects of RPO-supplementation on ischaemic cAMP and cGMP 
concentrarions 
The cAMP results are presented in Figure 5.3 and cGMP results in Figure 5.4. 
Baseline values for cAMP and cGMP refer to values at 25 minutes into 
perfusion before ischaemia was introduced (cAMP: control = 119,9 ± 7,7 
pmol/g; RPO = 91,7 ± 6,9 pmol/g; cholesterol = 97,5 ± 2,8 pmpl/g; 
cholesterol/RPO = 112,1 ± 18,2 pmol/g) and (cGMP: control = 21,6 ± 2,4 
pmol/g; RPO = 25,4 ± 4,0 pmol/g; cholesterol = 26,1 ± 2,8 pmol/g; 
cholesterol/RPO = 36,4 ± 9,1 pmol/g). All values in Figures 5.3 & 5.4 represent 
the percentage change in cAMP and cGMP concentrations between the 
baseline value and the value of the corresponding experimental group at 10 
and 25 minutes ischaemia and 10 minutes into reperfusion (n=5 per group per 
time point).  
* 
# * 
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There was a significant difference in myocardial cAMP concentrations between 
the control group and the RPO-supplemented group at all three sampling 
points (percent change from baseline: control 19,9 ± 7,7% versus RPO -8,3 ± 
6,9% at 10 minutes ischaemia; control 6,9 ± 7,0% versus RPO -11,9 ± 1,8% at 
25 minutes ischaemia and control 30.3 ± 7,1%, versus RPO -3,0 ± 9,7% at 10 
minutes reperfusion) (P<0,05).  
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Figure 5.3 % Change in myocardial cAMP concentrations in the 4 experimental 
groups before ischaemia, during ischaemia and in reperfusion (n=5 per group 
per time point) (*P<0,05 for the indicated group versus the control group) 
(#P<0,05 for the indicated group versus the cholesterol group) (mean ± SEM) 
 
The cholesterol/RPO-supplemented group showed a significant difference in 
cAMP at 10 minutes into reperfusion, when compared with the cholesterol 
group (percent change from baseline: cholesterol/RPO -8,5 ± 10,7% versus 
cholesterol 30,6 ± 8,9%,) (P<0,05). 
Myocardial cGMP concentrations (Figure 5.4) were significantly increased in 
the RPO-supplemented group when compared with the control group 10 
minutes into ischaemia (RPO 132,9 ± 36,3% versus control 42,7 ± 24,4%) 
(P<0,05). 
*
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Figure 5.4 % Change in myocardial cGMP concentrations in the 4 experimental 
groups before ischaemia, during ischaemia and in reperfusion (n=5 per group 
per time point) (*P<0,05 for RPO-supplemented group versus the control group) 
(mean ± SEM) 
 
5.4.4 Serum lipids 
Weight increase of rats remained stable between the control- and 
supplemented groups after the 6-week supplementation period.  
 
Figure 5.5 - Figure 5.7 represent the percentage change in serum total 
cholesterol-, high density lipoprotein cholesterol and triacylglycerol 
concentrations between the baseline value and the value of the corresponding 
experimental group after a 6-week supplementation period (n=10 per group).  
  
Although there were baseline differences between the control and RPO-
supplemented group (1,3 ± 0,04 mmol/l versus 1,4 ± 0,04 mmol/l, P<0,05), the 
 * 
 99
% change in serum total cholesterol between 4 experimental groups was not 
different after a 6-week supplementation period (n=10 per group) (Figure 5.5). 
 
Figure 5.5 % Change in serum total cholesterol in the 4 experimental groups 
after a 6-week supplementation period (n=10 per group)(mean ± SEM) 
 
 
HDL-cholesterol followed a similar trend with baseline differences between 
control and RPO-supplemented groups, but with no difference (% change in 
serum high density lipoprotein cholesterol) between the experimental groups 
after the 6-week diet (n=10 per group) (Figure 5.6).  
 
-8
-6
-4
-2
0
2
4
6
8
10
12
14
Control RPO Chol Chol/RPO
%
 C
ha
ng
e 
in
 s
er
um
 to
ta
l 
ch
ol
es
te
ro
l
 100
Figure 5.6 % Change in serum high density lipoprotein cholesterol in the 4 
experimental groups after a 6-week supplementation period (n=10 per group) 
(mean ± SEM) 
 
 
Serum concentrations of triacylglycerol were increased, P<0,05, in the RPO- 
and cholesterol supplemented groups after 6 weeks on the diet (0,6 ± 0,1 
mmol/l and 0,5 ± 0,1 mmol/l, respectively before 6-week diet and 0,9 ± 0,1 
mmol/l and 1,1 ± 0,2 mmol/l, respectively after 6-week diet). In the control 
group it was 0,5 ± 0,1 mmol/l before and 0,8 ± 0,1 mmol/l after the 6-week diet 
(n=10 per group) and in the cholesterol/RPO group (n=10) it was 0,8 ± 0,1 
mmol/l before and 0,9 ± 0,2 mmol/l after the 6-week diet. However, the % 
change in serum triacylglycerols between 4 experimental groups was not 
different after a 6-week supplementation period (Figure 5.7). 
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Figure 5.7 % Change in serum triacylglycerols in the 4 experimental groups 
after a 6-week supplementation period (n=10 per group) (mean ± SEM) 
 
 
5.4.5 Heart muscle total phospholipid fatty acid composition before and 
after ischaemia  
The major fatty acids of myocardial tissue total phospholipids that play a role in 
eicosanoid production are presented in Table 5.1. Our results show that dietary 
supplementation with cholesterol, RPO and cholesterol/RPO caused significant 
changes in fatty acid composition of myocardial tissue measured before and 
after ischaemia. The presence of n-3 fatty acids in the standard rat diet were 
most probably the reason for the high percentage n-3 PUFAs in the myocardial 
total phospholipids of all the groups. The high percentage myocardial tissue 
docosahexaenoic acid (DHA) in all the experimental rats may be due to direct 
incorporation of DHA from the diet, and metabolism of C18:3n-3 and EPA. 
Results from Table 5.1 show that for DHA, RPO (after ischaemia 17,3%), 
cholesterol (before ischaemia 19,9%), cholesterol (after ischaemia 19,5%), 
cholesterol/RPO (before ischaemia 18,8%) and cholesterol/RPO (after 
ischaemia 18,8%) was significantly different from control (15,9% before and 
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15,6% after ischaemia, respectively) (P<0,05). This occurrence was even more 
striking in the cholesterol and cholesterol/RPO groups where the high-
cholesterol diet may have influenced ALA and EPA metabolism to DHA. The 
high SFA intake associated with RPO-supplementation could explain the 
increased myocardial SFAs in RPO- and cholesterol/RPO-supplemented group 
when compared with the control and cholesterol group before ischaemia, 
respectively (Table 5.1). Only the RPO-fed rats demonstrated a significant 
increase in percentage EPA after ischaemia, which may suggest that EPA 
together with other PUFAs displaced the excess SFAs during ischaemia, which 
resulted in increased levels of EPA. The percentage MUFAs in the cholesterol 
group decreased by 0,3% during ischaemia while MUFAs in the control group 
increased by 0,3% during ischaemia. Cholesterol-supplementation resulted in 
a lower percentage C18:2n-6 in total phospholipid (TPL) fatty acids compared 
to the control diet (Table 5.1).  
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Table 5.1 Major fatty acids (%) of myocardial total phospholipid before and after 
ischaemia. 
 
CONTROL RPO CHOL CHOL/RPO   
Before After Before After Before After Before After 
Total SFA 35.4     
± 0.4 
36.1    
± 0.3 
38.0    
± 1.3 a 
33.6    
± 0.2 c 
35.5    
± 0.3 
35.5    
± 0.5 
37.5    
± 0.1 b  
36.4    
± 2.0 
Total MUFA 7.5       
± 0.3 
7.8      
± 0.8 
7.6      
± 0.2 
7.4      
± 0.3 
6.7      
± 0.2 a 
6.4      
± 0.2 a 
6.7      
± 0.2 
7.1      
± 0.2 
Total PUFA 57.0     
± 1.4 
56.0    
± 1.1 
54.5    
± 0.5 
59.0    
± 0.3 c 
57.8    
± 0.4 
58.0    
± 0.6 
55.8    
± 0.3 b 
56.5    
± 2.0 
Total N6  38.8     
± 0.7 
38.3    
± 1.3 
36.6    
± 1.0 
39.0    
± 0.2 
35.5    
± 0.6 a 
35.7    
± 0.6 
34.1    
± 0.5 
35.2    
± 1.1 
Total N3 18.3     
± 0.8 
17.7    
± 0.7 
17.8    
± 1.3 
20.0    
± 0.2 
22.4    
± 0.2 a 
22.3    
± 0.3a 
21.7    
± 0.4 
21.4    
± 1.2 
n-6/n-3 ratio 2.2       
± 0.1 
2.2      
± 0.1 
2.1      
± 0.2 
2.0      
± 0.03 
1.6     
 ±0.04a 
1.6  
± 0.04a 
1.6      
± 0.1 
1.7      
± 0.1 
18:2n-6 22.1     
± 0.6 
22.6    
± 1.5 
21.5    
± 0.6 
22.4    
± 0.3 
17.6    
± 1.0 a 
18.5    
± 0.7 a 
16.9    
± 0.7 
19.1    
± 1.4 
20:4n-6 15.5     
± 0.4 
14.5     
± 0.4 
13.9    
± 0.9 
15.4    
± 0.2 
16.8    
± 0.4 a 
16.2    
± 0.6a 
16.3    
± 0.4 
15.1    
± 0.8 
20:5n-3 0.7       
± 0.1 
0.6      
± 0.02 
0.6       
± 0.1 
0.9 ± 
0.04 ac 
0.6       
± 0.1 
0.5      
± 0.1 
0.5      
± 0.03 
0.6       
± 0.1 
22:6n-3 15.9     
± 0.7 
15.6    
± 0.7 
16.0    
± 1.0 
17.3    
± 0.2a 
19.9    
± 0.2 a 
19.5    
± 0.3 a 
18.8    
± 0.5 a 
18.8    
± 0.7 a 
 
SFA=Saturated fatty acids   MUFA=Monounsaturated fatty acids 
PUFA=Polyunsaturated fatty acids  TN6= (n-6) Polyunsaturated fatty acids 
TN3= (n-3) Polyunsaturated fatty acids 
(ap<0,05 for the group versus the Control group) 
(bp<0,05 for the group versus the Cholesterol group)  
(cp<0,05 for the group before ischaemia versus the corresponding group after 
ischaemia)  
 
 
All values in Figure 5.8 represent the percentage change in phospholipid fatty 
acid composition between the baseline value and the value of the 
corresponding experimental group at 10 minutes into reperfusion) (n=5 per 
group per time point). Baseline values for heart muscle total phospholipid fatty 
acid composition refer to values at 25 minutes into perfusion before ischaemia 
was introduced (Table 5.1). RPO and cholesterol/RPO-supplemented groups 
showed a significant decrease in % change in total SFAs when compared with 
control and cholesterol groups, respectively. Concurrently, the % change in 
EPAs and total PUFAs increased significantly in hearts of the RPO-
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supplemented group when compared with hearts of the control group. Hearts 
of the cholesterol-supplemented group showed a significant increase in % 
change of total SFAs when compared with hearts of the RPO-supplemented 
group, which was associated with a decrease in % change in EPA and total 
PUFAs in hearts of cholesterol-supplemented group when compared with 
hearts of RPO-supplemented group. 
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Figure 5.8 % Change in phospholipid fatty acid composition in the 4 
experimental groups after an ischaemic period of 25 minutes (n=5 for each 
group) (#P<0,05 for the indicated group versus the control group)(*P<0,05 for 
the group versus the RPO group)(^P<0,05 for the indicated group versus the 
cholesterol group) (mean ± SEM) 
 
 
5.5 Discussion 
Diets high in fat and cholesterol are associated with hypercholesterolaemia 
and are considered a major risk factor for the development of ischaemic heart 
disease (Ferdinandy et al., 1998; Giricz et al., 2003). To our knowledge little 
data exist on the effects of dietary RPO-supplementation on post-ischaemic 
cardiac recovery and the role of 1) the NO-cGMP pathway, 2) total heart 
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muscle phospholipid fatty acid composition and 3) antioxidant status on this 
recovery.  
The protective properties of NO-cGMP pathway activation could be 
responsible for improved aortic output recovery of hearts of the RPO-
supplemented group when compared with the control-fed animals. This 
improved functional recovery was associated with elevated cGMP and 
decreased cAMP concentrations early in ischaemia. However, although our 
data indicate that RPO-supplementation of a high-cholesterol diet improved 
functional recovery of the reperfused heart, this improvement could not be 
linked with altered NO-cGMP signalling. Based on our results we propose that 
the protective effect of RPO in high-cholesterol diets may be associated with 
either RPO antioxidant characteristics and/or changes in the phospholipid fatty 
acid composition of the myocardium during ischaemia/reperfusion. 
Abeywardena and co-workers (1995) provided supportive evidence for the 
existence of a complex interaction between fatty acids and antioxidants in 
RPO-induced protection during ischaemia/reperfusion. These data support the 
findings of Serbinova and co-workers (1992) which showed that palm oil 
vitamin E mixture containing both α-tochopherol and α-tocotrienol may be 
more effective in protecting the heart against ischaemia/reperfusion injury in 
the isolated Langendorff perfused rat heart than α-tocopherol alone. This 
higher antioxidant activity of the tocotrienols has been attributed to a number of 
mechanisms including efficient interaction with free radical species, higher 
recycling efficiency of chromanoxyl radical and uniform distribution in 
membrane bilayers (Theriault et al., 1999). 
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We have previously reported that RPO-supplementation increased total 
myocardial PUFAs over the 25-minute period of ischaemia (Esterhuyse et al., 
2003). In the present study we found that the % EPA in phospholipid (n-3 
PUFA) increased from 0,6 ± 0,1% to 0,9 ± 0,04% over the same period in the 
RPO-supplemented group. These findings suggest that EPA, together with 
other PUFAs, displaced the excess SFAs during ischaemia and thus leads to 
increased % EPA with subsequent production of DHA. The pathway leading to 
the biosynthesis of DHA from docosapentaenoic acid (C22:5n-3, DPA) has 
only recently been deciphered in mammals (Pereira et al., 2003). DPA is 
elongated to tetracosapentaenoic acid (C24:5n-3), which is then desaturated 
by a Δ6 desaturase to generate tetracosahexaenoic acid (C24:6n-3), which is 
then thought to be transported to the peroxisomes where it undergoes β-
oxidation to generate DHA (Figure 2.1 p.12). Cholesterol and cholesterol/RPO-
supplemented groups showed increased % DHA phospholipid before 
ischaemia when compared with control group. All the supplemented groups 
showed a similar DHA increase after ischaemia when compared with the 
corresponding control group. The relatively high % DHA in hearts in all the 
groups, including the control group, could be explained by the composition of 
the standard rat chow which contains a high percentage of n-3 PUFAs. It is 
well known that when on high cholesterol diets, membrane fatty acid 
composition shows increases in the longer chain PUFAs (such as DHA) in 
order to compensate for, and maintain membrane fluidity to some extent as a 
result of increased cholesterol molecules in the membrane. Van Rooyen and 
co-workers (1998) reported that the metabolic rate of EPA in the cell 
membranes of the erythrocyte decreased in animals consuming a typical 
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Western diet with high cholesterol content, which would lead to higher levels of 
EPA. Although our results showed % EPA in phospholipid to be unchanged in 
cholesterol and cholesterol/RPO-supplemented groups, decreased metabolic 
rate could explain the increased % DHA in hearts of the cholesterol and 
cholesterol/RPO-supplemented groups when compared with the other groups. 
Abeywardena and co-workers (1995) reported that EPA is either poorly 
incorporated in rat myocardium or futher elongated and desaturated to yield 
DHA, which may explain the high % DHA compared to EPA. Research has 
shown that DHA, EPA and free AA are antiarrhythmic and protect the heart 
against ischaemia/reperfusion injury (Li et al., 1997; Nair et al., 1997; Kang 
and Leaf, 2000; Pepe et al., 2002; Jump, 2003). Our results showed improved 
aortic output recovery in hearts of rats supplemented with RPO versus control 
hearts and hearts of rats fed cholesterol/RPO versus cholesterol-
supplementation, although DHA levels were increased in the cholesterol-
supplemented group as well. These findings suggest that protection may not 
only be associated with a change in fatty acid composition and eicosanoid 
production from dietary intake, but that accompanying non-fatty acid 
constituents may also be important. Furthermore, research has shown that 
thromboxane A2 and prostacyclin production are unlikely to be mediated via 
fatty acids alone, but that endogenous antioxidants may also play an important 
role (Abeywardena et al., 1991; Abeywardena and Charnock, 1995; Theriault 
et al., 1999).  
 
Generally, the mechanism of eicosanoid action is to bind to membrane- 
receptors, leading to generation of second messengers such as cAMP and 
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Ca2+ (Mohan et al., 1995; Li et al., 1997). In the current study myocardial cAMP 
concentrations were decreased in the RPO-supplemented group, compared to 
the other groups. Therefore, prevention of fatal cardiac arrhythmias may 
depend on the net effect of eicosanoids, which is determined by the status of 
AA metabolism and the contents of n-6 and other fatty acids (Abeywardena et 
al., 1991; Charnock et al., 1991; Nair et al., 1997; Kang and Leaf, 2000). Both 
NO and prostaglandins have important independent effects on cardiovascular 
function, but the interaction between them determines myocardial performance 
(Mohan et al., 1995). The mechanism of fatty acid protection remains elusive 
and needs further investigation. 
Research has shown that cholesterol-enriched diets impair NO-cGMP 
signalling in both endothelial and nonendothelial cells. Girics and co-workers 
(2003) showed that cholesterol diet-induced hyperlipidaemia decreased 
cardiac NO concentration, but it does not change nitric oxide synthases (NOS) 
activity. Therefore, the decreased NO-concentrations were not due to impaired 
NO synthesis, but caused by breakdown of cardiac NO due to increased ROS 
production in hyperlipidaemic rats (Girics et al., 2003). These authors also 
found an increased O2- production in hyperlipidaemic hearts, which support the 
assumption that elevated ROS production is responsible for decreased NO 
concentration in hyperlipidaemic myocardium.  
 
We have previously shown that RPO-supplementation increased cGMP 
concentrations early in ischaemia when compared with the control-fed rats, 
which may confer some of the cardioprotection to the ischaemia/reperfused 
heart (Esterhuyse et al., 2003). Although not indicated in Figure 5.4, the 
 109
present study has shown that cholesterol-supplementation for 6 weeks 
influenced the NO-cGMP signalling pathway by decreasing % change in cGMP 
concentrations in both the cholesterol and cholesterol/RPO-supplemented 
groups when compared with the RPO-supplemented group; yet it was not 
different from the control group. These data are in agreement with other 
studies, which showed that high-cholesterol diet impairs NO-cGMP signalling 
in both endothelial and non-endothelial cells (Deliconstantinos et al., 1995).  
 
The decreased myocardial cAMP concentrations in the RPO-supplemented 
group may be related with increased cGMP concentrations. In this regard it is 
possible that cGMP may attenuate this type of injury by inhibiting the cAMP-
induced increase in the slow inward calcium current, thus leading to a 
decrease in ischaemic cytosolic calcium concentrations (Sumii et al., 1995; Du 
Toit et al., 2001).  
 
High cholesterol-diets are also known to inhibit the formation of ubiquinone 
(coenzyme Q10) production. This coenzyme is a key polyprenyl derivative 
molecule in the mitochondrial electron transport system and as an endogenous 
antioxidant it protects the ischaemia/reperfused myocardium (Ferdinandy et 
al., 1998; Wall, 2000; Girics et al., 2003). CoQ10 is found naturally in small 
amounts in RPO (Nagendran et al., 2000), which may explain improved aortic 
output recovery in RPO and cholesterol/RPO-supplemented groups when 
compared with the control and cholesterol fed groups, respectively.  
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Supplementation with RPO appeared to raise TC and LDL cholesterol when 
hypercholesterolaemic subjects and high fat liquid formula diets were used 
(Sundram and Basiron). However, our results have shown that RPO-
supplementation in the presence of potentially harmful cholesterol did not lead 
to a significant difference in serum total cholesterol. We know that tocotrienols 
in RPO not only suppress cholesterol production in the liver and lower its 
serum concentration, but also lower the damaging LDL-cholesterol. 
Tocotrienols prenylated side-chains are thought to induce prenyl 
pyrophosphate pyrophosphatase that catalyzes the dephosphorylation of 
fernysal with a concomitant increase of cellular farnesol. Farnesol 
downregulates HMG CoA reductase activity by a post-transcriptional process 
involving protein degradation. This mechanism is different from cholesterol, 
which exerts a feedback transcriptional effect on HMG CoA reductase activity 
(Theriault et al., 1999). These data are in agreement with other studies, which 
showed that not all saturated dietary fats raise total serum cholesterol 
(Theriault et al., 1999; Kritchevsky, 2000; Sundram and Basiron).  
The findings of this study create opportunities for further investigations to 
elucidate RPO mediated mechanisms involved in cardiac protection.  
 
5.6 Conclusion 
Dietary RPO-supplementation offered protection of hearts from rats on a 
standard rat chow (control) and hypercholesterolaemic diet against 
ischaemia/reperfusion injury as reflected by improved aortic output recovery 
and rate pressure product. This was associated with an increase in cGMP 
early in ischaemia and a decrease in cAMP during ischaemia in the RPO-
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supplemented versus control group. However, with addition of cholesterol, 
cGMP concentrations in ischaemia were decreased, but RPO still offered 
protection. This suggests that cGMP may not be the only mechanism of 
protection. The improved functional recovery in the cholesterol/RPO-
supplemented group was associated with a significant decrease of cAMP 
concentrations during reperfusion, suggesting that RPO may also protect via 
the inhibition of the cAMP pathway. 
 
Furthermore, % total PUFAs in myocardial phospholipids were increased by 
ischaemia in the RPO-supplemented group, but not in the cholesterol/RPO-
supplemented group. This suggests that PUFAs may have influenced the 
tissue concentrations of cGMP and cAMP. 
 
Evidence in this study suggests that both antioxidants and fatty acids play a 
role in the cardioprotective mechanisms of dietary RPO and our next aim was 
to search for the cellular mechanisms whereby antioxidants and fatty acids 
offer this cardioprotection. We therefore aimed to investigate the effects of 
RPO-supplementation of rats on a standard rat chow and cholesterol-enriched 
diets on myocardial NO-synthesis and NO-cGMP signalling. 
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CHAPTER 6 
 
 
 
 
 
 
 
 
 
 
Proposed mechanisms for red palm oil-induced cardioprotection in a 
hyperlipidaemic perfused rat heart model.  
 
 
 
 
 
 
 
 
(Submitted 2005) 
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6.1 Abstract 
Introduction: High-cholesterol diets alter function of the myocardial and 
vascular NO-cGMP signalling pathway. These alterations have been 
implicated in both ischaemic/reperfusion injury and the development of 
ischaemic heart disease. We have previously shown that the cardioprotection 
offered by red palm oil (RPO)-supplementation could be related to NO-cGMP 
signalling in the control, but not in the hyperlipidaemic group. Aims: We 
investigated the effects of RPO-supplementation of rats on a standard rat chow 
(control)- and cholesterol-enriched diet on myocardial nitric oxide synthesis, 
superoxide dismutase- and nitric oxide synthase activity and lipid 
hydroperoxide production in the rat heart. Materials and Methods: Wistar rats 
were fed a standard rat chow (SRC), or a SRC plus cholesterol diet. In 2 
additional groups, these diets were supplemented with RPO for 6 weeks. Post-
ischaemic mechanical function, total myocardial nitric oxide concentrations, 
lipid hydroperoxide production and superoxide dismutase- and nitric oxide 
synthase activity were determined in isolated working rat hearts subjected to 
25 minutes of normothermic total global ischaemia. Results: Dietary RPO-
supplementation of the standard rat chow (control) diet and the cholesterol-
enriched diet improved aortic output recovery (72,1 ± 3,2% versus 54,0± 3,2% 
and 64,0 ± 2,5% versus 39,3 ± 4,9% respectively, P<0,05). The improved 
aortic output recovery of hearts from rats supplemented with RPO was 
associated with an elevation in the cGMP concentration early in ischaemia. 
Baseline myocardial nitric oxide content was significantly decreased in the 
cholesterol-enriched diet group when compared to the control group (1,6 ± 0,4 
mmol/l versus 2.8 ± 0,2 mmol/l, P<0,05). Direct intracellular nitric oxide 
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detection in isolated rat cardiomyocytes showed a significant increase in nitric 
oxide production after 120-minute simulated ischaemia (hypoxia) in both the 
RPO- and cholesterol/RPO-supplemented group when compared with non-
hypoxic control and cholesterol-supplemented groups, respectively (2,9 ± 0,1 
arbitrary units and 2,5 ± 0,1 arbitrary units versus 2,4 ± 0,1 arbitrary units and 
2,1 ± 0,1 arbitrary units, respectively, P<0,05). Conclusions: Our data show 
that dietary RPO-supplementation protects the hearts of animals on a standard 
rat chow or hypercholesterolaemic diet against ischaemia/reperfusion injury. 
Mechanisms for this cardioprotection may include RPO-induced preservation 
of myocardial ischaemic NO-concentrations, which causes elevated cGMP 
concentrations in hearts of rats on a standard rat chow diet. 
Key words: Hyperlipidaemia - Working heart perfusion - Ischaemia - RPO 
protection - Nitric Oxide - Free radicals 
 
6.2 Introduction 
Nitric oxide (NO) is, by virtue of its vasodilator, antioxidant, anti-platelet and 
anti-neutrophil actions, an essential molecule for normal heart function 
(reviewed by Ferdinandy and Schultz, 2003). It has also been shown to be 
cardioprotective in the ischaemic heart (reviewed by Bolli, 2002). However, NO 
is detrimental when it is combined with superoxide (O2-) to form peroxynitrite 
(ONOO-), which rapidly decomposes to highly reactive oxidant species leading 
to tissue injury (Figure 2.4). There is a critical balance between cellular 
concentrations of NO, O2- and superoxide dismutase (SOD) which 
physiologically favour NO production, but in pathological conditions such as 
ischaemia and reperfusion, result in ONOO- formation (reviewed by 
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Ferdinandy and Schultz, 2003). These oxygen free radicals can react with 
nucleic acids, proteins and lipids, resulting in damage to the cell membrane or 
intracellular organelles (Gilham et al., 1997). 
 
Protective effects of NO are also mediated through the production of cGMP. 
Du Toit and co-workers (2001) found that nitric oxide donor treatment reduces 
ischaemia/reperfusion injury by increasing cGMP concentrations and 
suggested that the cAMP-to-cGMP ratio might play an important role in this 
cardioprotection. Maulik and co-workers (1995) showed that NO plays a 
significant role in transmembrane signalling in the ischaemic myocardium. This 
group suggested that NO signalling is switched off due to inactivation of NO by 
reactive oxygen species and were the first to suggest that reactive oxygen 
species may alter NO-cGMP signalling.  
 
Cardiac stress adaptation is possibly jeopardized in hyperlipidaemia due to 
altered NO-cGMP pathway function in vascular and myocardial tissue. 
Szilvassy and co-workers (2001) found that a cholesterol-enriched diet 
decreased both vascular NO and cGMP concentrations and increased aortic 
O2- production. Several other studies have also shown that a high-cholesterol 
diet impairs NO-cGMP signalling in both endothelium (Deliconstantinos et al., 
1995) and non-endothelial cells with a significant decrease in cardiac NO-
concentrations (Ferdinandy et al., 1997; Szekeres et al., 1997). Girics and co-
workers (2003) found an increase in O2- production with decreased cardiac 
NO-concentration in cholesterol-fed rats. Nitric oxide synthase (NOS) activity 
was unchanged which may suggest that NO synthesis was not impaired and 
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that increased O2- production was responsible for the decreased NO-
concentrations in the hyperlipidaemic myocardium. Furthermore, 
hyperlipidaemia stimulates ONOO- generation in the heart, which leads to 
myocardial dysfunction (Onody et al., 2003). 
 
Diniz and co-workers (2004) showed that changes in dietary fatty acid 
composition also affect cardiac oxidative stress. They showed that, despite 
their beneficial effects on serum lipid levels, diets rich in polyunsaturated fatty 
acids (PUFAs) were deleterious to the heart by increasing cardiac 
susceptibility to lipid peroxidation. PUFA-fed rats also showed diminished SOD 
activities when compared to saturated fatty acid (SFA)-fed rats.  
 
We have previously shown that dietary RPO-supplementation protects against 
the harmful consequences of global ischaemia in the isolated perfused rat 
heart on a standard rat chow or cholesterol-enriched diet (Esterhuyse et al., 
2005). RPO contains a mixture of SFAs (51%), MUFAs (38%), PUFAs (11%) 
and natural antioxidants, tocopherols and tocotrienols (Nagendran et al., 
2000). These natural antioxidants can act as scavengers of damaging oxygen 
free radicals (Cottrell, 1991; Serbinova et al., 1991; Chandrasekharan, 1999; 
Theriault et al., 1999; Kritchevsky, 2000). Newaz and co-workers (2003) 
showed an antioxidant protection by γ-tocotrienols in hypertensive rats when 
compared with control animals. This group suggested that improved NOS 
activity in blood vessels and increased NO availability were mediated through 
the antioxidant properties of γ-tocotrienol where it effectively scavenges the 
free radicals. Venditti and co-workers (1999) also reported that vitamin E 
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treatment offers protection against ischaemia/reperfusion-induced oxidative 
stress. However, the precise mechanism of action remains unknown. 
Little is known about the effects and possible protective mechanisms of RPO-
supplementation against ischaemia/reperfusion injury, particularly when used 
as a supplement with a high-cholesterol diet.  
 
The aims of this study were to determine whether RPO-supplementation 
influences 1) myocardial susceptibility to ischaemia/reperfusion injury in hearts 
from rats on a standard rat chow or hypercholesterolaemic diet, 2) myocardial 
NO-cGMP signalling pathway function, 3) production of cardiac NO and lipid 
hydroperoxides (LPO) and 4) enzymatic NOS and SOD activities. 
 
6.3 Materials and methods 
 
6.3.1 Experimental groups and model used  
 
Wistar rats were fed a standard rat chow (SRC), or a SRC plus cholesterol 
diet. In 2 additional groups, these diets were supplemented with RPO for 6 
weeks. The protocol used has been discussed in Chapter 3 under Materials 
and Methods (Experimental Model 3 p.60).  
 
 
6.3.2 Functional parameters measured  
Described in Chapter 3 under Materials and Methods (Experimental Model 1 
p.50).  
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6.3.3 Biochemical parameters measured 
 
6.3.3.1 Measurement of cGMP  
Myocardial cGMP concentrations were determined using a radioimmunoassay 
method as described in Chapter 3 under Materials and Methods (Experimental 
Model 1 p.50).  
 
6.3.3.2 Measurement of cardiac nitric oxide concentrations  
 
Myocardial NO concentrations were determined using a Nitrate/Nitrite kit 
(Cayman Chemicals, Cayman Islands) as described in Chapter 3 under 
Materials and Methods (Experimental Model 3 p.60). We also measured 
intracellular myocyte NO-production with DAF-2/DA by flow cytometry 
(Strijdom et al., 2004) as described in Chapter 3 under Materials and Methods 
(Experimental Model 3 p.60). 
 
6.3.3.3 Measurement of cardiac nitric oxide synthase activity  
Total nitric oxide (NOS) activity was measured using a NOS assay-kit which is 
based on biochemical conversion of L-arginine to L-citrulline by NOS (Cayman 
Chemicals, Cayman Islands). For detail about principle and method used, see 
full description in Chapter 3 under Materials and Methods (Experimental Model 
3 p.60).  
 
6.3.3.4 Measurement of cardiac superoxide dismutase activity 
Total activity of superoxide dismutase (SOD) was measured as described in 
Chapter 3 under Materials and Methods (Experimental Model 3 p.60) using a 
SOD kit (Cayman Chemicals, Cayman Islands). 
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6.3.3.5 Measurement of cardiac lipid hydroperoxide production 
Lipid hydroperoxide (LPO) production in cardiac muscle was assessed using a 
LPO assay kit (Cayman Chemicals, Cayman Islands) as described in Chapter 
3 under Methods and Materials (Experimental Model 3 p.60). 
 
 
6.3.3.6 Statistical methods 
 
Statistical methods used in this experiment have been discussed in Chapter 3 
under Materials and Methods (Experimental Model 1 p.50). 
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6.4 Results 
6.4.1 Cardiac functional parameters in isolated perfused rat hearts 
 
In order to compare the functional recovery of the hearts in the different 
groups, the heart rate (beats/min), coronary flow (ml/min), aortic flow (ml/min) 
and left ventricular developed pressure (mmHg) were monitored at 20 minutes 
perfusion and 25 minutes during reperfusion as shown in Table 6.1. Results 
showed no significant difference between the groups for all parameters 
measured before and after ischaemia, which suggests that RPO-, cholesterol 
and cholesterol/RPO-supplementation did not have a negative effect on 
cardiac function. 
 
Table 6. 1 Cardiac functional parameters in the 4 experimental groups before 
and after ischaemia 
Time Point Group HR CF AO LVDevP 
Control 271.7± 10.4 21.6±1.9 48.1±2.8 123.4±3.5 
RPO 278.1±19.2 20.4±1.4 46.4±3.2 131.4±4.0 
Chol 237.4± 25.4 21.0±1.7 51.3±3.7 124.1±6.0 
 
20 min 
Perfusion 
Chol/RPO 202.9±14.1 16.2±1.5 47.2±1.6 124.1±3.7 
Control 244.9±11.8 22.3±1.7 28.6±2.9 101.4±4.1 
RPO 283.1±15.8 21.3±1.9 33.4±2.5 114.4±5.5 
Chol 212.9±12.8 23.0±3.6 23.6±4.1   98.6±6.8 
 
25 min 
Reperfusion 
Chol/RPO 209.0±23.3 17.4±2.0 31.3±1.8 121.0±3.7 
 
Working heart perfusion cardiac functional parameters of control and cholesterol-fed 
rats with/without red palm oil-supplementation for 6 weeks. Heart rate (HR, beats/min); 
Coronary flow (CF, ml/min); Aortic output (AO, ml/min); Left ventricular developed 
pressure (LVDevP). Values are mean ± SEM (n= 7 in each group)  
 
 
6.4.1.1 Aortic output recovery (%) 
Results are presented in Figure 6.1. The percentage aortic output recovery of 
hearts of the group supplemented with RPO was higher than in the hearts of 
the control group, suggesting that RPO protected against the consequences of 
ischaemia/reperfusion (72,1 ± 3,2% versus 54,0 ± 3,2%, P<0,05) (n=7 per 
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group per time point). Cholesterol-supplementation caused a poor aortic output 
recovery when compared with the control group (42,9 ± 6,3% versus 54,0± 
3,2%, P<0,05). However, when RPO was added to the cholesterol diet, the 
percentage aortic output recovery of hearts from rats in the cholesterol/RPO-
supplemented group was significantly increased when compared with aortic 
output recovery of hearts from the cholesterol-fed group (64,7 ± 2,4% versus 
42,9 ± 6,3%, p<0,05) (n=7 per group).  
 
 
 
Figure 6.1 % Aortic output recovery of hearts from rats fed a standard rat chow 
(control) or standard rat chow plus cholesterol and/or RPO-supplemention 25 
minutes into reperfusion (n=7 per group) (*P<0,05 for the indicated group 
versus the control group) (#P<0,05 for the indicated group versus the 
cholesterol group) (mean ± SEM) 
 
 
6.4.2 Cardiac cGMP concentrations 
Baseline cGMP concentrations refer to values at 25 minutes into perfusion 
before ischaemia was introduced (control = 21,6 ± 2,4 pml/g; RPO = 25,4 ± 4,0 
pmol/g; cholesterol = 26,1 ± 2,8 pmol/g and cholesterol/RPO = 36,4 ± 
0
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9,1pmol/g). All values in Figure 6.2 represent the percentage change in cGMP 
concentrations between the baseline value and the value of the corresponding 
supplemented group at 10 and 25 minutes ischaemia and 10 minutes into 
reperfusion. The cGMP concentrations were significantly increased in hearts of 
the group supplemented with RPO when compared with hearts of the control 
group 10 minutes into ischaemia (RPO 132,0 ± 36,3% versus control 42,7 ± 
24,4%, P<0,05) (n=5 per group per time point).  
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Figure 6.2 % Change in myocardial cGMP concentrations in the 4 experimental 
groups between the baseline value and the value of the corresponding 
supplemented group at 10 and 25 minutes ischaemia and 10 minutes into 
reperfusion. (n=5 per group per time point) (*P<0,05 for the indicated group 
versus the control group) (mean ± SEM) 
 
 * 
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6.4.3 Cardiac nitric oxide content 
Baseline myocardial NO content was significantly decreased in the cholesterol-
enriched diet group when compared to the control group (1,6 ± 0,4 mmol/l 
versus 2.8 ± 0,2 mmol/l, P<0,05) (Figure 6.3). 
 
However, baseline myocardial NO content of the RPO-supplemented group 
showed no significant difference when compared with control group. Similarly, 
the cholesterol/RPO-supplemented group was unchanged when compared 
with cholesterol-enriched group. Myocardial NO concentrations were also 
significantly decreased in the cholesterol-enriched diet group when compared 
to the control group at 10 minutes ischaemia (2,1± 0,2 mmol/l versus 4,4 ± 1,2 
mmol/l, P<0,05), but similar in all the other groups and also when compared 
with baseline values (Figure 6.3).  
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Figure 6.3 Total myocardial NO concentrations in the 4 experimental groups 
before ischaemia, during ischaemia and in reperfusion (*P<0,05 for the 
indicated group versus the control group) (n=5 per group per time point) (mean 
± SEM) 
 
However, direct intracellular NO detection in isolated rat cardiomyocytes 
showed a significant increase in NO production after 120 minutes of simulated 
ischaemia (hypoxia) in the RPO-supplemented group when compared with 
* *
 124
0
1
2
3
4
5
non-hypoxic 2hr hypoxia
D
A
F 
Fl
uo
re
sc
en
ce
 
(A
rb
itr
ar
y 
U
ni
ts
)
Control 
RPO 
baseline (non-hypoxic) value in RPO-supplemented group and hypoxic control 
group (2,9 ± 0,1 arbitrary units versus 2,5 ± 0,1 arbitrary units and 2,4 ± 0,1 
arbitrary units, respectively, P<0,05) (Fig 6.4A). The cholesterol/RPO-
supplemented group showed a similar increase in myocardial NO production  
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Figure 6.4 Intracellular nitric oxide as detected by DAF fluorescence in isolated 
cardiomyocytes. (A) (*P<0,05 for the indicated group versus the control group) 
(#P<0,05 for the hypoxic group versus the non-hypoxic group) (n=6) (B) (#P< 
0,05 for the hypoxic group versus the non-hypoxic group) (n=6) Experimental 
groups consist of samples from different hearts (mean ± SEM) 
 
#
*
#
A 
B 
 125
 
after 120 minutes of simulated ischaemia (hypoxia) when compared with 
baseline NO-concentration in cholesterol/RPO-supplemented group (2,5 ± 0,1 
arbitrary units versus 2,1 ± 0,1 arbitrary units, P<0,05) (Fig 6.4B). 
 
6.4.4 Cardiac nitric oxide synthase activity 
Myocardial NOS activity was significantly decreased in the control group at 10 
minutes ischaemia when compared with baseline values in control group (5,7 ± 
0,3% versus 3,9 ± 0,5%, P<0,05) (n=5 per group per time point) (Figure 6.5).  
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Fig 6.5 % Myocardial NOS activity in the 4 experimental groups before 
ischaemia, during ischaemia and in reperfusion (n=5 per group per time 
point)(*P<0,05 for the indicated group versus the same group before ischaemia) 
(#P<0,05 for the indicated group versus the cholesterol group) (mean ± SEM) 
 
Baseline myocardial NOS activity was unchanged for cholesterol-, 
cholesterol/RPO- and RPO-supplemented groups. However, myocardial NOS 
activity was significantly increased in cholesterol/RPO-supplemented group 
* #
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when compared with cholesterol group at 10 minutes ischaemia (6,8 ± 0,6% 
versus 4,5 ± 0,6%, P<0,05) (n=5 per group per time point).  
 
6.4.5 Cardiac superoxide dismutase activity 
Baseline (20-minute perfusion), ischaemic- and reperfusion SOD activity was 
similar in all groups at all time points investigated (Table 6.2).  
 
6.4.6 Cardiac lipid hydroperoxide production 
Direct measurement of myocardial lipid hydroperoxides in rats fed a standard 
rat chow or a standard rat chow plus cholesterol and/or RPO-supplemention 
showed no significant difference in baseline-, ischaemic- and reperfusion 
hydroperoxide levels when compared with the control group (Table 6.2). 
 
Table 6.2 Baseline (20-minute perfusion), ischaemic and post-ischaemic 
myocardial super oxide dismutase activity and lipid hydroperoxide levels in the 
4 experimental groups (n=5 per group per time point) 
 
 Group 20 minutes 
perfusion 
10 minutes 
ischaemia 
10 minutes 
reperfusion 
Control 1.6±0.2 1.9±0.5 1.9±0.1 
RPO 1.8±0.4 1.6±0.1 2.1±0.2 
Chol 2.3±0.3 2.0±0.4 1.7±0.3 
 
SOD 
(U/ml) 
Chol/RPO 1.9±0.2 2.0±0.3 2.4±0.1 
Control 10.4±0.4 11.9±0.8 10.1±0.3 
RPO 9.2±0.5 9.5±0.7 9.4±0.2 
Chol 9.5±0.5 9.7±0.7 9.3±1.4 
 
LPO 
(nM/L) 
Chol/RPO 9.6±1.0 9.5±1.2 10.1±1.8 
 
SOD = Superoxide dismutase 
LPO = Lipid hydroperoxide 
(values are mean ± SEM) 
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6.5 Discussion 
 
Our data show that RPO-supplementation of a standard rat chow (control) or 
cholesterol-enriched diet improves aortic output recovery when compared with 
control and cholesterol-fed groups, respectively. The improved functional 
recovery in hearts from rats on a control diet supplemented with RPO was 
associated with an elevation in ischaemic cGMP concentration. Cholesterol-
supplementation decreased baseline myocardial NO-concentration when 
compared with the control group, but the decrease was not associated with 
changes in cardiac NOS activity. Intracellular NO concentrations in isolated 
cardiomyocytes from RPO-supplemented rats were increased after 120 
minutes of simulated ischaemia (hypoxia) when compared with baseline (non-
hypoxic) value in RPO-supplemented group and hypoxic control group. The 
cholesterol/RPO-supplemented group showed a significant increase in 
myocardial NO production after hypoxia compared to the non-hypoxic 
conditions, a trend that was not observed in hearts of cholesterol-fed rats 
without RPO-supplementation. Ischaemia decreased myocardial NOS activity 
in the control hearts. However, hearts of the cholesterol/RPO-supplemented 
group showed a significant increase in ischaemic NOS activity compared to 
hearts of the cholesterol-supplementated group.  
 
6.5.1 Effects of cholesterol-enriched diet on baseline myocardial NO 
concentrations  
 
It is well known that hyperlipidemia leads to increased production of ROS in 
the vasculature which in turn leads to formation of ONOO- (Deliconstantinos et 
al., 1995). Onody and co-workers (2003) showed that a cholesterol-enriched 
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diet reduces cardiac NO concentrations, enhances cardiac formation of O2- 
and stimulates ONOO- generation in the heart, which leads to myocardial 
dysfunction. Another study by the same group confirmed these results, but 
also showed that a cholesterol-enriched diet does not change NOS activity 
(Girics et al., 2003). They speculated that the decreased myocardial NO 
concentrations were not due to impaired NO synthesis, but was possibly 
caused by increased breakdown of cardiac NO due to hyperlipidaemia 
(Ferdinandy et al., 1998; Girics et al., 2003). The mechanism of decreased 
myocardial NO level in hyperlipidaemia is still unknown. Girics and co-workers 
(2003) further propose that increased superoxide production in hyperlipidaemic 
hearts would promote the reaction of ROS with NO to form ONOO- and support 
the assumption that elevated ROS production is responsible for decreased NO 
concentrations in the hyperlipidaemic myocardium.  
 
6.5.2 NO production during ischaemia  
Our results showed that myocardial NOS activity was impaired under 
ischaemic conditions in control hearts when compared with baseline (non-
ischaemic) values of the same group. Surprisingly, ischaemic myocardial NOS 
activity of hearts from the cholesterol/RPO-supplemented group was increased 
when compared with cholesterol-supplemented group. These findings are 
supported by the data obtained with the isolated cardiomyocytes. The hearts of 
rats supplemented with cholesterol/RPO showed an increased intracellular 
cardiomyocyte NO production after 120 minutes of simulated ischaemia 
(hypoxia) when compared with baseline NO-concentration in cholesterol/RPO-
supplemented group. Newaz and co-workers (2003) demonstrated antioxidant-
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mediated protection by γ-tocotrienols in hypertensive rats. This group 
suggested that improved NOS activity in blood vessels and increased NO 
availability were mediated through the antioxidant properties of γ-tocotrienol, 
which effectively scavenges the free radicals. Previous studies (Onody et al., 
2003) have demonstrated that a cholesterol-enriched diet increased basal 
myocardial superoxide generation. Based on these data we speculate that free 
radical generation would be further increased during ischaemia. Elevated 
concentrations of free radicals may contribute to the suppressed NOS activity 
in the ischaemic hearts of the cholesterol fed rats. The inclusion of RPO 
containing tocopherols and tocotrienols, could potentially improve NOS activity 
in the cholesterol/RPO-supplemented group by reducing free-radical induced 
NOS enzyme damage.  
 
Although there appears to be a discrepancy between ischaemic NOS activity 
and NO concentrations in the hearts, these data may be explained by the 
findings of Zweier and co-workers (1999). These authors have shown that NO 
generation from nitrite via a NOS-independent pathway can be the major 
source of NO during ischaemia.  
 
6.5.3 Dietary vitamin E and generation of NO, O2- and ONOO- in 
cholesterol-enriched diets 
Although our data indicate that RPO-supplementation of rats on a high-
cholesterol diet improved functional recovery of the ischaemic/reperfused 
heart, this improvement could not be linked with increased NO-cGMP 
signalling, despite the increased intracellular cardiomyocyte NO concentrations 
as observed in the cholesterol/RPO-supplemented group after 120-minute 
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hypoxia when compared with the non-hypoxic cholesterol/RPO-supplemented 
group. Research has shown that cholesterol-enriched diets impair NO-cGMP 
signalling in both endothelial and non-endothelial cells (Deliconstantinos et al., 
1995; Ferdinandy et al., 1997; Szekeres et al., 1997; Szilvassy et al., 1997). 
Therefore, based on our results we propose that the protective effect of RPO in 
high-cholesterol diets may be due to the dietary RPO vitamin E antioxidant 
characteristics. Vitamin E acts as a free radical scavenger that can react with 
oxygen, superoxide anion radical and hydroxyl radical (Abudu et al., 2004). 
Due to its lipid solubility, it is predominantly a chain breaking antioxidant within 
the lipoprotein (Abudu et al., 2004).  
Chow and co-workers (2002) reported that dietary vitamin E is capable of 
reducing the production and/or availability of not only O2-, but also NO and 
ONOO-. By reducing available O2- and NO, vitamin E may alleviate nitric oxide 
toxicity via reduced formation of reactive ONOO-.  
However, it is not clear if the action of vitamin E to reduce the generation of O2-  
and other ROS is independent of its antioxidant function. 
 
6.5.4 RPO-supplementation and NO-cGMP signalling 
Improved functional recovery of hearts of rats supplemented with RPO when 
compared with hearts of rats on a control diet was associated with elevated 
cGMP concentrations early in ischaemia. Increased intracellular cardiomyocyte 
NO concentrations as observed in the RPO-supplemented group after 120-
minute hypoxia may contribute to the elevated cGMP concentration and may 
confer some of the cardioprotection to the ischaemic/reperfused heart. Maulik 
and co-workers (1995) showed that NO plays a significant role in 
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transmembrane signalling in the ischaemic myocardium. The signalling seems 
to be transmitted via cGMP and they suggested that NO signalling is switched 
on and off due to inactivation of NO by reactive oxygen species. Therefore, if 
dietary RPO containing vitamin E antioxidants act as free radical scavengers, 
elevated cGMP concentrations in early ischaemia through increased nitric 
oxide signalling could be responsible for improved functional recovery in hearts 
of rats supplemented with RPO versus non-RPO fed rat hearts in the control 
group. 
 
6.5.6 Effects of diets rich in PUFAs and SFAs in cardiovascular disease  
In a previous study we reported an increase in baseline myocardial total % 
SFA composition of total phospholipid with RPO-supplementation of the control 
and cholesterol groups, respectively (Esterhuyse et al., 2005).  
 
Diniz and co-workers (2004) reported that changes in dietary fatty acids affect 
cardiac oxidative stress. They showed that diets rich in PUFAs, despite the 
beneficial effects on serum lipids, were deleterious when compared with SFAs 
in the heart by increasing cardiac susceptibility to lipid peroxidation. Their 
observation that SFA-fed rats had lower myocardial hydroperoxide 
concentrations than PUFA-fed rats demonstrates the importance of the PUFA: 
SFA ratio on lipid peroxidation and the level of antioxidants. They also showed 
that PUFA-fed rats had diminished SOD activity. 
 
We have also reported in a previous study that RPO-supplementation of rats 
on a standard rat chow (control) increased total myocardial PUFAs over the 
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25-minute period of ischaemia (Esterhuyse et al., 2003). Bagchi and co-
workers (1998) reported that vitamin E protects PUFAs in cell membranes from 
peroxidation, which may confer some of the cardioprotection in RPO-
supplemented control and cholesterol-treated rats.  
 
The findings of this study create opportunities for further investigations to 
elucidate RPO mediated mechanisms involved in cardiac protection.  
 
6.6 Conclusion 
Our data show that RPO-supplementation improves aortic output recovery in 
hearts from both standard rat chow (control) and cholesterol fed animals. The 
improved functional recovery seen in control RPO-supplemented hearts may 
be due to preservation of ischaemic myocardial NO and cGMP concentrations. 
However, RPO-supplementation of a high cholesterol diet probably protects 
the isolated rat heart against ischaemia/reperfusion injury by mechanisms 
independent of the NO-cGMP signalling pathway.  
 
Myocardial hypoxia-reoxygenation is associated with upregulation of a number 
of endogenous enzymes, including the matrix metalloproteinases (MMPs), 
which can induce apoptosis with subsequent exacerbation of cardiac 
dysfunction (Chen et al., 2003). Therefore, the next study was designed to 
determine whether RPO-supplementation offers cardioprotection during 
ischaemia/reperfusion by influencing the regulation of both mitogen-activated 
protein kinases and serine/threonine protein kinases.  
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CHAPTER 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p38-MAPK and PKB/Akt, possible role players in red palm oil-induced  
protection of the isolated perfused rat heart? 
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7.1 ABSTRACT 
 
Introduction: It has been shown that dietary red palm oil (RPO) 
supplementation improves reperfusion function. However, no exact protective 
cellular mechanisms have been established. Aims: To determine a potential 
mechanism for functional improvement by investigating the regulation of both 
mitogen-activated protein kinases (MAPKs) and serine/threonine protein 
kinases (PKB/Akt) in the presence, and absence, of dietary RPO-
supplementation in ischaemia/reperfusion. Materials and Methods: Wistar 
rats were fed a standard rat chow (control) diet or standard rat chow diet plus 
7g RPO per kg diet for 6 weeks. Hearts were excised and mounted on an 
isolated working heart perfusion apparatus. Cardiac function was measured 
before and after hearts were subjected to 25 minutes of total global ischaemia. 
Hearts subjected to the same conditions were freeze-clamped and used to 
characterize the degree of phosphorylation of extracellular signal-regulated 
kinase (ERK), p38, c-Jun NH2-terminal protein kinase (JNK) and PKB/Akt. 
Results: Dietary RPO-supplementation significantly improved aortic output 
recovery (72.1 ± 3.2% versus 54.0 ± 3.2%, P<0.05). This improved aortic 
output recovery was associated with significant increases in p38- and PKB/Akt 
phosphorylation during reperfusion when compared with control hearts. 
Furthermore, a significant decrease in JNK phosphorylation and attenuation of 
PARP cleavage occurred in the RPO-supplemented group during reperfusion. 
Conclusions: Our results suggest that dietary RPO-supplementation caused 
differential phosphorylation of the MAPKs and PKB/Akt during 
ischaemia/reperfusion-induced injury. These changes in phosphorylation were 
associated with improved functional recovery and reduced cleavage of an 
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apoptotic marker, arguing that dietary RPO-supplementation may confer 
protection via the MAPK and PKB/Akt signalling pathways during 
ischaemia/reperfusion induced injury.  
 
7.2 Introduction 
 
Cardiovascular disease remains one of the major causes of death in modern 
society. Although it was previously shown that dietary red palm oil (RPO)-
supplementation protects against ischaemia/reperfusion injury in the isolated 
perfused rat heart (Esterhuyse et al., 2005), the mechanism of action of RPO 
remains to be elucidated. 
 
Several signal transduction pathways in the heart are regulated in direct 
response to ischaemia/reperfusion-induced injury. One of the best-
characterized signal transduction pathways in the heart is the family of 
mitogen-activated protein kinases (MAPKs). The MAPKs are a family of serine-
threonine kinases that are activated in response to a variety of extracellular 
stimuli (Robinson and Cobb, 1997; Ip and Davis, 1998). Three major MAPKs 
including extracellular signal-regulated protein kinase (ERK), p38, and c-Jun 
NH2-terminal protein kinase (JNK), have been implicated in the response to 
ischaemia and reperfusion in the heart (Bogoyevitch et al., 1996; Knight and 
Buxton, 1996). All three MAPKs have been shown to play pivotal roles in 
transmission of signals from cell surface receptors to the nucleus and are 
involved in cell growth, differentiation and apoptosis (Mansour et al., 1994; 
Leppa et al., 1998; Nemoto et al., 1998). Another potential target of RPO might 
be the serine/threonine kinase PKB/Akt. PKB/Akt contains a pleckstrin 
homology (PH) domain that is part of a slightly larger portion in the NH2 
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terminus, called the Akt homology domain. The phosphoinositide 3-kinase 
(PI3-K) product phosphatidylinositol-3,4-bisphosphate binds in vitro directly to 
the PH domain and increases enzyme activity (Downward, 1998). PKB/Akt has 
been shown to be activated by factors that stimulate PI3-K including thrombin, 
platelet-derived growth factor and insulin (Downward, 1998). There is also 
increasing evidence that the PKB/Akt pathway participates in 
ischaemia/reperfusion-induced injury (Brar et al., 2002; Andreucci et al., 2003). 
 
Very little information regarding the effects of fatty acids and antioxidants 
(major components of RPO) on the MAPK family and PKB is available in the 
heart. Chen and co-workers (2003) reported that eicosapentaenoic acid 
inhibits hypoxia-reoxygenation-induced injury by attenuation of p38 MAPK. 
Furthermore, it was reported that antioxidant treatment of myocytes 
suppressed the increase in ROS and blocked ERK activation and the 
subsequent cardiac hyperthropy induced by these stimuli (Tanaki et al., 2001). 
 
However, as far as we know, no evidence exists for an interaction between 
RPO and the activation/inhibition of the MAPKs and the pro-survival kinase, 
PKB during ischaemia and reperfusion. In order to assess the possible 
mechanisms of protection, the isolated perfused rat heart model was used to 
determine whether dietary RPO-supplementation was associated with changes 
in the regulation of the MAPKs and PKB/Akt during ischaemia and reperfusion. 
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7.3 Materials and Methods 
 
7.3.1 Antibodies and chemicals 
 
Antibodies were purchased form Cell Signalling Technology and all other 
chemicals were obtained from Sigma (St Louis, MO). 
 
7.3.2 Experimental groups and model used 
 
Wistar rats were fed a standard rat chow (control) diet or control diet plus 7g 
RPO per kg diet for 6 weeks. The working heart perfusion method used in this 
experiment, as well as the methods for assessment of myocardial MAPKs 
activities, have been discussed in Chapter 3 under Materials and Methods 
(Experimental Model 4 p.65).  
 
7.3.3 Functional parameters measured  
Post-ischaemic mechanical function was measured as described in Chapter 3 
under Materials and Methods (Experimental Model 1 p.50).  
 
7.3.4 Western blot analysis 
Hearts were freeze-dried and used to characterize the degree of activation (i.e. 
phosphorylation) of extracellular signal-regulated kinase (ERK), p38, c-Jun 
NH2-terminal protein kinase (JNK) and PKB/Akt as described in Chapter 3 
under Materials and Methods (Experimental Model 4 p.65).  
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7.3.5 Statistical methods 
Statistical methods used in this experiment have been discussed in Chapter 3 
under Materials and Methods (Experimental Model 4 p.65). 
 
7.4 Results 
 
7.4.1 Aortic output recovery (%)  
We used aortic output recovery as an indirect index of the severity of 
ischaemia/reperfusion injury. These data suggests that RPO protected against 
the consequences of ischaemia/reperfusion (RPO 72,1 ± 3,2% versus control 
54,0 ± 3,2%, P<0.05) (n=7 per group) (Figure 7.1).  
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Figure 7.1 % Aortic output recovery of hearts from RPO-supplemented group 
versus control group. (n=7 per group) (*P<0,05 for RPO-supplemented group 
versus control group) (mean ± SEM) 
 
7.4.2 The effect of RPO-supplementation on the phosphorylation of p38, 
JNK and ERK in hearts subjected to ischaemia and reperfusion  
 
Phosphorylation of p38, JNK (p46/p54-MAPK) and ERK 1/2 (p42/p44-MAPK) 
was determined by Western blotting using phospho-specific antibodies. As 
* 
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shown in Figure 7.2A, p38 phosphorylation was significantly increased in the 
RPO-supplemented group during reperfusion versus the control (reperfusion) 
group (RPO: 4,42 ± 0,35 fold versus control: 1,84 ± 0,39 fold, P<0,001). 
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Figure 7.2A The effect of dietary RPO-supplementation on p38 phosphorylation 
in hearts subjected to ischaemia and reperfusion. Samples were analysed by 
Western blotting with phospho-specific antibodies recognizing dual 
phosphorylated MAPKs. Results are expressed as mean ± SEM for 4 
independent experiments (n=4 per group/time point). 10 minutes reperfusion 
RPO versus 10 minutes reperfusion control (*P<0,001) 
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Ischaemia/reperfusion caused significant increases in both JNK54 and JNK46 
phosphorylation of control group from 20 minutes perfusion to 10 minutes 
reperfusion (from 1,0 ± 0 fold to 3,9 ± 0,23 fold, P<0,001 for JNK54 and 1,0 ± 0 
to 6,83 ± 0,66 fold, P<0,001 for JNK46) (Figure 7.2B).  
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Figure 7.2B The effect of dietary RPO-supplementation on JNK phosphorylation 
in hearts subjected to ischaemia and reperfusion. Samples were analysed by 
Western blotting with phospho-specific antibodies recognizing dual 
phosphorylated MAPKs. Results are expressed as mean ± SEM for 4 
independent experiments (n=4 per group/time point). JNK54: 10 minutes 
reperfusion RPO versus 10 minutes reperfusion control (**P<0,001). JNK 54 and 
46: 10 minutes reperfusion control versus 20 minutes perfusion control 
(*P<0,001); 10 minutes reperfusion RPO versus 10 minutes reperfusion control 
(**P<0,001)  
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Phosphorylation of JNK54 and JNK46 was increased significantly less in 
hearts of the group supplemented with RPO when compared with hearts of the 
corresponding control group at 10 minutes reperfusion, respectively (1,65 ± 
0,06 fold versus 3,90 ± 0,23 fold, p<0,001 for JNK54 and 1,87 ± 0,13 fold 
versus 6,83 ± 0,66 fold, P<0,001 for JNK46). 
 
There were significant increases in ERK44 and ERK42 phosphorylation during 
ischaemia and reperfusion in hearts of both the RPO-supplemented and 
control groups when compared with baseline ERK44 and ERK42 
phosphorylation. RPO-supplementation did not offer cardioprotection at any of 
these time points as measured by increased phosphorylation of ERK44 and 
ERK42 when compared with ERK44 and ERK42 phosphorylation of control 
groups, respectively (Figure7.2C). 
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Figure 7.2C The effect of dietary RPO-supplementation on ERK phosphorylation 
in hearts subjected to ischaemia and reperfusion. Samples were analysed by 
Western blotting with phospho-specific antibodies recognizing dual 
phosphorylated MAPKs. Results are expressed as mean ± SEM for 4 
independent experiments (n=4 per group/time point). ERK44: 10 minutes 
ischaemia control versus 20 minutes perfusion control (#P<0,01); 10 minutes 
reperfusion control versus 10 minutes ischaemia control ($P<0,01); 10 minutes 
reperfusion RPO versus 20 minutes perfusion RPO (&P<0,001). ERK42: 10 
minutes ischaemia control versus 20 minutes perfusion control (#P<0,05); 10 
minutes reperfusion control versus 10 minutes ischaemia control ($P<0,01); 10 
minutes reperfusion RPO versus 20 minutes perfusion RPO (&P<0,001) 
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7.4.3 The effect of RPO-supplementation on the phosphorylation of 
PKB/Akt in hearts subjected to ischaemia and reperfusion  
Phosphorylation of PKB/Akt (Ser473) was determined by Western blotting using 
phospho-specific antibodies. There was a significant increase in PKB/Akt 
phosphorylation of hearts in the RPO-supplemented group compared to the 
control group during reperfusion (4,03 ± 1,1 fold versus 1,03 ± 0,11 fold, 
P<0,01) (Figure 7.3). 
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Figure 7.3 The effect of dietary RPO-supplementation on PKB phosphorylation 
in hearts subjected to ischaemia and reperfusion. Samples were analysed by 
Western blotting with phospho-specific antibodies recognizing dual 
phosphorylated MAPKs. Results are expressed as mean ± SEM for 4 
independent experiments (n=4 per group/time point). 10 minutes reperfusion 
RPO versus 10 minutes reperfusion control (*P<0,01) 
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7.4.4 The effect of RPO-supplementation on PARP cleavage and caspase-
3 activation in hearts subjected to ischaemia and reperfusion  
 
The control group showed a significant increase in PARP cleavage during 
reperfusion compared to PARP cleavage in the control perfusion group (2,1 ± 
0,27 fold versus 1,0 ± 0 fold, P<0,01) (Figure 7.4A). However RPO-
supplementation significantly attenuated PARP cleavage (0,6 ± 0,17 fold for 
RPO-group versus 2,1 ± 0,27 fold for control group, P<0,001) during 
reperfusion.  
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Figure 7.4A: The effect of dietary RPO-supplementation on PARP cleavage 
during ischaemia and reperfusion. Samples were analysed by Western blotting 
with antibodies recognizing cleaved PARP and caspase-3. Results are 
expressed as mean ± SEM for 4 independent experiments (n=4 per group/time 
point). PARP: 10 minutes reperfusion control versus 20 minutes perfusion 
control (#P<0,01); 10 minutes reperfusion RPO versus 10 minutes reperfusion 
control (*P<0,001).  
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Hearts of the control group showed a significant increase in caspase-3 
activation during reperfusion when compared with caspase-3 activation of 
hearts during perfusion (P<0,05). (Figure 7.4B). 
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Figure 7.4B: The effect of dietary RPO supplementation on caspase-3 activation 
during ischaemia and reperfusion. Samples were analysed by Western blotting 
with antibodies recognizing cleaved PARP and caspase-3. Results are 
expressed as means ± S.E.M. for 4 independent experiments (n=4 per group/per 
time point). Caspase-3: 10 minutes reperfusion control versus 20 minutes 
perfusion control (*P<0.05)  
 
 
7.5 Discussion 
 
We have demonstrated that RPO-supplementation offered significant 
protection against ischaemia/reperfusion-induced injury in the isolated 
perfused working heart as reflected by improved functional recovery. Except 
for our own, no other evidence exists for the role of RPO in functional recovery 
after ischaemia/reperfusion induced injury (Esterhuyse et al., 2005). However, 
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some evidence does exist for the effect of some of the major components of 
RPO on cardiac function. Meehan and co-workers (1994) demonstrated that 
oleic acid improved functional recovery in ischaemic/reperfused hearts. 
Serbinova and co-workers (1992) showed that RPO vitamin E was more 
effective than tocopherols in protecting against ischaemia/reperfusion injury in 
the isolated Langendorff perfused heart. Das and co-workers (in press) also 
demonstrated that palm tocotrienol provided cardioprotection as proved by 
reduction of ischaemia/reperfused-mediated increases in ventricular 
dysfunction, ventricular arrhythmias and myocardial infarct size. Furthermore, 
Bilgin-Karabulut and co-workers (2001) has showed that pre-treatment with a 
combination of vitamin A and vitamin E offered protection against venous 
ischaemia/reperfusion-induced injury, Interestingly, these vitamins were not 
effective when used as single agents (Bilgin-Karabulut et al., 2001). 
  
In response to ischaemia, cells activate various signal transduction pathways 
which may be either harmful, or allow adaptation to this stressful environment. 
Recent studies suggested that the MAPKs are important regulators of 
apoptosis in response to myocardial ischaemia/reperfusion. Therefore, we 
characterized the three major MAPK subfamily members that are activated 
during ischaemia and reperfusion in our model and investigated the influence 
of RPO on their phosphorylation status. 
Dietary RPO-supplementation significantly increased the generic p38 isoform 
phosphorylation during reperfusion (Figure 7.2A). Despite reports to the 
contrary (Mackay and Mochly-Rosen, 2000; Marais et al., 2001), several 
investigators support the concept that p38 activation protects the heart from 
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ischaemia/reperfusion-induced injury (Maulik et al., 1996; Weinbrenner et al., 
1997). These opposing results may be attributed to the different isoforms (α 
and β) expressed in the heart (Saurin et al., 2000), which appear to mediate 
opposing effects. The p38α-isoform is implicated in apoptosis, whereas p38β is 
anti-apoptotic in rat cardiac myocytes. JNK phosphorylation (JNK54 and 
JNK46) was significantly increased during reperfusion but was attenuated by 
dietary RPO supplementation. JNK phosphorylation appears to be pro-
apoptotic in many cell types (Obata et al., 2000; Park et al., 2000), however 
their exact role in regulating cell death is unclear. For example, Hreniuk and 
co-workers (2001) found that inhibition of JNK46, but not JNK54, significantly 
reduced reoxygenation-induced apoptosis. Wang and co-workers (1998), on 
the other hand, reported that activation of JNK by transfection of cultured rat 
neonatal cardiomyocytes with mitogen activated protein kinase kinase 7 
(MKK7), an upstream activator of JNK, induced hypertrophy rather than 
apoptosis. Although dietary RPO-supplementation had no effect on ERK 
phosphorylation compared to the control group, the ERK cascade appears to 
specifically mediate cell growth and survival signals. For instance, it has been 
shown that inhibition of ERK enhances ischaemia/reperfusion-induced 
apoptosis and that sustained activation of this kinase during simulated 
ischaemia mediates adaptive cytoprotection in cultured neonatal 
cardiomyocytes (Punn et al., 2000).  
 
We also investigated the involvement of PKB/Akt in the cellular response to 
dietary RPO supplementation. RPO was responsible for a significant increase 
in PKB phosphorylation during reperfusion (Figure 7.3). This is in agreement 
with results of Fujio and co-workers (2000) who showed that PKB/Akt 
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promotes survival of cardiomyocytes in vitro and protects against 
ischaemia/reperfusion injury in the mouse heart. PKB is activated downstream 
of PI-3-kinase by the phosphoinositide-dependent protein kinases PDK-1 and 
PDK-2 (Anderson et al., 1998). PKB in turn phosphorylates a number of 
downstream targets relevant to cell survival functions, including the pro-
apoptotic Bcl-2 family member BAD (Del Peso et al., 1997). Phosphorylation of 
BAD on Ser136 by PKB inhibits its pro-apoptotic function, thus promoting cell 
survival (Datta et al., 1997). Interestingly, BAD is not only a substrate for PKB, 
but is also phosphorylated by the MAPK kinase MEK (Punn et al., 2000), 
linking the classical Ras-MAPK pathway to cell survival.  
 
Apoptosis has been consistently observed in cardiac myocytes after 
reperfusion and may represent a direct mechanism by which myocytes are 
damaged (Abe et al., 2000). Indeed, in our model, reperfusion injury also 
resulted in cleavage of PARP to its proteolyzed products, a phenomenon well 
known to result from caspase-3 activation. RPO-supplementation significantly 
reduced PARP cleavage during reperfusion, and attenuated caspase-3 
activation, although not significantly. 
 
In summary, our results have shown that RPO-supplementation caused 
increased phosphorylation of p38 and PKB and reduce phosphorylation of 
JNK. Both increased PKB and p38 phosphorylation and the inhibition of JNK 
phosphorylation may contribute to the protection of the cell against apoptosis. 
The attenuation of PARP cleavage would in turn be expected to inhibit 
apoptosis. Results presented in other studies (Bogoyevitch et al., 1996; Punn 
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et al., 2000), as well as our own (Engelbrecht et al., 2004), indicate that the 
MAPKs are central regulators of reactive signalling in cardiac myocytes. 
Dietary RPO-supplementation was associated with increased percentage 
myocardial EPA after ischaemia in our perfusion model, which may effect 
intracellular signalling cascades. The ability to directly manipulate MAPK 
signalling has been shown to protect cardiomyocytes from 
ischaemia/reperfusion-induced apoptosis/injury. This notion suggests that 
members of the MAPK signalling cascade would be ideal targets for 
pharmacological intervention to treat ischaemia/reperfusion injury. Therefore, 
according to our results, a daily dosage RPO of 0,58 mg/kg suggest to be 
beneficial to humans.  
 
 In the current study we have demonstrated for the first time that RPO might 
exert its beneficial effects during reperfusion through increased PKB/Akt and 
p38 phosphorylation and dephosphorylation of JNK, which might be associated 
with inhibition of apoptosis and improved function. Thus, RPO might offer an 
alternative, non-pharmacological strategy to protect the heart against 
ischaemia/reperfusion-induced injury. 
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CHAPTER 8 
 
CONCLUSION 
 
To our knowledge no previous studies have investigated the effect of dietary 
RPO-supplementation on cell signalling associated with cardioprotection 
during ischaemia/reperfusion injury. In the current study we provide data of 
dietary RPO-intervention on the signalling pathways that may be involved in 
cardioprotection during ischaemia and reperfusion.  
An in vitro working rat heart perfusion model was used to investigate the 
effects of dietary RPO-supplementation on myocardial post-ischaemic 
functional recovery and the mechanisms involved. Our results clearly indicated 
that dietary RPO-supplementation of a standard rat chow diet protects against 
the consequences of global ischaemia/reperfusion in the isolated perfused rat 
heart as reflected by improved aortic output recovery. Based on our results, we 
propose that the protective effect of RPO may be associated with either its 
antioxidant characteristics, and/or changes in the phospholipid fatty acid 
composition of the myocardium during ischaemia/reperfusion injury. We 
hypothesize that the palm oil vitamin E antioxidant properties may contribute to 
elevated cGMP and decreased cAMP concentrations early in ischaemia. This 
may be the more prominent mechanism of cardioprotection in this model using 
a standard rat chow diet. It is possible that cGMP may attenuate 
ischaemia/reperfusion injury by inhibiting the cAMP induced increase in the 
slow inward calcium current, thus leading to a decrease in ischaemic cytosolic 
calcium concentrations. 
 
We also investigated whether RPO-supplementation offers the same 
protection against ischaemia/reperfusion injury when supplemented with a 
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high-cholesterol diet and tried to elucidate possible mechanisms involved in 
this protection. Increased reperfusion aortic output recovery and rate pressure 
product values with RPO-supplemention of a high-cholesterol diet were 
associated with a decreased cAMP concentration during reperfusion. Although 
suppression of cAMP during reperfusion could be involved in cardioprotection, 
we were of the opinion that this was not the only mechanism of protection. In 
addition, our results clearly demonstrated that the RPO-induced protection of a 
high-cholesterol diet could not be linked with increased NO-cGMP signalling 
and confirms our hypothesis that cGMP may not be the only mechanism of 
protection. This following sequence of events should be considered: In the 
presence of cholesterol, superoxide production is increased. Superoxide would 
compete to re-direct the reaction towards lipid peroxidation, instead of cGMP 
production. Our results indicate that neither SOD activity, nor LPO production 
increased. We therefore speculate that RPO antioxidants acted as free radical 
scavengers and could potentially improve NO availability. However, we have 
no data to support this argument, but it does create an opportunity for future 
investigations. 
 
From our work it is also evident that most of the RPO-induced changes 
occurred during the ischaemic period with the NO-cGMP pathway being a 
major role player.  
 
Recent studies suggested that the MAPK family, PKB/Akt and signal 
transduction caspases are important regulators of apoptosis in response to 
myocardial ischaemia/reperfusion. We demonstrated for the first time that 
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dietary RPO-supplementation protects the isolated perfused working rat heart 
from ischaemia/reperfusion-induced apoptosis/injury through MAPK-, PKB/Akt- 
and caspase dependent pathways during the reperfusion period. Dietary RPO-
supplementation exerts its beneficial effects through increased PKB/Akt and 
p38 phosphorylation and dephosphorylation of JNK, all of which might be 
associated with inhibition of apoptosis and improved functional recovery. 
Dietary RPO-supplementation was associated with increased percentage 
myocardial EPA after ischaemia in our perfusion model, which could be 
involved in the modulation of MAPK enzyme activity. 
 
In summary our results suggest that dietary RPO-supplementation offered 
protection against ischaemia/reperfusion injury as reflected by improved aortic 
output recovery. We could not demonstrate whether the fatty acids (although 
little contribution to that of diet) or antioxidant content individually, or as a 
combination, was responsible for these protective effects. Our results suggest 
that hearts of cholesterol-fed animals were protected through a different 
mechanism (may possibly include the antioxidant capacity of RPO). The 
proposed mechanisms include RPO protection in ischaemia via the NO-
cGMPpathway and MAPK, PKB/Akt and caspase involvement during 
reperfusion (Figure 8.1).  
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Figure 8.1 Proposed mechanisms for dietary RPO protection 
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ADDENDUM 
 
CONGRESSES 
 
A: International 
 
1. International Palm Oil Congress (PIPOC 2003) 
24-28 August 2003, Putrajaya Marriott Hotel, Putrayaya , Malaysia 
Paper: Dietary red palm oil supplementation improves post ischaemic 
functional recovery in the isolated perfused rat heart. AJ Esterhuyse, 
EF du Toit, J van Rooyen.  
 
2. 2004 ISHR World Congress Satellite: Cellular Injury in Ischaemia, 
Kruger Park, South Africa, 13-15 August 2004. 
Poster: NO-cGMP pathway involved in red palm oil mediated ischaemic 
protection. Jacques van Rooyen, Johan Esterhuyse, Spinnler Benade, 
Eugene du Toit. (Abstract accepted and published in CVSA). 
 
3. Oils and fats International Congress, Putra World Trade Centre, 
Kuala Lumpur, Malaysia, 29 September-2 October 2004 
Invited Speaker: Red palm oil: Myth or Magic? The effect of the NO-
cGMP pathway. Van Rooyen J; Esterhuyse AJ; Du Toit EF. 
 
B: National 
 
1. 32ndAnnual Congress of the PSSA, September 12-15, 2004. Coffee 
Bay,Transkei, South Africa.  
Plenary Speaker : Red palm oil: Myth or Magic. Jacques van Rooyen; 
Johan Esterhuyse; Eugene F du Toit.  
 
Poster: A role for dietary red palm oil induced cardioprotection in 
isolated rat hearts. Esterhuyse AJ; Du Toit EF; Bester DJ; Benadé  
AJS; Van Rooyen J.  
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Poster: Cardiac function in isolated perfused rat heart is not negatively 
affected by dietary red palm oil. Bester DJ; Van Rooyen J; Du Toit EF; 
Benadé AJS; Esterhuyse AJ.  
 
2. Academic Day, University of Stellenbosch, South Africa, 18 August 
2004 
Poster: Dietary red palm oil offers protection against 
ischaemia/reperfusion injury. Esterhuyse AJ; Bester DJ; Van Rooyen 
J; Du Toit  EF.  
 
 
PUBLICATIONS 
 
1. Esterhuyse AJ; Du Toit EF; Van Rooyen J. Dietary red palm oil 
supplementation protects against the consequences of global ischaemia 
in the isolated perfused rat heart. Asia Pac J Clin Nutr (accepted 
2004).  
 
2. Esterhuyse AJ; Du Toit EF; Benadé AJS; Van Rooyen J. Dietary red 
palm oil improves reperfusion cardiac function in the isolated perfused 
rat heart of animals fed a high cholesterol diet. Prostagl, Leukot 
Essent Fatty Acids 2005; 72:153-161. 
 
3. Anna-Mart Engelbrecht; Johan Esterhuyse; Eugene Du Toit; 
Jacques van Rooyen. p38-MAPK and PKB/AKT, possible role players 
in red palm oil induced protection of the isolated perfused rat heart. J 
Nutr Biochem (accepted 2005). 
 
Submitted: 
3. Johan Esterhuyse; Jacques van Rooyen; Hans Strijdom; Dirk 
Bester; Eugene du Toit. Proposed mechanisms for red palm oil 
induced cardioprotection in a hyperlipidaemic perfused rat heart model. 
(2005).  
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